

# A comprehensive proteomic and bioinformatics analysis of human spinal cord injury plasma identifies proteins associated with the complement cascade as potential prognostic indicators of neurological outcome

## 1 Abstract

### Introduction

Spinal Cord Injury (SCI) is a major cause of disability, with complications post-injury often leading to life-long health issues with need of extensive treatment. Neurological outcome post-SCI can be variable and difficult to predict, particularly in incomplete injured patients. The identification of specific SCI biomarkers in blood, may be able to improve prognostics in the field. This study has utilised proteomic and bioinformatics methodologies to investigate differentially expressed proteins in plasma samples across human SCI cohorts with the aim of identifying prognostic biomarkers and biological pathway alterations that relate to neurological outcome.

### Methods and Materials

Blood samples were taken, following informed consent, from **AIS grade C “Improvers” (AIS grade improvement) and “Non-Improvers” (No AIS change), and AIS grade A and D at <2 weeks (“Acute”) and approx. 3 months (“Sub-acute”) post-injury. The total protein concentration from each sample was extracted, with pooled samples being labelled and non-pooled samples treated with ProteoMiner™ beads. Samples were then analysed using two 4-plex isobaric tag for relative and absolute quantification (iTRAQ) analyses and a label-free experiment for comparison, before quantifying with mass spectrometry. Proteomic datasets were analyses using** bioinformatics...

Proteins of interest identified from this analysis were further validated by enzyme-linked immunosorbent assay (ELISA). OpenMS (version 2.6.0) was used to process the raw spectra data. R (version 4.1.4) and in particular, the R packages MSstats (version 4.0.1), STRINGdb (version 2.4.2) and pathview (version 1.32.0) were used for downstream analysis.

### Results

The data demonstrated proteomic differences between the cohorts, with the results from the iTRAQ approach supporting those of the label-free analysis. A total of 79 and 87 differentially abundant proteins across AIS and longitudinal groups were identified from the iTRAQ and label-free analyses, respectively. Alpha-2-macroglobulin (A2M), retinol binding protein 4 (RBP4), serum amyloid A1 (SAA1), Peroxiredoxin 2, alipoprotein A1 (ApoA1) and several immunoglobulins were

identified as biologically relevant and differentially abundant, with potential as individual prognostic biomarkers of neurological outcome. Bioinformatics analyses revealed that the majority of differentially abundant proteins were components of the complement cascade and most interacted directly with the liver.

## Conclusions

Many of the proteins of interest identified using proteomics were detected only in a single group and therefore have potential as a binary (present or absent) biomarkers. Additional investigations into the chronology of these proteins, and their levels in other tissues (cerebrospinal fluid in particular) are needed to better understand the underlying pathophysiology, including any potentially modifiable targets. The complement cascade was confirmed using pathway analysis \*\*as...

## 2 Introduction

Spinal cord injury (SCI) is the transient or permanent loss of normal spinal sensory, motor or autonomic function, and is a major cause of disability. Globally, SCI affects around 500,000 people each year and is most commonly the result of road traffic accidents or falls.(Crozier-Shaw, Denton, and Morris 2020) Patients typically require extensive medical, rehabilitative and social care at high financial cost to healthcare providers. The lifetime cost of care in the UK is estimated to be £1.12 million (mean value) per SCI, with the total cost of SCI in the UK to the NHS being £1.43 billion in 2016.(McDaid et al. 2019) Individuals with SCI show markedly higher rates of mental illness relative to the general population.(Furlan, Gulasingham, and Craven 2017) Complications arising post-SCI can be long-lasting and often include pain, spasticity and cardiovascular disease, where the systemic inflammatory response that follows SCI can frequently result in organ complications, particularly in the liver and kidneys.(Gris, Hamilton, and Weaver 2008; X. Sun et al. 2016)

- I need to add a reference here -

The recovery of neurological function post-SCI is highly variable, requiring any clinical trials to have an impractically large sample size to prove efficacy, hence the translation of novel efficacious therapies is challenging and expensive.(Spiess et al. 2009) Being able to more accurately predict patient outcomes would aid clinical decisions and facilitate future clinical trials. Therefore, novel biomarkers that allow for stratification of injury severity and capacity for neurological recovery would be of high value to the field.

Biomarkers studies in SCI often investigate protein changes in cerebral spinal fluid (CSF) as the closer proximity of this medium is thought to be more reflective of the parenchymal injury.(Brian K. Kwon et al. 2019; Hulme et al. 2017) Whilst this makes CSF potentially more informative for elucidating the pathology of SCI, the repeated use of CSF for routine analysis presents challenges in clinical care due to the risk and expense associated with the invasiveness of the collection procedure. In contrast, systemic biomarkers measurable in the blood represent a source of information that can be accessed and interpreted both a lower cost and risk. Studies of traumatic brain injury have demonstrated that protein markers identified in CSF are also detectable in both plasma and serum.(Wang et al. 2018) More recently, circulating white blood cell populations have also been identified as potential SCI injury biomarkers, with a 2021 study showing that elevated levels of neutrophils were associated with no AIS grade conversion, while conversely an increase in lymphocytes during the first week post-SCI were associated with an AIS grade improvement.

- Another Reference -

A number of individual proteins have been shown to be altered in the bloods post-SCI, including multiple interleukins (IL), tumour necrosis factor alpha (TNF- $\alpha$ ) and C-reactive protein (CRP).(Segal et al. 1997; Hayes et al. 2002; Frost et al. 2005)

Further, changes in inflammatory marker levels detected in acute SCI patients were found to be mirrored in donor-matched blood and CSF, albeit at lower absolute concentrations systemically.(Brian K. Kwon et al. 2010)

Previously, we have shown that routinely collected blood measures associated with liver function and inflammation added predictive value to AIS motor and sensor outcomes at discharge and 12-months post-injury.(Bernardo Harrington et al. 2020; Brown et al. 2019) The current study uses an unbiased shotgun proteomic approach to investigate differentially expressed proteins in SCI patients, coupled with bioinformatics pathway and network analyses.

### 3 Methods and Materials

**Table 1.** Patient demographics. ± denotes interquartile range

	n	Percent
<b>Polytrauma</b>		
Yes	16	41
No	23	59
<b>Gender</b>		
F	13	33
M	26	67
<b>Diabetes</b>		
Yes	7	18
No	32	82
<b>Neurological level</b>		
C	26	67
L	4	10
T	9	23
<b>AIS change</b>		
A	11	28
C	7	18
C->D	10	26
D	11	28
Age at injury (Median years±IQR)	53±26	-

#### 3.1 Patients

Blood samples were taken from SCI patients who had provided informed consent and in accordance to ethical provided by the National Research Ethics Service [NRES] Committee North West Liverpool East [11/NW/0876]. “Improvers” were defined as individuals who experienced an AIS grade improvement from admission to a year post-injury, whereas “non-improvers” were defined as patients who saw no change in AIS grade in the same period.

#### 3.2 Plasma collection and storage

Plasma samples were collected within 2 weeks of injury (acute) and at approximately 3 months post-injury (subacute). Upon collection in \*\*EDTA coated tubes samples were centrifuged at 600g for 15 minutes, to pellet erythrocytes and the resultant plasma fraction was aspirated and divided into aliquots for long-term storage in -80°C

101 briefly and liquid nitrogen in the longer term.

### 102 **3.3 Sample preparation and analysis using iTRAQ proteomics**

103 Thawed plasma samples (2 $\mu$ l) each were diluted with distilled water (98 $\mu$ l). Total protein was  
104 quantified using a Pierce™ 660nm Protein Assay (Thermo Fisher Scientific, Hemel Hempstead,  
105 UK)(Stoscheck 1987).

106 In brief, 10 $\mu$ l of the diluted sample was added to 150 $\mu$ l of Thermo Pierce 660nm protein assay  
107 reagent in triplicate and the optical density was read at 660nm.

108 A total of 100mg of plasma protein was taken from each sample and pooled equally to form a  
109 patient test group. For example, the AIS C improver group was pooled from 10 separate patient  
110 samples, 10mg of protein per patient.

111 The pooled plasma samples were then precipitated by incubation of the sample in 6 times the vol-  
112 ume of chilled acetone for 1 hour at -20°C. The samples were then centrifuged at 6,000G for 10  
113 minutes at 4°C, and re-suspended in 200 $\mu$ l of triethylammonium bicarbonate buffer. Sequencing  
114 Grade Modified Trypsin (10 $\mu$ g:85 $\mu$ g of protein; Promega, Madison, WI, USA) was then added to the  
115 samples for overnight digestion at 37°C. Proteins then underwent reduction and alkylation (ac-  
116 cording to the manufacturer's instructions; Applied Biosystems, Bleiswijk, The Netherlands). Tryp-  
117 tic digests were labelled with iTRAQ tags (again according to the manufacturer's instructions for the  
118 iTRAQ kit), before being pooled into test groups and dried in a vacuum centrifuge. The following  
119 tags were used for each group of patient samples 114 tag - acute improvers, 115 tag - sub-acute  
120 improvers, 116 tag - acute non-improvers and 117 tag - sub-acute non-improvers for run 1 and 114  
121 tag - acute improvers, 115 tag - acute non-improvers, 116 tag - AIS grade A and 117 tag - AIS grade  
122 D for run 2.

123 **3.3.0.1 iTraQ mass spectrometry analysis** The samples were analysed at the BSRC St. An-  
124 drews University Mass Spectrometry and Proteomics Facility using methods previously described.

125 iTRAQ-labelled peptides were re-suspended in 0.6ml of loading buffer (10mM monopotassium  
126 phosphate [KH<sub>2</sub>PO<sub>4</sub>], 20% acetonitrile [MeCN], pH 3.0), followed by sonication. The pH was ad-  
127 justed to 3.0 with 0.5M orthophosphoric acid (H<sub>3</sub>PO<sub>4</sub>). The peptides were separated by strong  
128 cation exchange chromatography (SCX) on a PolySulfoethyl A column (200mm x 2.1mm, 5 $\mu$ l, 200nm  
129 pore size, PolyLC, Columbia, MD, USA). The column was washed with 100% buffer Ascx at 1ml min<sup>-1</sup>  
130 for 22 minutes so the optical density on the ultraviolet chromatogram would return to baseline.  
131 A gradient of 0–50% Bscx (10 mM [KH<sub>2</sub>PO<sub>4</sub>], 20% MeCN, 500mM KCl, pH 3.0) was applied for 20  
132 minutes, 50–100% Bscx for 3 minutes, followed by 100% Bscx for another 3 minutes to wash the  
133 column, prior to re-equilibration in 100% Ascx for a further 11 minutes. Fractions (0.5mL) were  
134 collected every 30 seconds for total of 12 fractions, which were then desalted on C18 spin columns  
135 (PepClean C18 spin columns, ThermoFisher Scientific, Waltham, MA, USA) using the manufacturer's  
136 instructions, eluting in 20 $\mu$ l of 70% MeCN. The elution solvent was removed by vacuum concentra-  
137 tion and the fractions re-suspended in 20 $\mu$ l of 0.1% formic acid (FA) prior to mass spectrometric  
138 analysis.

139 **3.3.0.2 Mass spectrometry analysis** A total of 12 SCX fractions were analysed by nano-  
140 electrospray ionisation-liquid chromatography/tandem mass spectrometry (LC-MS/MS) using  
141 a TripleTOF 5600 tandem mass spectrometer (AB Sciex, Framingham, MA, USA) as described  
142 previously.(Fuller et al. 2015)

143 Each fraction (10 $\mu$ l) was then analysed by nanoflow LC-ESI-MSMS. The peptides were separated  
144 using a nanoLC Ultra 2D plus loading pump and nanoLC AS-2 autosampler chromatography system

(Eksigent, Redwood City, CA, USA), using a PepMap RSLC column (75 $\mu$ L x 15cm) and an Acclaim PepMap100 trap (100 $\mu$ m x 2cm) (ThermoFisher Scientific, Waltham, MA, USA). After washing the peptides on the trap column for 20 minutes at 5 $\mu$ L min<sup>-1</sup>, the trap was switched in line with the column and the peptides eluted with a gradient of increasing MeCN from 95% buffer A (98% H<sub>2</sub>O, 2% MeCN, 0.1% FA), 5% buffer B (2% H<sub>2</sub>O, 98% MeCN, 0.1% FA) to 65% buffer A, 35% buffer B over 60 minutes, then to 50% buffer A, 50% buffer B over a further 20 minutes, before increasing the concentration of buffer B to 95% over a further 10 minutes. The column was then washed with 95% buffer B before re-equilibration in 95% buffer A. A flow rate of 300nL min<sup>-1</sup> was employed. The eluent was sprayed into a TripleTOF 5600 tandem mass spectrometer (ABSciex, Foster City, CA, USA), using a NANOSpray III source, and analyzed in Information Dependent Acquisition (IDA) mode, performing 250ms of MS followed by 100ms MSMS analyses on the 20 most intense peaks with a charge state of +2 to +5. Parent (MS) ions were accepted with a mass tolerance of 50 mDa and MSMS was conducted with a rolling collision energy (CE) inclusive of preset iTRAQ CE adjustments. Analyzed parent ions were then excluded from analysis for 13 s after 3 occurrences.

### 3.3.1 Sample preparation and analysis using label-free proteomics

No sample pooling was used, and so each of the 73 samples were maintained separately throughout protein equalisation, mass spectrometry, and label-free quantification steps. Thus, protein abundance was quantified for each sample, whereupon mean protein abundance across experimental groups was calculated to assess protein changes.

To reduce the dynamic range of proteins, ProteoMiner™ beads (BioRad, Hemel Hempstead, UK) were used. Firstly, plasma was treated with 1  $\mu$ g·mL of hyaluronidase. Digestion was confirmed with Coomassie stained 1D-SDS PAGE gel. The supernatant was centrifuged through a 0.22  $\mu$ m cellulose acetate membrane (Costar Spin-X, Corning, Tokyo, Japan) tube filter (5000g for 15 minutes) to remove insoluble material. Total protein was quantitated with a Pierce™ 660nm Protein Assay (Thermo Fisher Scientific, Hemel Hempstead, UK), whereupon 5 mg of total protein was applied to ProteoMiner™ beads, and processed as described previously.(Stoscheck 1987) 3.7.3.2 LC separation and Quadrupole-Orbitrap instrument

**3.3.1.1 LC separation and Quadrupole-Orbitrap instrument** Tryptic peptides were subjected to LC-MC/MC via a 2-h gradient on a NanoAcquity™ ultraperformance LC (Waters, Manchester, UK) connected to a Q-Exactive Quadrupole-Orbitrap instrument (Thermo-Fisher Scientific Hemel Hempstead, UK) as described \*\*previously.

The Q-Exactive was operated in a data dependent positive electrospray ionisation mode, automatically switching between full scan MS and MS/MS acquisition. Survey full scan MS spectra ( $m/z$  300–2000) were acquired in the Orbitrap with 70,000 resolution ( $m/z$  200) following accumulation of ions to 1  $\times 10^6$  target value based on the predictive automatic gain control values from the previous full scan. Dynamic exclusion was set to 20s, the 10 most intense multiply charged ions ( $z \geq 2$ ) were sequentially isolated and fragmented in the octopole collision cell by higher energy collisional dissociation (HCD), with a fixed injection time of 100ms and 35,000 resolution. The following mass spectrometric conditions were used: spray voltage, 1.9kV, no sheath or auxiliary gas flow; normalised HCD collision energy 30%; heated capillary temperature, 250°C. MS/MS ion selection threshold was set to 1  $\times 10^4$  count and 2Da isolation width was set.

### 3.3.2 iTRAQ data processing

Data analyses were performed with the statistical programming language R version 4.1.3 (2022-03-10), please see table ?? for a list of packages used and the respective version numbers.(R Core Team 2022; Francois 2020; Morgan 2021; **bookdown?**; Alatheia 2015; Dowle and Srinivasan 2021;

190 **datasets?**; Iannone 2022; **forcats?**; **Formula?**; Gao 2021; **glmnet1?**; **graphics?**; **grDevices?**; Harrell Jr 2021; H. Zhu 2021; Xie 2014; Pedersen and Benesty 2021; Golemund and Wickham 2011; 191 **Matrix?**; **methods?**; Choi et al. 2014; Tierney et al. 2021; Revelle 2022; Henry and Wickham 2020, 192 2022; Neuwirth 2014; G. Yu and He 2016b; Wickham and Bryan 2019; **remotes?**; **stats?**; al. 2019; 193 Wickham 2019; **survival1?**; **survival2?**; Wickham et al. 2019; **utils?**; **zoo?**) 194

195 The mass spectrometry data files were combined and analysed using the ProteinPilot 4.5 software 196 with the Paragon<sup>TM</sup> and ProGroup<sup>TM</sup> algorithms (ABSciex) against human protein sequences in 197 the SwissProt database. Searches were performed with the default iTRAQ settings in ProteinPilot. 198 The cleavage enzyme was set to Trypsin and MMTS modification of cysteines with a “Thorough ID” 199 search effort. ProteinPilot’s Bias correcting setting was used, which assumes no change in protein 200 abundance between groups. Detected proteins were reported with a Protein Threshold [Unused 201 ProtScore (confidence)] >0.05 and included in the quantitative analysis if identified with two or 202 more peptides with >95% confidence. False Discovery Rate (FDR) analysis was also performed 203 using the ProteinPilot. ProteinPilot calculated P-values for the iTRAQ ratios and those with P > 0.05 204 were considered statistically significant. Proteins with iTRAQ ratios  $\geq$  1.2 fold change (FC) were 205 used for network analysis.

### 206 3.3.3 iTRAQ OpenMS analysis

207 TripleTOF 5600 tandem mass spectrometer output files produced in the ABSciex proprietary .wiff 208 file format were converted to an open file format, .mzML for analysis with OpenMS (version 2.6.0). 209 The docker image of ProteoWizard version 3.0.20287 was used for conversion, and peak picking 210 was applied on conversion (Chambers et al. 2012). OpenMS version 2.6.0 was used for further anal- 211 ysis.(Röst et al. 2016) Unless otherwise stated, default arguments were used. The 12 fraction files 212 were merged and sorted by retention time. A decoy database was generated with DecoyDatabase 213 and the -enzyme flag set to Trypsin, the human reference proteome was taken from Uniprot (Pro- 214 teome ID: UP000005640, downloaded: 2020-10-01), as was the .fasta for porcine trypsin (Entry: 215 P00761, downloaded: 2020-10-01).(The UniProt Consortium 2021)

216 The MSFGPlusAdapter was used to run the search. For the -fixed\_modifications “Methylthio (C)” 217 and “iTRAQ4plex (N-term)” were passed due to the alkylating agent used in sample preparation 218 and to account for the N-terminus modifications made by iTRAQ tags. “Oxidation (M)” was passed 219 to -variable\_modifications to reflect the likely occurrence of methionine oxidation. To reflect the 220 instrument the following flags were also set: -precursor\_mass\_tolerance 20 -enzyme Trypsin/P 221 -protocol iTRAQ -instrument high\_res.

222 To annotate the search results PeptideIndexer and PSMFeatureExtractor were used. For peptide 223 level score estimation and filtering PercolatorAdapter was used with the following arguments: 224 -score\_type q-value -enzyme trypsinp. IDFilter was used to filter to a peptide score of 0.05 225 with -score:pep 0.05

226 IsobaricAnalyzer with -type itraq4plex was used with the merged .mzML files to assign protein- 227 peptide identifications to features or consensus features with IDMapper. The files for each run 228 output by IDMapper were then merged with FileMerger. Bayesian score estimation and protein 229 inference was performed with Epifany and the following flags: -greedy\_group\_resolution 230 remove\_proteins\_wo\_evidence -algorithm:keep\_best\_PSM\_only false Decoys were removed 231 and 0.05 FDR filtering was done via IDFilter with -score:protgroup 0.05 -remove\_decoys. 232 Finally, IDConflictResolver was used to resolve ambiguous annotations of features with peptide 233 identifications, before quantification with ProteinQuantifier.

#### 234 **3.3.4 Label free OpenMS analysis**

235 For quantification, the raw spectra files were analysed via OpenMS (version 2.6.0) command line  
236 tools, with the workflow from the prior section (3.3.3) adapted to suit a label-free analysis. The  
237 files were first converted from the proprietary .Raw format to the open .mzML standard with the  
238 FileConverter tool via the open-source ThermoRawFileParser.(Röst et al. 2016; Hulstaert et al.  
239 2020) Unless otherwise stated, default arguments were used throughout.

240 The decoy database generated in the prior section (iTRAQ OpenMS analysis) was also re-used. The  
241 CometAdapter was used to run the search.(Eng, Jahan, and Hoopmann 2013) Fixed modifications  
242 were set to "Carbamidomethyl (C)" and "Oxidation (M)" was set as a variable modification. To reflect  
243 the instrument the following flags were also set: `-precursor_mass_tolerance 20 -isotope_error`  
244 `0/1`.

245 To annotate the identified peptides with proteins the PeptideIndexer tool was used. PeptideIndexer  
246 and PSMFeatureExtractor were used for annotation. For peptide level score estimation and fil-  
247 tering PercolatorAdapter was used with the following flags: `-score_type q-value -enzyme`  
248 `trypsin`. IDFilter was used to filter to a peptide score of 0.01 with `-score:pep 0.01` followed  
249 by IDScoreSwitcher with the following flags: `-new_score "MS:1001493" -new_score_orientation`  
250 `lower_better -new_score_type "pep" -old_score "q-value"`. The ProteomicsLFQ was used for  
251 subsequent processing with the flags: `-proteinFDR 0.05 -targeted_only true`. The `-out_msstats`  
252 flag was also used to produce quantitative data for downstream statistical analysis with the R  
253 package MSstats.(Choi et al. 2014)

### 254 **3.3.5 Enzyme-linked immunosorbent assays**

255 Four proteins identified by the iTRAQ analysis were measured by enzyme-linked immunoab-  
256 sorbent assay (ELISA) from non-pooled samples to validate the iTRAQ findings.

257 These proteins were alpha-2-macroglobulin (A2M), retinol binding protein 4 (RBP4), serum amy-  
258 loid A1 (SAA1) and apolipoprotein A1 (ApoA1). They were selected for their biological relevance  
259 and differential abundance between AIS C improvers and non-improvers, implying potential as  
260 biomarkers of neurological outcome prediction. A2M, RBP4 and SAA1 were assessed using a hu-  
261 man DuoSet® ELISAs (R&D Systems, Abingdon, UK). ApoA1 was assessed using a human Quan-  
262 tikine® ELISA (R&D Systems, Abingdon, UK). Samples were diluted 1:600,000 for A2M and RBP4,  
263 1:100 for SAA1 and 1:20,000 for ApoA1 in the respective assay kit diluent. Samples that were above  
264 the assay detection limit were rerun at 1:300 and 1:40,000 for SAA1 and ApoA1 respectively. All  
265 ELISAs were carried out according to the manufacturer's protocol. Protein concentrations were  
266 normalised to the sample dilution factor. Statistical analysis was performed using the statistical  
267 programming language R version 4.1.3 (2022-03-10). Pairwise t tests with bonferroni adjusted P-  
268 values with the R `rstatix` package were used to assess differential abundance.



### 269 3.3.6 Network and pathway analysis

270 Protein interaction networks were created using the Bioconductor package STRINGdb which pro-  
271 vides an R interface to STRING version 11.(Szkarczyk et al. 2019) Instantiation of the STRINGdb  
272 reference class was done with `species` and `score_threshold` set to 9606, for *Homo sapiens* , and  
273 400 respectively. Clustering of networks with STRINGdb used the “fastgreedy” algorithm from the  
274 iGraph package.

275 The Bioconductor package ReactomePA, which employs the open-source, open access, manually  
276 curated and peer-reviewed pathway database Reactome was used for network analysis.(G. Yu and  
277 He 2016b; Jassal et al. 2020)

## 278 4 Results

### 279 4.1 Results

280 In the interest of brevity, only the plots of acute and subacute AIS C improvers VS non-improvers  
281 are included here, please see the appendix for the other comparisons (section ??).

#### 282 4.1.1 Comparing OpenMS and ProteinPilot

283 A total of 79 and 64 unique, largely overlapping, proteins were identified across both runs for  
284 OpenMS and ProteinPilot respectively, though OpenMS consistently produced more proteins for  
285 each group (Tables 2, 3 and Figure 1). AIS C improvers had 18 more abundant proteins, and 49 less  
286 abundant proteins at the acute phase with OpenMS, as opposed to 8 and 20 with ProteinPilot (Fig-  
287 ure 2). At the subacute phase, AIS C improvers had 34 and 9 proteins of increased abundance were  
288 found, whereas 34 and 6 proteins were less abundant, for OpenMS and ProteinPilot respectively  
289 (Figure 2).

290 The AIS A group had 56 and 26 more abundant and 9 and 6 less abundant proteins respectively.  
291 Acutely, AIS C improvers relative to AIS A and D had 21 and 53 more abundant and 46 and 12 less  
292 abundant for OpenMS, whereas ProteinPilot had 5 and 19 more abundant proteins, and 18 and 6  
293 less abundant.

**Table 2.** OpenMS log<sub>2</sub> fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury respectively.

gene	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C improvers acute vs subacute	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS A vs D	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D
A1BG	-0.9031824	-0.1017534	-0.6087849	0.1926441	0.2252650	0.7937347	-0.3497633	0.4439714	-0.5750284	0.2187064
A2M	-1.0385788	-0.2464392	-0.6760613	0.1160783	-1.2300968	1.4247538	-1.6029796	-0.1782258	-0.3728828	1.0518710
AFM	-0.3788476	-1.2248641	0.4815192	-0.3644973	0.5517904	1.1923601	-1.2566085	-0.0642484	-1.8083989	-0.6160388
AHSG	1.1794532	NA	-0.5545288	NA	NA	NA	NA	NA	NA	NA
AMBP	0.6562004	-0.3433433	0.8606588	-0.1388849	-0.9023293	NA	1.2037841	NA	2.1061134	NA
APCS	0.1498290	0.2108936	-0.0114011	0.0496636	NA	0.3557242	NA	NA	-0.0494567	0.3062675
APOA1	-0.1816744	-0.6923621	-0.2337557	-0.7444434	-0.7677301	0.6941282	-1.3172834	-0.6231553	-0.5495533	0.1445749
APOA2	0.0900143	-1.1461360	-0.6667620	-1.9029124	NA	NA	NA	NA	NA	NA
APOA4	0.1295961	0.9636781	-1.2312803	-0.3971983	-1.3254088	0.7876011	-1.3346720	-0.5470709	-0.0092632	0.7783379
APOB	0.1379231	-0.0164100	-0.6332751	-0.7876082	-0.8570393	0.5260041	-1.2345864	-0.7085823	-0.3775471	0.1484570
APOE	-1.2133754	0.2930673	-0.6884490	0.8179937	-0.9078302	0.7746514	-1.5477490	-0.7730977	-0.6399188	0.1347326
APOH	-0.3602386	-0.7024687	-0.6444887	-0.9867188	-0.9996639	2.8143614	-1.0091799	1.8051815	-0.0095159	2.8048455
APOL1	-1.1790763	-0.5193515	-1.0440264	-0.3843015	-0.1152769	0.5652696	0.1299333	0.6952029	0.2452102	0.8104799
APOM	-1.2167971	-0.6819883	0.6934807	1.2282895	NA	0.6561807	NA	NA	0.6664954	1.3226762
ATRN	NA	NA	-1.0062957	NA	NA	NA	NA	NA	NA	NA
AZGP1	1.2191679	1.0251503	0.0811400	-0.1128776	-3.3889514	-3.6440501	0.3702887	-3.2737614	3.7592401	0.1151900
C1QB	-0.8410072	-2.0020393	0.7071113	-0.4539208	-1.9729191	1.3563310	-2.0066282	-0.6502972	-0.0337090	1.3226219
C1R	-0.4335115	-0.7632158	0.0366498	-0.2930545	-0.1467491	0.7976066	0.3564300	1.1540366	0.5031791	1.3007857
C1S	0.0295224	-0.8193739	0.1679558	-0.6809404	NA	NA	NA	NA	NA	NA
C2	NA	NA	NA	NA	-2.5581036	2.5640965	-2.5952702	-0.0311737	-0.0371665	2.5269300
C3	-0.7440620	-0.6968585	0.0652375	0.1124410	-1.0730763	1.2388421	-2.1616420	-0.9227999	-1.0885657	0.1502764
C4BPA	-0.1810388	-2.4454980	1.6627662	-0.6016930	-1.2378707	1.5489731	-1.8448914	-0.2959183	-0.6070207	0.9419523
C5	-0.5447843	-0.2031226	0.9230001	1.2646617	-0.7200022	1.2710496	-1.6768797	-0.4058301	-0.9568775	0.3141721
C6	-1.3936214	1.7817023	-1.3097108	1.8656129	-3.0451914	1.7642372	-3.2550019	-1.4907647	-0.2098105	1.5544267
C7	-0.9642124	0.8848082	-0.7827165	1.0663041	0.9970185	0.0708650	-1.1136320	-1.0427670	-2.1106505	-2.0397855
C8A	-0.5117891	0.2736564	-0.7630145	0.0224310	-2.8108340	0.1731241	-2.1285385	-1.9554144	0.6822955	0.8554196
C8B	-2.1950427	0.2789045	-1.5954883	0.7874589	-1.8943958	-0.4802611	-0.9597537	-1.4400148	0.9346421	0.4543810
C8G	NA	NA	-1.6304866	NA	NA	NA	NA	NA	NA	NA
C9	-2.2199059	0.4534093	-1.9249790	0.7483361	-0.7345863	0.6495872	-3.2424254	-2.5928382	-2.5078391	-1.8582519
CD5L	-0.9293248	-0.6204735	-0.7145571	-0.4057058	-2.4642871	0.4482534	-2.3260120	-1.8777586	0.1382751	0.5865285
CFH	-1.1239737	0.7406948	-1.6480885	0.2165801	-1.0358708	0.1380093	-1.3260484	-1.1880391	-0.2901776	-0.1521683
CFI	NA	0.5359696	NA	1.2578110	NA	NA	NA	NA	NA	NA
CLU	-1.1958984	-0.8681850	-0.1721921	0.1555214	-1.3664377	0.8251962	-2.1976184	-1.3724222	-0.8311807	-0.0059845
CP	-0.3892064	0.2565411	-0.4537277	0.1920199	-0.6657547	0.4235353	-0.2695812	0.1539541	0.3961736	0.8197089
F12	0.4852010	-0.9397905	0.6702925	-0.7546990	-0.8534307	0.5549559	-1.3145850	-0.7596291	-0.4611543	0.0938016
F2	-0.7493082	-0.7563593	0.0982877	0.0912367	-0.5408805	1.1677146	-1.5476188	-0.3799042	-1.0067383	0.1609763
FCN3	NA	0.9644778	NA	NA	NA	NA	NA	NA	NA	NA

**Table 2.** OpenMS log<sub>2</sub> fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury respectively. (continued)

gene	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C improvers acute vs subacute	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS A vs D	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D
FGA	-0.9591400	-0.5109050	0.4841704	0.9324054	-1.0155684	1.0486717	-1.4707952	-0.4221236	-0.4552268	0.5934449
FGB	-0.8339088	-0.1253771	0.0684287	0.7769604	-0.8343143	1.0951087	-1.4646547	-0.3695460	-0.6303405	0.4647683
FGG	-1.1432907	-0.0247316	-0.2978078	0.8207513	-0.7191139	0.7606622	-1.0780014	-0.3173392	-0.3588876	0.4017746
FN1	-0.2795610	-0.3153249	0.2899102	0.2541463	-0.5777631	1.1462731	-1.2550759	-0.1088028	-0.6773129	0.4689602
GC	-0.5583474	0.4050629	-0.7950103	0.1684001	-1.8700166	-0.2961353	-1.2641016	-1.5602369	0.6059149	0.3097797
GSN	0.0704855	0.0479440	-0.6709561	-0.6934976	NA	NA	NA	NA	NA	NA
HABP2	NA	NA	NA	NA	-0.5367242	1.4445961	-0.7070902	0.7375059	-0.1703660	1.2742301
HP	-1.2468596	0.5276209	-0.3488061	1.4256744	-0.6393503	0.9683391	-1.2963281	-0.3279890	-0.6569779	0.3113613
HPX	-0.4104644	-0.2880781	-0.7114901	-0.5891038	-0.3597680	0.9360243	-1.1034368	-0.1674125	-0.7436687	0.1923556
HRG	0.5979026	1.0672891	0.0321566	0.5015431	-0.7300739	0.6893699	-0.8231701	-0.1338002	-0.0930962	0.5962737
IGHA1	1.7635882	1.3476620	0.3628909	-0.0530353	-2.0152404	0.4328016	-2.2081140	-1.7753124	-0.1928737	0.2399280
IGHD	NA	NA	NA	NA	-2.4499647	0.4182281	-3.4284738	-3.0102457	-0.9785091	-0.5602810
IGHG1	-0.0855309	0.9292134	-0.4962961	0.5184482	-0.0970233	-1.8091062	0.4814333	-1.3276728	0.5784566	-1.2306496
IGHG2	0.9720422	0.3501681	0.4607992	-0.1610748	-0.6249433	-1.5106734	0.2705475	-1.2401258	0.8954908	-0.6151826
IGHG3	-0.1941508	1.4323226	-0.9309878	0.6954857	-1.8543540	-0.3927284	-1.8870246	-2.2797530	-0.0326705	-0.4253990
IGHM	-0.6318126	-0.8967300	-0.4174693	-0.6823867	-1.1741740	1.7915993	-2.3508710	-0.5592717	-1.1766971	0.6149023
IGKC	-0.0697458	0.0420359	-0.1150304	-0.0032487	-1.1868447	-0.2875492	-1.1765257	-1.4640749	0.0103190	-0.2772302
IGKV3D-20	NA	NA	NA	NA	-0.3699302	-0.0536821	0.2114801	0.1577980	0.5814103	0.5277282
ITIH1	-0.9766570	0.7057133	-0.5211753	1.1611951	-0.6149247	0.5495684	-0.5039432	0.0456252	0.1109815	0.6605499
ITIH2	-0.3142692	-0.5283214	-0.2363320	-0.4503842	-0.7431549	0.6757214	-1.2136587	-0.5379373	-0.4705037	0.2052177
ITIH3	-0.5456033	0.6138901	0.3512683	1.5107617	-2.0564371	1.2902341	-1.8743188	-0.5840847	0.1821183	1.4723525
ITIH4	-0.0669542	-0.2189363	0.3808668	0.2288847	-1.0843698	0.9773070	-1.8198452	-0.8425382	-0.7354753	0.2418317
KLKB1	NA	-2.2093082	NA	-0.2713600	NA	NA	NA	NA	NA	NA
KNG1	-0.6198162	-0.0025326	-0.0676278	0.5496558	-0.6644071	0.8052877	0.0312278	0.8365155	0.6956349	1.5009226
LRG1	-0.7988007	0.2565104	0.1402188	1.1955298	-0.9515964	1.7017682	-2.1951046	-0.4933364	-1.2435082	0.4582600
LUM	0.0832323	0.6580097	-1.2635566	-0.6887792	NA	NA	NA	NA	NA	NA
ORM1	-0.1974770	1.1178187	-0.2240143	1.0912814	-1.9126407	1.6761382	-1.3025982	0.3735400	0.6100425	2.2861806
PGLYRP2	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
PLG	-0.3680073	0.0880557	-0.8410370	-0.3849741	-1.0701631	2.7112467	-2.8493306	-0.1380838	-1.7791675	0.9320793
PROS1	-0.3300860	0.0623958	-0.7963440	-0.4038621	-0.5089636	1.5349629	-3.8745298	-2.3395668	-3.3655662	-1.8306032
RBP4	0.4505693	0.4185795	-0.0211740	-0.0531638	-4.0971240	1.4352287	-2.9877294	-1.5525007	1.1093946	2.5446233
SAA1	-2.7778116	2.3463574	-0.5151865	4.6089825	-1.3858800	2.4855048	-2.5593861	-0.0738814	-1.1735062	1.3119986
SERPINA1	0.6825593	0.0481996	1.7824248	1.1480651	-0.0999129	-0.1558972	-1.3635079	-1.5194051	-1.2635950	-1.4194922
SERPINA3	-0.7582369	-0.1617666	0.1836958	0.7801661	-0.7417534	2.2311097	-2.0353461	0.1957637	-1.2935927	0.9375171
SERPINA4	0.0099121	NA	-1.0180116	NA	-1.4473701	NA	-0.6571525	NA	0.7902176	NA
SERPINA5	NA	NA	NA	0.2757029	NA	NA	NA	NA	NA	NA

**Table 2.** OpenMS log<sub>2</sub> fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury respectively. *(continued)*

gene	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C improvers acute vs subacute	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS A vs D	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D
SERPINC1	-0.5553486	-0.2339361	-0.5421237	-0.2207112	-0.7720265	1.1066666	-1.3464506	-0.2397839	-0.5744241	0.5322425
SERPIND1	0.2536120	NA	0.0459257	NA	0.3050057	2.3844297	-1.6468854	0.7375442	-1.9518911	0.4325386
SERPING1	-1.1614755	0.1191571	-1.3510892	-0.0704566	-0.9301893	1.0766804	-1.0904641	-0.0137837	-0.1602748	0.9164056
TF	-0.2823635	-0.1105094	-0.4843676	-0.3125135	-0.7681926	0.5875721	-0.9945649	-0.4069929	-0.2263723	0.3611997
VTN	-0.6186100	-0.0323770	-0.2690009	0.3172321	-1.7234623	1.4918535	-2.1517604	-0.6599069	-0.4282982	1.0635554
VWF	NA	1.0585752	NA	1.3917877	-2.5662912	0.5161630	-1.9774026	-1.4612396	0.5888885	1.1050516

**Table 3.** ProteinPilot fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury respectively.


Protein	AIS C improvers acute vs subacute	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D	AIS A vs D
A1BG	-1.644372	-1.472312	NA	NA	NA	NA	NA	NA	NA	NA
A2M	-6.137620	-9.908319	NA	1.380384	-5.861382	-3.467369	NA	1.659587	5.861382	3.564511
AFM	NA	2.511886	NA	-4.055085	NA	NA	NA	NA	NA	-3.499452
AHSG	NA	NA	NA	-2.249055	NA	NA	NA	NA	NA	NA
APCS	NA	1.870682	NA	NA	NA	4.207266	1.721869	NA	NA	NA
APOA1	-11.803206	-3.698282	NA	-3.250873	-2.884031	-2.884031	-3.801894	NA	-1.406047	NA
APOA2	-14.321879	NA	NA	-4.965923	NA	NA	NA	NA	NA	NA
APOA4	-11.587774	-5.915616	NA	-2.108628	-2.964831	-1.555966	-2.488857	1.870682	NA	-1.629296
APOB	-2.443430	3.019952	NA	-6.025596	3.732502	-1.282331	1.367729	-4.742420	-2.805434	1.721869
APOC1	NA	NA	NA	-4.528976	NA	NA	NA	NA	NA	NA
APOC4	NA	NA	NA	NA	NA	1.318257	NA	4.920395	NA	-4.528976
APOE	NA	NA	-1.527566	-1.753880	NA	-1.836538	-3.019952	-1.803018	-3.019952	NA
AZGP1	2.269865	2.630268	3.597493	NA	1.819701	4.446313	NA	NA	NA	-4.130475
C1QB	NA	NA	NA	NA	NA	-1.513561	NA	NA	NA	NA
C1R	NA	NA	NA	NA	NA	-4.446313	NA	NA	NA	NA
C3	2.754229	-1.940886	NA	3.981072	-2.398833	-4.365158	1.614359	-1.976970	3.597493	6.546362
C4B	2.269865	-2.147830	-1.940886	2.654606	NA	NA	NA	NA	NA	NA
C4BPA	NA	-1.419058	NA	NA	NA	NA	1.659587	-2.013724	NA	3.250873
C5	1.737801	NA	NA	2.228435	NA	-2.333458	NA	-1.770109	NA	2.167704
C6	1.887991	NA	NA	NA	NA	-2.070141	-2.805434	NA	NA	NA
C9	NA	-2.421029	NA	9.908319	NA	-4.055085	NA	-1.499685	7.177943	9.375620
CD5L	NA	-2.831392	-3.280953	NA	-1.819701	-1.819701	NA	NA	NA	NA
CFB	NA	-1.674943	2.535129	4.285485	NA	-2.128139	2.032357	-1.690441	2.511886	4.055085
CFH	NA	NA	NA	2.558586	NA	NA	NA	NA	2.333458	1.803018
CFI	NA	NA	NA	NA	NA	NA	NA	NA	NA	2.269865
CLU	NA	NA	NA	NA	NA	NA	NA	-2.582260	NA	NA
CP	NA	NA	2.582260	3.019952	NA	NA	2.187762	NA	2.779713	NA
F2	NA	NA	NA	NA	NA	NA	1.674943	NA	NA	1.527566
FGA	3.467369	-1.644372	NA	12.133888	-3.531832	-2.654606	NA	NA	5.199960	4.092606
FGB	3.280953	NA	2.443431	9.204495	-2.187762	-1.330454	2.654606	NA	5.248075	3.133286
FGG	2.032357	-1.958845	NA	9.638290	-2.312065	-1.644372	4.325138	NA	9.204495	6.367955

**Table 3.** ProteinPilot fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury repectively. *(continued)*


Protein	AIS C improvers acute vs subacute	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D	AIS A vs D
FN1	2.582260	2.228435	NA	NA	1.940886	-2.466039	1.472312	-4.875285	NA	3.404082
GC	NA	NA	NA	NA	NA	NA	1.541700	NA	2.606154	2.398833
GSN	-2.312065	NA	NA	-4.055085	-3.019952	NA	-4.365158	NA	NA	NA
HBA1	NA	3.133286	NA	-4.017908	NA	NA	NA	NA	-2.654606	-2.535129
HBB	NA	10.000000	NA	-15.995580	5.058247	2.167704	NA	NA	-6.137620	-2.558586
HP	3.499452	NA	2.511886	13.427649	NA	-2.964831	NA	NA	4.092606	4.786301
HPX	NA	-2.147830	NA	NA	NA	NA	1.995262	NA	2.208005	NA
HRG	NA	NA	NA	NA	NA	3.531832	NA	3.908409	NA	NA
IGHM	NA	-5.152286	-3.664376	NA	-5.199960	-4.655861	NA	NA	3.221069	2.937650
IGKC	NA	NA	NA	NA	NA	1.753880	5.649370	1.786488	5.807644	NA
ITIH1	NA	NA	NA	NA	NA	NA	NA	-3.597493	NA	NA
ITIH2	NA	NA	NA	-1.629296	NA	-2.089296	-2.208005	-2.070141	-2.208005	NA
ITIH3	NA	-2.051162	NA	2.466039	NA	NA	NA	NA	2.108628	2.630268
ITIH4	1.819701	-2.312065	NA	3.104560	-1.836538	-3.104560	NA	-1.737801	2.376840	4.092606
JCHAIN	NA	NA	-4.130475	NA	-5.011872	NA	NA	NA	NA	NA
KNG1	NA	NA	NA	NA	NA	NA	2.754229	NA	NA	NA
LPA	NA	NA	10.764652	14.723126	NA	NA	NA	NA	NA	NA
LRG1	NA	-2.167704	NA	3.047895	-6.367955	-9.727472	NA	-1.629296	NA	3.311311
LUM	-4.405549	NA	NA	-3.250873	NA	NA	NA	NA	NA	NA
ORM1	NA	NA	16.904409	NA	NA	NA	3.630781	NA	NA	2.992265
PLG	1.555966	NA	NA	NA	2.312065	1.870682	2.937650	NA	NA	NA
RBP4	NA	5.495408	NA	NA	NA	NA	NA	NA	NA	NA
SAA1	NA	NA	28.054337	51.522865	NA	NA	NA	NA	NA	NA
SAA4	NA	NA	NA	NA	NA	-2.805434	NA	NA	NA	1.905461
SERPINA1	NA	-2.333458	NA	7.585776	-2.754229	-5.597576	NA	-2.187762	3.221069	7.112135
SERPINA3	2.108628	-1.737801	3.837072	12.705741	-1.976970	-5.915616	NA	-3.250873	4.325138	12.246162
SERPINC1	NA	NA	NA	NA	NA	NA	NA	-2.070141	NA	NA
SERPIND1	1.770109	NA	NA	NA	2.032357	NA	NA	NA	NA	NA
SERPINF1	NA	NA	NA	NA	-4.365158	-5.248075	NA	NA	NA	NA
SERPINF2	NA	NA	NA	NA	NA	-4.207266	NA	-3.467369	NA	NA
SERPING1	NA	-2.535129	NA	2.964831	-1.836538	-4.365158	NA	-2.488857	2.187762	5.248075

**Table 3.** ProteinPilot fold changes in the plasma proteome of SCI patients. 'Acute' and 'Subacute' samples collected within 2 week and approximately 3-months post-injury repectively. *(continued)*

Protein	AIS C improvers acute vs subacute	Acute AIS C improvers vs non-improvers	Subacute AIS C improvers vs non-improvers	AIS C non-improvers acute vs subacute	AIS C improvers vs non-improvers	AIS C improvers vs A	AIS C improvers vs D	AIS C non-improvers vs A	AIS C non-improvers vs D	AIS A vs D
TF	-2.728978	NA	-1.527566	-5.445027	NA	NA	1.721869	NA	NA	NA
TTN	NA	NA	NA	NA	-1.706082	-2.208005	-1.770109	NA	NA	1.258925



**Figure 1.** Venn diagram of the overlap in unique proteins identified from analysis with ProteinPilot and OpenMS respectively on data from 2 4-plex iTRAQ experiments.



**Figure 2.** The number of proteins found to be up- or down-regulated via ProteinPilot and OpenMS.



#### 294 4.1.2 STRINGdb network plots

295 Network interaction plots generated from the OpenMS processed data via STRINGdb revealed that  
296 all test groups contained similar proteins, albeit with different abundances, with no distinct group-  
297 specific networks observed (Figures 3, 4, ??, ??, ??, ??, ??, ?? and ??). Clustering of these networks  
298 produced three groups of differentially expressed proteins in acute AIS C improvers compared  
299 to non-improvers (Figure ??). The first cluster is comprised of proteins from the complement and  
300 coagulation cascade (Figure ?? (a)). The second cluster is comprised of proteins associated with  
301 cholesterol metabolism (Figure ?? (b)). The final cluster is a single protein; ATRN, AKA attractin,  
302 which is implicated in immune cell clustering during inflammatory responses and may regulate  
303 the chemotactic activity of chemokines (Figure ?? (c)).


304 These three clusters are also represented in the subacute AIS C improvers compared to non-  
305 improvers, with an additional fourth small cluster made up of proteins predominately associated  
306 with the complement cascade (Figure ?? (a, b, c)). This pattern of clusters is replicated in all of the  
307 remaining comparison groups (Figures ??, ??, ??, ??, ??, ?? and ??).

308 Please see appendix section ?? for additional plots.

### 4.1.3 Heatmaps


Please see appendix section ?? for additional plots.

proteins: 69  
interactions: 1085  
expected interactions: 50 (p-value: 0)




**Figure 4.** Interaction network of differentially abundant proteins from plasma 3-months post-injury, between AIS C patients who experienced an AIS grade conversion and those who did not. The coloured “halo” denotes fold change whereby green indicates that protein is less abundant and red that there is greater abundance. Edges represent protein-protein associations; these are known interactions from: curated databases and those that are experimentally determined . Predicted interactions from: gene co-occurrence ; gene fusions ; gene neighbourhood . Others are from gene co-expression ; text-mining and protein homology .

### Acute AIS C Improvers VS non-Improvers



**Figure 5.** Heatmap denoting the log<sub>2</sub> fold change of proteins in plasma collected 2-weeks post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.




**Figure 6.** Heatmap denoting the log<sub>2</sub> fold change of proteins in plasma collected 3-months post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.

#### 315 **4.1.4 Cnetplots**

316 Similar to the heatmaps, network plots highlight the majority of proteins are associated with the  
317 complement cascade and pathways linked to platelets (Figure 7, 8, ??, ??, ??, ??, ??, ??, ??, ??). Several  
318 proteins are also associated with the regulation of insulin-like growth factor.


319 Please see appendix section ?? for additional plots.

Acute AIS C Improvers VS non-Improvers



**Figure 7.** Network plot denoting the log<sub>2</sub> fold change of proteins in plasma collected 2-weeks post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.

Subacute AIS C Improvers VS non-Improvers




**Figure 8.** Network plot denoting the log<sub>2</sub> fold change of proteins in plasma collected 3-months post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.




#### 320 **4.1.5 ELISAs**

321 No statistically significant difference between groups for A2M abundance in plasma via Du-  
322 oSet&reg ELISAs, though there were outliers in the AIS A and D groups, and particularly in the AIS  
323 C patients at 3-months who did not experience an AIS grade conversion (Figure 9). A significant  
324 difference was found between AIS C non-improvers at 2-weeks and AIS D for SAA1, with outliers  
325 in AIS C non-improvers at 2-weeks, and both AIS C improvers and non-improvers at 3-months  
326 post-injury (Figure 10). For ApoA1 plasma abundance estimated via Quantikine&reg ELISAs,  
327 statistically significant differences were found between AIS C improvers at 2-weeks and both AIS C  
328 improvers and non-improvers at 3-months, AIS C 3-month improvers and AIS A and D, and AIS C  
329 3-month non-improvers and AIS A and D (Figure 11). A statistically significant difference was also  
330 found between AIS C improvers and non-improvers at 2-weeks post-injury for RBP4 (Figure 12).




**Figure 9.** Normalised estimated concentration of  $\alpha$ -2-macroglobulin. Estimates were calculated from the optical density of a standard curve produced via a DuoSet<sup>®</sup> ELISA. Plasma from each patient that made up the pooled iTRAQ samples was assayed and pairwise t-tests with bonferroni adjusted P-values were preformed to assess differential abundance.


331 **4.1.5.1 example of a plot grid** There's good documentation for using `cowplot` that can be found  
 332 here Here's an example using the elisa plots  
 333 Alternative with `patchwork`, docs here Could be improved by cleaning up the x axis, either reduce  
 334 font size or rotate labels 45 or 90 degrees




**Figure 10.** Normalised estimated concentration of serum amyloid A1. Estimates were calculated from the optical density of a standard curve produced via a DuoSet&reg ELISA. Plasma from each patient that made up the pooled iTRAQ samples was assayed and pairwise t-tests with bonferroni adjusted P-values were preformed to assess differential abundance.



**Figure 11.** Normalised estimated concentration of apolipoprotein A1. Estimates were calculated from the optical density of a standard curve produced via a Quantikine&reg ELISA. Plasma from each patient that made up the pooled iTRAQ samples was assayed and pairwise t-tests with bonferroni adjusted P-values were preformed to assess differential abundance.




**Figure 12.** Normalised estimated concentration of retinol binding protein 4. Estimates were calculated from the optical density of a standard curve produced via a DuoSet&reg ELISA. Plasma from each patient that made up the pooled iTRAQ samples was assayed and pairwise t-tests with bonferroni adjusted P-values were preformed to assess differential abundance.




335

336 Maybe better in this orientation



**Figure 13.** Normalised estimated concentration of retinol binding protein 4. Estimates were calculated from the optical density of a standard curve produced via a DuoSet<sup>®</sup> ELISA. Plasma from each patient that made up the pooled iTRAQ samples was assayed and pairwise t-tests with bonferroni adjusted P-values were performed to assess differential abundance.





## 343 **4.2 Label-free results**

344 In the interest of brevity, only the plots of acute and subacute AIS C improvers VS non-improvers  
345 are included here, please see the appendix for the other comparisons (section ??).


346 The data processed by MSstats was filtered to proteins with a adjusted P-value of  $< 0.05$  and a  $\log_2$   
347 FC of  $> 1.2$ . The total number of significant proteins is `nrow(foldchange_df)`.

### 348 **4.2.1 Volcano plots**

349 The mean number of down-regulated and up-regulated significant proteins in each group is  
350 10.5714286, and 6.7857143. Between AIS C improvers and non-improvers, 8 and 4 proteins  
351 were up- and down-regulated acutely, whereas 6 and 6 were up- and down-regulated subacutely  
352 (Figures 15 and 16). Longitudinally, AIS C acute improvers had 10 up-regulated and 7 down-  
353 regulated proteins relative to subacute improvers, while for non-improvers 6 and 12 were up- and  
354 down-regulated respectively (Figures ?? and ??).

355 Please see appendix section ?? for additional plots.





**Figure 15.** Volcano plot of  $\log_{10}$  fold change and  $\log_{10}$  adjusted p-value for plasma proteins from 2-weeks post-injury between AIS C patients who experienced an AIS grade conversion and those who did not. Proteins with a fold changes beyond 1.2 and an adjusted p-value less than 0.05 are labelled.

#### 356 4.2.2 STRINGdb network plots


357 Network interaction plots generated of the significant proteins via STRINGdb revealed that all groups  
 358 contained similarly smaller networks, with many proteins with no know interactions in the STRING  
 359 database (Figures 17, 18, ??, ??, ??, ??, ??, ??, ??).

360 Clustering of these plots furhter highlights the smaller groups of interacting proteins, many of  
 361 which are linear networks of proteins interacting in a chain (Figures ??, ??, ??, ??, ??, ??, ??, ??, ??).  
 362 Please note that only clusters containing more than one protein are shown.

363 Please see appendix section ?? for additional plots.


#### 364 4.2.3 Heatmaps

365 Similarly to the iTRAQ data (4.1.3), many of the Reactome pathways are associated with the com-  
 366 plement cascade, platelets and clotting (Figures 19, 20, ??, ??, ??, ??, ??, ??, ??).




**Figure 16.** Volcano plot of  $\log_{10}$  fold change and  $\log_{10}$  adjusted p-value for plasma proteins from 3-months post-injury between AIS C patients who experienced an AIS grade conversion and those who did not. Proteins with a fold changes beyond 1.2 and an adjusted p-value less than 0.05 are labelled.

proteins: 9  
interactions: 2  
expected interactions: 1 (p-value: 0.141)



**Figure 17.** The interaction network of differentially abundant proteins found in plasma 2-weeks post-injury, between AIS C patients who experienced an AIS grade conversion and those who did not. The coloured “halo” denotes fold change whereby green indicates that protein is less abundant and red indicates greater abundance. Edges represent protein-protein associations; these are known interactions from: curated databases and those that are experimentally determined . Predicted interactions from: gene co-occurrence ; gene fusions ; gene neighbourhood . Others are from gene co-expression ; text-mining and protein homology .


proteins: 10  
interactions: 3  
expected interactions: 1 (p-value: 0.024)




**Figure 18.** Interaction network of differentially abundant proteins from plasma 3-months post-injury, between AIS C patients who experienced an AIS grade conversion and those who did not. The coloured “halo” denotes fold change whereby green indicates that protein is less abundant and red that there is greater abundance. Edges represent protein-protein associations; these are known interactions from: curated databases and those that are experimentally determined . Predicted interactions from: gene co-occurrence ; gene fusions ; gene neighbourhood . Others are from gene co-expression ; text-mining and protein homology .

<sup>367</sup> Please see appendix section ?? for additional plots.

### Acute C Improvers Vs Acute C Non-Improvers



**Figure 19.** Heatmap denoting the log<sub>2</sub> fold change of proteins in plasma collected 2-weeks post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not. Grey blocks denote proteins not present in the comparison.




**Figure 20.** Heatmap denoting the log<sub>2</sub> fold change of proteins in plasma collected 3-months post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not. Grey blocks denote proteins not present in the comparison.

#### 368 **4.2.4 Cnetplots**

369 Similarly to the heatmaps and the iTRAQ data (4.1.4), network plots highlight the majority of pro-  
370 teins are associated with the complement cascade and pathways linked to platelets (Figures 21,  
371 22, ??, ??, ??, ??, ??, ??, ??).


372 Please see appendix section ?? for additional plots.





**Figure 21.** Network plot denoting the  $\log_2$  fold change of proteins in plasma collected 2-weeks post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.


Subacute C Improvers Vs Subacute C Non-Improvers



**Figure 22.** Network plot denoting the log<sub>2</sub> fold change of proteins in plasma collected 3-months post-injury, and the biological pathways these proteins are associated with on Reactome. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.

### 373 4.2.5 Pathway analysis


As with the iTRAQ data (section 4.1.6), pathway analysis via the *pathview* R package returned the complement and coagulation cascade to be on the sole significant KEGG pathway. The majority of the proteins present in this pathway were less abundant in the 2-week post-injury plasma of AIS C patients who experienced an AIS grade conversion and those who did not, much the same as the iTRAQ data (Figure 23 and section 4.1.6).



**Figure 23.** KEGG complement cascade pathway annotated with  $\log_2$  fold change of proteins in plasma collected 2-weeks post-injury. This compares AIS C SCI patients who experienced an AIS grade improvement and those who did not.

#### 379 4.2.6 Comparing iTRAQ and label-free proteins

380 A total of 87 and 79 unique proteins were identified across the label-free and iTRAQ experiments  
381 respectively, with modest overlap in those identified (Figure 24).



**Figure 24.** Venn diagram of the overlap in unique proteins identified from iTRAQ and label-free proteomic experiments analysed via OpenMS.

## 382 5 Discussion

### 383 5.1 thesis iTRAQ discussion

384 This work builds on the previous chapters (??) modelling of routine bloods by analysing the plasma  
385 proteome of SCI patients grouped by injury severity and improver status. In addition to continuing  
386 the pursuit of novel biomarkers of SCI, the link between the liver and neurological recovery hinted  
387 at in the aforementioned chapter is examined here.

#### 388 5.1.1 ProteinPilot and OpenMS

389 Mass spectrometry is a major technique used in several fields, including metabolomics, lipidomics,  
390 interactomics and proteomics, each of which demands a variety of differing approaches to data  
391 acquisition and analysis. Multiple separation methods (liquid chromatography, gas chromatog-  
392 raphy), fragmentation methods (electron-capture dissociation, electron-transfer dissociation,  
393 collision-induced dissociation, etc.) and acquisition strategies (targeted, data-dependent and  
394 data-independent) are used in any combination. With quantification there are different label-  
395 free, isotopic or isobaric labelling approaches to employ. Finally the data analysis may require  
396 a database search, as in proteomics and metabolomics, spectral library search or a targeted  
397 analysis, depending on the experiment. This complexity necessitates a multi-interdependent-step  
398 workflow tailored to the given experiment.

399 The manufacturers of mass spectrometers often offer software tailored to their instruments which  
400 is often used in the literature. However, the source code for these software suits is not pub-  
401 licly available, and indeed manufactures often boast of their particular inscrutable proprietary  
402 algorithms, often related to peak picking. This combination of completixy and opacity in analy-  
403 sis methodolotgy can make it extremely difficult to reproduce results from other labs, or even  
404 analysis from one's own lab.("Devil in the Details" 2011)

405 To address this issue many open-source (meaning the source code is publicly available) software  
406 packages which may perform one or several steps of a complex analysis workflow have been devel-  
407 oped. This issue here is that incorporating multiple software packages together can be both time-  
408 consuming and error-prone, and require significant maintenance and documentation to maintain  
409 reproducibility.

410 The OpenMS project aims to address these challenges by providing a flexible software environ-  
411 ment, with both pre-assembled workflows that aim to provide best-practices, and allow for more  
412 granular control with both command line and Python scripting interfaces. OpenMS is also inte-  
413 grated with graphical workflow systems such as KNIME and Galaxy, increasing the accessibility of  
414 the platform.(Berthold et al. 2009; Goecks et al. 2010)

415 Here we used both the vendor provided proprietary ProteinPilot and OpenMS to analysis two 4-  
416 plex iTRAQ experiments. We observe that both approaches produce similar results, with a similar  
417 number of total proteins identified, a large degree of overlap in the specific proteins identified, and  
418 similar fold changes (Figures 1 and 2). As the results are similar we choose to focus on the OpenMS  
419 results due to aforementioned superior reproducibility.

#### 420 5.1.2 Proteins identified

421 A total of 79 proteins were identified across both runs for OpenMS, many of which are related in  
422 function. (Figure 1). Here we explore the potential these proteins have a biomarkers of SCI.

423 **5.1.2.1 Alpha-2-macroglobulin** A2M is an inhibitor of an unusually diverse array of proteinases  
424 by a unique 'trapping' mechanism. The protein achieves this with a peptide stretch, called the

425 “bait region”, which contains specific cleavage sites for different proteinases. When a proteinase  
426 cleaves the bait region, a conformational change is induced whereby A2M traps the proteinase.  
427 The entrapped enzyme retains active against low molecular weight substrates, whereas activity  
428 against high molecular weight substrates is greatly reduced. Following cleavage in the bait region, a  
429 thioester bond is hydrolysed and mediates the covalent binding of the protein to the proteinase.(P.  
430 K. Hall et al. 1981; Sottrup-Jensen et al. 1984) A2M is unique in it’s ability to inhibit virtually any  
431 protease regardless of it’s specificity, origin or catalytic mechanism.(Khan 2004; Lin et al. 2012)

432 Alpha macroglobulins are an integral part of innate immunity and thus are evolutionarily con-  
433 served.(Buresova et al. 2009) Alpha macroglobulins have significant primary sequence homology  
434 with complement components C3, C4 and C5. The A2M-proteinase complex is cleared from circu-  
435 lation primarily by receptors on hepatocytes.(Bond, Cianciolo, and Pizzo 2007; Travis and Salvesen  
436 1983) The mammalian receptor for proteinase-reacted A2M is a low-density lipoprotein receptor  
437 related protein.(Fujiyoshi et al. 2011; Larios and Marzolo 2012; Wyatt and Wilson 2013)

438 A2Ms definitive function is the delivery of proteinase to an endocytotic proteinase clearance path-  
439 way. A2Ms trap the proteinases released by granulocytes and other cells during inflammation and  
440 also regulate the extracellular proteolytic activity resulting from clotting and fibrinolysis. A2M can  
441 also help protect against pathogens as it can trap proteinases from non-human origins as well.  
442 A2M can be recognised and phagocytosed by macrophages and hepatocytes, and it has been pro-  
443 posed to aid in the clearance of defensins and other peptide mediators in inflamed tissues, thus  
444 contributing to the regulation and containment of inflammation.(Rehman, Ahsan, and Khan 2013)

445 Myelin basic protein is released into the circulation following traumatic injury and A2M has been  
446 seen to be the only major myelin basic protein-binding protein in human plasma, suggesting A2M  
447 protects the immunogenic protein from degradation by proteases and help in its clearance from  
448 circulation.(Gunnarsson and Jensen 1998) A study looking at male infertility after SCI with pro-  
449 teomics found A2M to be elevated approximately 3-fold in the sperm plasma of SCI patients relative  
450 to normal controls.(Silva et al. 2016)

451 We observe A2M to be less abundant in AIS C improvers, within 2-weeks post injury and at 3-  
452 months, albeit to a lesser extent (Tables 2 and 3). Similarly, A2M was more abundant in AIS As  
453 relative to all groups, and whilst A2M was less abundant in AIS C improvers at 2-weeks compared  
454 to AIS Ds, AIS C non-improvers had more A2M than AIS Ds. (Table 2). With less A2M there would  
455 be more protease activity in these individuals, which may aid in the clearance of damaged tissue,  
456 and in particular may lessen the development of an astroglial scar, thus aiding repair. However,  
457 glial scarring is not entirely negative, the primary benefit it offerers is minimising the extent of sec-  
458 ondary damage to neighbouring areas by functioning as a barrier around the injury site. Animal  
459 studies have demonstrated that prevention of astroglial scar formation following CNS injury leads  
460 to greater lesion size and poorer function outcomes.(Anderson et al. 2016; Wilhelmsson et al.  
461 2006) Interestingly, a rat study using quantitative liquid chromatography-mass spectrometry with  
462 CSF, found A2M to be more abundant in moderately injured animals compared to more severe  
463 injuries.(Lubieniecka et al. 2011)

464 **5.1.2.2 Apolipoproteins** We found ApoA1, ApoA2, ApoH, ApoL1 and ApoM to be less abundant  
465 in AIC improvers at both time points, whereas ApoA4 was more abundant at both time points (Ta-  
466 bles 2 and 3). ApoA1 is the main protein component of high-density lipoproteins (HDL). Plasma  
467 HDL include two main apolipoproteins, these being ApoA1 and ApoA2 (~70% and ~20% of total  
468 HDL protein content respectively), but some HDL particles can also contain small amounts of other  
469 apolipoproteins, including ApoA4, ApoA5, ApoC, ApoD, ApoE, ApoJ and ApoL. The primary function  
470 of HDL in plasma is the transport of cholesterol, which can have dietary origins, but also be pro-  
471 duced endogenously in the liver.

472 **5.1.2.2.1 HDL Activity** HDLs have serve a wide range of functions, including contributing to  
473 anti-inflammatory activity. They can limit chemokine secretion from multiple cells types including  
474 endothelial cells and monocytes.(Cockerill Gillian W. et al. 1995; Vorst et al. 2013; Bursill Christina  
475 A. et al. 2010) Rats injected with ApoA1 showed significant reduction in expression of CCR2 and  
476 CX<sub>3</sub>CR1, the receptors for chemokines of the same name, which play a role in leukocyte migration.  
477 (Bursill Christina A. et al. 2010)

478 HDL is also associated with protection from oxidative damage, also inhibiting the potentially  
479 atherogenic oxidised LDL formation.(Anatol, Sandrine, and John 2003) The exact mechanisms of  
480 these antioxidant effect is still actively researched, the enzyme paraoxonase-1, which is present on  
481 HDL particles are likely important.(Mackness, Durrington, and Mackness 2004) Apolipoproteins,  
482 including ApoA4 and ApoAE also have antioxidant properties, for example phospholipid hydroper-  
483 oxidase can be reduced by methionine residues of ApoA1, forming redox-inactive phospholipid  
484 hydroxides.(Christison, Rye, and Stocker 1995; Zerrad-Saadi Amal et al. 2009)

485 HDLs can also suppress proliferation of haematopoietic stem cells, thus reducing leucocytosis and  
486 monocytosis.(Yvan-Charvet et al. 2010) Furthermore, HDLs are implicated in the transport of mi-  
487 croRNAs, though the mechanisms of loading the microRNAs and their biological significance is still  
488 under study.(Vickers et al. 2011)

489 ApoE was less abundant in AIS C improvers within 2-weeks and more abundant at 3-months, and  
490 more abundant in more severe injury, such as AIS A relative to D or C and in AIS C relative to D  
491 (Table 2). ApoE is primarily produced by hepatocytes in the liver, but second-most in the brain,  
492 synthesised in and secreted by astrocytes, and has been found to an important determinant in  
493 response to types of CNS injuries in both animal and human studies.(Teasdale et al. 1997; Poirier  
494 1994) A key function of ApoE is as a ligand for the LDL receptor family of proteins, which mediate  
495 trafficking of cholesterol to neurons, which is vital for axonal growth, and for synapse formation  
496 and remodelling.(Xu, Finkelstein, and Adlard 2014) Additionally, ApoE is implicated in the clearance  
497 of neuronal apoptotic bodies.(Elliott et al. 2007) In humans there are three variants/alleles of ApoE:  
498 ApoE2, ApoE3 and ApoE4, which have a frequency of 8.4%, 77.9% and 13.7% globally.(C.-C. Liu et  
499 al. 2013) The variant proteins differ by one or two amino acids and have been found to result in  
500 substantial physiological alterations.(Mahley and Rall 2000; Jha et al. 2008) The presence of the  
501 ApoE4 variant has been linked to worse outcomes in SCI and TBI.(Jha et al. 2008; C. Sun et al. 2011;  
502 Smith et al. 2006; Friedman et al. 1999) More specifically, the SCI study reported significantly lower  
503 change in the median AIS motor score compared the individuals without the ApoE4 allele during  
504 rehabilitation.(Jha et al. 2008)

505 Prior *in vivo* rodent studies have demonstrated up-regulation of ApoE following SCI and TBI, though  
506 ApoE is not observed in neurons of rodents under normal neuropathology, and they only posses  
507 a single ApoE allele.(Iwata et al. 2005; Seitz et al. 2003; Mahley, Weisgraber, and Huang 2006) A  
508 separate rodent study reported ApoE levels decreased for the first 3 days post-injury, and then in-  
509 creased peak expression at 7 days post-injury, a similar pattern to our results.(X. Yang et al. 2018)  
510 Furthermore, mouse studies have demonstrated replacement of ApoE in neurons with human  
511 ApoE4 have impaired neurite outgrowth compared to replacement with ApoE2 or ApoE3, suggest-  
512 ing ApoE4 interferes with neuroplasticity.(Seitz et al. 2003; White et al. 2001) The underlying mech-  
513 anism/s by which ApoE and its alleles effect neuroplasticity is not currently known, but proposals  
514 have been made. One possibility is reduced lipid transport from astrocytes to neurons, poten-  
515 tially impeding the membrane generation required to support axon growth or dendrite sprouting.  
516 ApoE has anti-oxidant properties, so others have suggested impaired anti-oxidant activity may con-  
517 tribute. ApoE4 has been found to be both secreted less than ApoE2 or ApoE3, and to have inferior  
518 anti-oxidant abilities, lending some credence to this idea.(Mishra and Brinton 2018; Miyata and  
519 Smith 1996) Knowing this, whilst ApoE may make for a useful biomarker for SCI, it will be impor-  
520 tant that particular variants of ApoE a given patient has could be just as important, if not more so,

521 than simple abundance.

522 **5.1.2.3 Serum Amyloid A1** SAA1 was less abundant in AIS C improvers at 2-weeks relative to  
523 non-improvers, but more abundance in plasma at 3-months (Table 2. SAA1 was also more abun-  
524 dant in AIS A relative to less severe injuries, and in AIS Cs relative to Ds (Table 2. SAA1 is a major  
525 acute-phase protein mainly produced in the liver by hepatocytes in response to infection, tissue  
526 injury and malignancy.(L. Sun and Ye 2016) SAA1 is a precursor of amyloid A (AA), the aberrant  
527 deposition of which leads to inflammatory amyloidosis.(Tape et al. 1988) There are 5 known SAA1  
528 variants, though currently, no indication of substantial functional differences have been identi-  
529 fied.(J. Lu et al. 2014) However, some alleles have been linked to disease, including increased amy-  
530 loidogenesis and tumour suppression.[van der Hilst et al. (2008); lung\_saa1\_2015]

531 During the APR, plasma levels of SAA increase up to 1000-fold, and so serves as a well-established  
532 clinical biomarker for inflammatory disorders.(Gabay and Kushner 1999) SAA isoforms produced  
533 by hepatocytes during an APR are swiftly released into the blood where they associate with HDL,  
534 displacing ApoA1 and becoming an apolipoprotein of HDL.(Banka et al. 1995; Benditt and Erik-  
535 sen 1977) Reverse cholesterol transport, whereby cholesterol in non-hepatic tissues is transported  
536 back to the liver, is conducted via plasma components such as HDL, ABCA1 and ABCG1. ApoA1 acts  
537 as an acceptor for cholesterol in this process, and studies have found that SAA in lipid-free form  
538 can similarly function as a cholesterol acceptor for ABCA1. Whilst SAA is thought to be an important  
539 facet of lipid metabolism, its role is likely complex as mice knockout studies which eliminate SAA1  
540 and SAA1 have shown little effect on cholesterol transport, HDL levels and ApoA1 clearance.(de  
541 Beer et al. 2010, 2011) These studies indicate that the *in vivo* functions of SAA related to lipid  
542 metabolism are more complex than prior *in vitro* studies implied.

543 SAA1 can both induce anti-inflammatory interleukin 10 (IL-10)-secreting neutrophils, but also pro-  
544 motes the interaction of invariant natural killer T cells with those neutrophils, which limits their  
545 suppressive activity by diminishing the production of IL-10 and enhancing the production of IL-12,  
546 indicating that SAA1 can have both pro- and anti-inflammatory effects.(Santo et al. 2010) There has  
547 however been conflicting results reported of SAAs cytokine induction abilities, and some studies  
548 have suggested that recombinant human SAA1 provided by some vendors may have additional  
549 cytokine-inducing activity due to the altered amino acid sequence.(M.-H. Kim et al. 2013)

550 Macrophages are a major source of SAA in inflammatory tissues, and elevated SAA production has  
551 been observed in rheumatoid arthritis, Crohn's disease, Type 2 diabetes and atherosclerosis.(Marzi  
552 et al. 2013; Dong et al. 2011; Vallon et al. 2001; C, F, and B 1997; Meek, Urieli-Shoval, and Benditt  
553 1994) SAA binding to HDL was reported to increase affinity for macrophages whilst decreasing  
554 affinity for hepatocytes.(R. Kisilevsky and Subrahmanyam 1992) This change is thought to favour  
555 the removal of cholesterol from site of inflammation.(R. Kisilevsky 1991) SAA inhibits the binding of  
556 the scavenger receptor SR-BI and cholesterol efflux is enhanced in a SR-BI-dependent manner.(Cai  
557 et al. 2005; van der Westhuyzen et al. 2005) It has been suggested that the SR-BI-mediated re-  
558 uptake of cholesterol underpins the role of SAA in cholesterol recycling during tissue repair, where  
559 a great deal of cholesterol is required.(Robert Kisilevsky and Manley 2012)

560 In blood circulation SAA1 may also function as an immune opsonin for increased neutrophil up-  
561 take of Gram-negative bacteria.(Shah, Hari-Dass, and Raynes 2006) Both human and mouse SAA  
562 proteins have been found to bind retinol with nanomolar affinity that limits bacterial burden in  
563 tissues after acute infection.(Derebe et al. 2014) Retinol is important to the body's response to mi-  
564 crobial infection, so SAA may also have a role in limiting bacterial burden, particularly in the liver,  
565 spleen and intestine. The aforementioned study demonstrated that mice lacking in both SAA1 and  
566 SAA2 have a higher bacterial burden in the liver and spleen following infection.(Derebe et al. 2014)  
567 All 3 SAA isoforms are found in intestinal epithelium, which is exposed to the gut microbiome, in



mice. The anti-bacterial properties of SAA isoforms may therefore explain the role of SAA as an acute-phase protein that protects the host in tissues and organs exposed to bacteria.

**5.1.2.4 Retinol-binding protein 4 (RBP4)** In plasma within 2-weeks post-injury, RBP4 was less abundant in AIS C improvers relative to AIS D and A, and more abundant in AIS C non-improvers again, relative to AIS D and A (Table 2. Similarly, AIS A plasma had more RBP4 compared to AIS D, and AIS C improvers were also more abundant in RBP4 compared to non-improvers at both 2-weeks and 3-months post-injury (Table 2.

Vitamin A is a collective term for a group of fat-soluble compounds with a range of essential biological activities including aspects of growth, vision and metabolism.(Blomhoff and Blomhoff 2006) Following dietary absorption, vitamin A is ferried from the intestine, with chylomicrons as retinyl esters, to tissues for immediate use or the liver for storage in hepatic stellate cells. A subsequent dietary deficiency of vitamin A will result in these liver stores being mobilised by hydrolysing the retinyl esters to release retinol. The retinol is then bound by RBP4, which is also mainly synthesised in the liver, and secreted into circulation from hepatocytes, whereupon it is bound by an additional transport protein, transthyretin.(P. A. Peterson 1971) The membrane plasma protein STRA6 facilitates retinol transport from RBPs across the cell membrane.(Berry et al. 2012) Once delivered to target cells, retinol can either be converted to retinaldehyde, which is required for functional vision, or oxidised to retinoic acid, which is a ligand for nuclear receptors, thus regulating gene expression.(Lane and Bailey 2005; J. E. Balmer and Blomhoff 2002)

RBPs are localised in the ventral region, associated with motor neurons, in the mammalian developing neural tube.(Pierani et al. 1999; Maden, Ong, and Chytil 1990) The role of retinoid signalling in spinal cord and motor neuron differentiation, including development of regions of the spinal cord has been outlined, and implies a possible involvement in maintaining motor neuron integrity.(Colbert et al. 1995; Sockanathan and Jessell 1998)

The mRNA of a rodent homologue of RBP, named cytosolic retinol binding protein, was found to be up-regulated at 24 hours post-SCI and may promote cell proliferation and regeneration by increasing retinoid metabolism.(Song et al. 2001; Hurst et al. 1999) Another study of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease, comparing gene expression between post-mortem spinal cord samples of ALS and controls also observed up-regulation of RBP1 in ALS spinal cord.(Malaspina, Kaushik, and Belleruche 2001) Furthermore, a transgenic mouse study reported retinoid signalling may contribute to the retained plasticity and regenerative potential of the mature spinal cord.(Haskell et al. 2002)

The results found here support these findings for AIS C improvers relative to non-improvers as improver had increased levels of RBP4. Whether this is due to increased expression or due to higher vitamin A intake is unclear from this data, though at 3-months post-injury this is still that case even though patients diets could be more similar throughout hospital admission.

### 5.1.3 Metabolism and SCI

**5.1.3.1 Acute phase response** The bodies first response to injury or infections, including SCI, is often referred to as the “acute phase response” (APR), which is non-specific, innate reaction that precedes more specific and situational immune reactions.(Gordon and Koj 1985; Gruys et al. 2005) This systemic response is largely coordinated by factors released from the liver, but the APRs effects extend to multiple peripheral organs including the kidneys, lungs and spleen.(Bao et al. 2012; S. J. Campbell, Zahid, et al. 2008; Fleming et al. 2012; Gris, Hamilton, and Weaver 2008) This hepatic response is typically transient and quickly fades, but prolonged liver inflammation and pathology has been observed in rodent SCI models.(Goodus et al. 2018; Sauerbeck et al. 2014)



613 Basic liver functions are chronically impaired by SCI, including metabolising carbohydrates, fats  
614 and proteins, storage of minerals vitamins and glycogen and filtering blood from the digestive  
615 tract.(García-López et al. 2007; DeLeve 2007; Farkas and Gater 2018; Chow et al. 2012; Sauerbeck  
616 et al. 2014) This is likely related to the elevated incidence of metabolic disease in the SCI cohort,  
617 including insulin resistance, impaired glucose tolerance and cardiovascular disease.(Bauman and  
618 Spungen 2001; Maruyama et al. 2008; Lee et al. 2004; J. Myers, Lee, and Kiratli 2007) Long-term  
619 survival is noticeably lower relative to the general population and, whilst mortality in the first 2  
620 year following SCI has decreased in recent decades, long-term survival has not.(Strauss et al. 2006;  
621 Shavelle et al. 2015) More recently, a longitudinal study found SCI patients had a significantly higher  
622 incidence of acute pancreatitis relative to a matched healthy cohort.(Ho, Yeh, and Pan 2021)

623 The acute (1-7 days) liver response to SCI is well documented; the inflammatory cytokines in-  
624 cluding  $\text{TNF}\alpha$ ,  $\text{IL-1}\alpha$ ,  $\text{IL-1}\beta$  and IL-6, released at the injury site, reach the liver through the blood-  
625 stream.(Fleming et al. 2012; Hundt et al. 2011) This provokes the liver to enter the APR and pro-  
626 duce acute phase proteins (APPs) thus stimulating a greater immune response.(Anthony and Couch  
627 2014; Fleming et al. 2012) The hepatocytes that make up the majority of the liver biomass, express  
628 receptors that bind the aforementioned inflammatory cytokines; similarly the hepatic macrophage  
629 Kupffer cells also bind these cytokines, complement proteins and lipopolysaccharide (LPS) and  
630 swiftly remove microorganisms, endotoxins and other debris from the blood.(C.-Y. Yang et al. 2013;  
631 Szalai et al. 2000; Crispe 2016; S. J. Campbell et al. 2005) Hepatic stellate cells act as sensors of  
632 tissue integrity by exposure to signals of oxidative stress, danger/pathogen associated molecu-  
633 lar patterns (DAMPs/PAMPs), chemokines/cytokines and factors secreted from neighbour hepatic  
634 cells, and can stimulate innate immunity by releasing cytokines and as antigen presenting cells  
635 during the APR. (Weiskirchen and Tacke 2014; Fujita and Narumiya 2016)

636 SCI studies in rodent and canine models have found the APPs serum amyloid (SA) A, SAP, CRP, fib-  
637 rinogen, haptoglobin and  $\alpha_1$ -antichymotrypsin are elevated 4-24 hours post-injury in blood.(Pepys  
638 and Baltz 1983; Gabay and Kushner 1999; J. C. E. Hall et al. 2012; Steel and Whitehead 1994) In ro-  
639 dents, hepatic CD68 mRNA is observed to be elevated within 24 hours post-SCI and CD68+ Kupffer  
640 cell numbers increase during the first 7 days post-SCI.(Sauerbeck et al. 2014)

641 Furthermore, it has been suggested that liver inflammation and Kupffer cells activity promote re-  
642 cruitment of leukocytes to the injury site in brain or spinal trauma, potentially enhancing CNS in-  
643 jury.(Anthony and Couch 2014; S. J. Campbell et al. 2005) For example, a rodent study demon-  
644 strated depletion of Kupffer cells prior to injury resulted in few neutrophils infiltrating the injury  
645 site.(S. J. Campbell, Zahid, et al. 2008; S. J. Campbell, Anthony, et al. 2008)

#### 646 **5.1.4 Microbiome & SCI**

647 Circulating factors from the injury site are not the only potential driver of hepatic inflammation.  
648 Within 24 hours post-SCI in rodents tight junctions between epithelial cells become more perme-  
649 able, thus allowing gut bacteria and the endotoxins they can produce to enter the bloodstream.(J.  
650 Liu et al. 2004) This will reach the liver through the portal vein where Kupffer cells function as a  
651 “first line of defence”.(Jenne and Kubes 2013; M. L. Balmer et al. 2014) It has been proposed that  
652 elevated LPS+ endotoxins caused by the post-SCI “leaky gut” causes acute liver inflammation by  
653 overloading hepatic filtrations capacity, allowing microbes to bypass the liver and elicit systemic  
654 inflammation.(J. Liu et al. 2004; O'Connor et al. 2018) The binding of LPS to Kupffer cells results  
655 in the production of a range of growth factors, including  $\text{TNF-}\alpha$ , multiple interleukins and reactive  
656 oxygen species (ROS), stimulating bone-marrow-derived monocytes and neutrophils to infiltrate  
657 the liver.(S. A. Myers et al. 2019; Milosevic et al. 2019; Kazankov et al. 2019) A rodent study found  
658 transcription factors for tight junctions down-regulated following SCI, and that application of pro-  
659 biotics improved neurological outcomes.(Kigerl, Mostacada, and Popovich 2018; Kigerl et al. 2016)

Human studies of the microbiome post-SCI have also demonstrated dysbiosis, both chronically and more acutely post-injury.(Zhang et al. 2018; Gungor et al. 2016; Bazzocchi et al. 2021)

### 5.1.5 Drivers of liver steatosis

Steatosis, the abnormal retention of lipids within cells or organs, most commonly associated with the liver, has been observed to increase in rodents during the first week post-injury.(Sauerbeck et al. 2014) The liver takes up circulating fatty acids, and when levels exceed the oxidative and secretory limits of the liver, hepatocytes store the excess as triglycerides.(Diraison and Beylot 1998) Adipose tissue lipolysis during elevated sympathetic activity leading to spikes in circulating fatty acids has been reported in human subjects following SCI.(Karlssohn 1999)

*De novo* lipogenesis occurring within the liver can also drive hepatic steatosis.(Lavoie and Gauthier 2006) Ceramides are lipid signalling molecules and regulators of apoptosis and inflammation; they can contribute to insulin resistance, oxidative stress and inflammation-induce liver adiposity through sustained Toll-like-receptor(TLR)-4 activation.(Schilling et al. 2013; Bhargava and Lee 2012; Pagadala et al. 2012) If released into the circulatory system, ceramides can cause CNS toxicity, including oxidative damage and changes to the aggregation of proteins associated with diseases such as Parkinson's, Huntington's and Alzheimer's.(Pagadala et al. 2012; Vidaurre et al. 2014; Czubowicz et al. 2019) Mature and precursors of hepatic ceramides and enzymes which contribute to ceramide synthesis are elevated by 1 day post-injury.(Sauerbeck et al. 2014) Endotoxins can also stimulated the synthesis of ceramides and so the aforementioned "leaky gut" may also contribute to this elevation.(Chang et al. 2011) Ceramide synthesis and lipogenesis genes are also stimulated by TNF- $\alpha$ , which, as touched on in the general introduction (??), has been found to be elevated post-SCI, and associated with differential neurological recovery.(Davies, Hayes, and Dekaban 2007; Hasturk et al. 2009; Biglari et al. 2015; Sauerbeck et al. 2014; Bikman 2012)

### 5.1.6 Chronic liver inflammation in SCI

The hepatic APR and associated inflammation that typically follows bodily trauma, subsequently rapidly subsides, whereas post-SCI this hepatic inflammation persists chronically. This chronic phase may be due in part to long-term changes in intestinal permeability via fewer tight junctions in intestinal epithelial cells, resulting in gut dysbiosis.(Milosevic et al. 2019; O'Connor et al. 2018; Kigerl, Mostacada, and Popovich 2018; Kigerl et al. 2016) Bacterial translocation and gut dysbiosis can be the result of non-mechanical intestinal obstruction, impaired intestinal motility and systemic immune suppression, all of which are potential complications of SCI.(Balzan et al. 2007) Specifically, butyrate-producing bacteria have been found to be reduced in SCI relative to a healthy cohort.(Gungor et al. 2016) Butyrate is known to modulate epithelial differentiation and cell growth, and suppress macrophages, including CNS inflammation, thus the reduction in butyrate from bacteria may contribute to recovery post-SCI, though links to the liver specifically have not yet been studied.(H. J. Kim et al. 2007; Arpaia et al. 2013; Park et al. 2005; P. S. Chen et al. 2007)

LPS is another potential modulator of post-SCI chronic liver physiology. Kupffer cells, hepatic endothelial cells and hepatocytes all participate in the clearance of LPS via CD14- and TLR4-dependent mechanisms.(Mimura et al. 1995; van Oosten et al. 2001; Vodovotz et al. 2001) LPS induced the release of factors such as TNF- $\alpha$

### 5.1.7 Longitudinal metabolic health

Prior work has found at least 25% of acute SCI patients to be obese, which is well known to induce low-level systemic inflammation, and that this cohort has significantly worse outcomes compared to non-obese SCI patients (Stenson et al. 2011). Alcohol abuse has also been associated with

poorer SCI neurological outcomes (Elliot et al. 2002). Furthermore, advancing age is associated with increased liver inflammation and the SCI population has followed the general populations ageing trend (Bertolotti et al. 2014; Y. Chen, He, and DeVivo 2016). Taken together, it is not unreasonable to assume that a large number of SCI patients may have pre-existing liver inflammation at injury. This may be an important differentiator that contributes to the degree of neurological recovery a given patient may experience. Future experiments investigating neurological outcomes of SCI may benefit from establishing parameters of metabolic health, including the composition of the microbiome, as close to injury as possible, and potentially monitoring changes in these parameters longitudinally.

### 5.1.8 Validation of results

The ELISAs used to validate the proteomic data often did not demonstrate significant differences between the groups (Figures 9, 10, 11 and 12). This may be in part to the individual variability of the samples. However, the trends of the data do largely reflect those found in the iTRAQ data, suggesting that with greater statistical power there may be a more robust validation. Furthermore, the ApoA1 ELISAs resulted in the most significant differences, and was the only Quantikine<sup>®</sup> kit used (Figure 11). As the Quantikine<sup>®</sup> kits are highly optimised, including for use with plasma, whereas the DuoSet<sup>®</sup>s, which were used for the other proteins, are not. Future studies should therefore consider either simply using Quantikine<sup>®</sup> kits, or ensure good optimisation of the DuoSet<sup>®</sup> kits in advance. These results are also corroborated by a recent label-free proteomic SCI study, using a rodent model, which reported similar proteins associated with complement cascade, including A2M and C3.(Yao et al. 2021)

### 5.1.9 Conclusion

This work shows that proteins associated with the complement cascade, and apolipoproteins in particular, have potential as prognostic biomarkers for SCI. For some of these biomarkers, ApoE in particular, it may not be pure abundance, but also the particular allele of the patient that may provide valuable insight. However, the relatively small number of proteins identified here is a limitation, likely due to highly abundant proteins impacting the dynamic range of the samples. The pooling of samples also obscures individual variability in protein abundance. Subsequent proteomics experiments using label-free techniques, and depletion of highly abundant proteins may allow for more in-depth pathway analysis. These results, in concert with the prior chapters findings (??), provide further evidence of a link between metabolic function and functional neurological recovery post-SCI. Further work is needed elucidate the precise biochemistry at play, and perhaps more importantly, whether modulation of these pathways has the potential to improve outcomes. Experiments that closely monitor the liver, modify diet and analyse metabolites, particularly longitudinally post-injury, would all give further insight into this relationship.

## 5.2 thesis label-free discussion

As outlined previously (5.1.9), two key limitations of the iTRAQ experiments were the pooling of samples, which prevents statistically robust group-wise comparisons, and the high dynamic range of protein abundances in plasma potentially obscuring less abundant proteins. This work seeks to address these factors by a combination of Proteominer<sup>™</sup> beads to shrink the dynamic range of protein abundances, and by not pooling samples.

### 5.2.1 Proteins identified

A total of 87 proteins were identified, many of which were only detected in one group. Proteins only present in limited groups could be highly suited for use as biomarkers as binary indicators are

much simpler to test for, and suggest more dramatic biological differences. Here we explore the potential these proteins have as biomarkers of SCI.

**5.2.1.0.1 Peroxiredoxins** Peroxiredoxins are a large and highly conserved family of enzymes that reduce peroxides. Peroxiredoxin 2 (PRX-2) is highly abundant in RBCs and intracellularly serves as an important anti-oxidant role in various cell types, including neurons.(Low, Hampton, and Winterbourn 2008) By contrast, extracellular PRX-2 has been suggested to act as an inflammatory DAMP, leading microglia and macrophages to release a plethora of pro-inflammatory factors.(Salzano et al. 2014; Garcia-Bonilla and Iadecola 2012; Shichita et al. 2012) An *in vitro* primary neurons and microglia co-culture study reported PRX-2 activating microglia via TLR-4, potentially leading to neuronal apoptosis.(Y. Lu et al. 2018) A mouse study found over-expression of PRX-2 attenuated oxidative stress and neuronal apoptosis following subarachnoid haemorrhage.(Y. Lu et al. 2019) Over-expression of PRX-2 is speculated to protect against ischaemic neuronal injury by modulating the redox-sensitive thioredoxin-apoptosis signal-regulating kinase (ASK) 1 signalling complex.(Gan et al. 2012) Several molecular chaperones can interact with ASK1, including thioredoxin and TNF receptor-associated factor 6.(Matsuzawa et al. 2005) The dissociation of the thioredoxin-ASK1 complex activates ASK1. PRX-2 is oxidised after scavenging free radicals, whereupon its antioxidant activity is reduced. This inactivation can be reversed by the thioredoxin-thioredoxin reductase system, whereby oxidised PRX-2 can regain its activity by reducing thioredoxin, leading to the dissociation of the thioredoxin-ASK1 complex.(Rhee and Woo 2011) Additionally, oxidised PRX-1 can inhibit ASK1-induced apoptosis via the thioredoxin-binding domain on ASK1.(S. Y. Kim, Kim, and Lee 2008)

PRX-2 was found to be present in AIS C improvers and AIS D patients acutely, and in AIS A and D patients subacutely. The differences in abundance between these groups was not statistically significant, though acute AIS D had less PRX-2 relative to subacute AIS D ( $\log_2$  fold change -1.9) and subacute AIS A also had less abundant PRX-2 relative to subacute AIS D ( $\log_2$  fold change -1.7). The presence of PRX-2 in acute AIS C improvers and absence in acute C non-improvers suggests the protein could indicate a more protective action against oxidative stress, and implies the protein has potential value as a biomarker of functional outcomes. Similarly, PRX-2 may be acting as a healthy response to trauma-induced oxidative stress in both acute AIS D, although the persistence to the subacute time-point is less clear. Likewise, the presence of PRX-2 in AIS A subacutely, but not acutely is more perplexing. It should be noted that as plasma was used and cells lysed, so there is no distinguishing between intracellular and extracellular PRX-2. Perhaps in the more severe AIS A injury, secondary injuries, including oxidative stress, are greater and so persist to the subacute time-point. The acute absence may be a result of an overwhelmed physiology unable to respond or prioritise managing oxidative stress.

**5.2.1.1 Neuroinflammation post-SCI** The neuro-inflammatory response begins immediately post-trauma, and involves a complex series of events that can persist well into the chronic phase. The sudden emergence of necrotic cell debris and associated DAMPs lead surviving CNS-resident cells to produce cytokines, complement factors and ROS. Within minutes CNS cells at the lesion site have been found to secrete several pro-inflammatory mediators, including TNF- $\alpha$  and interleukins, in both rodent models and human patients with SCI.(Pineau and Lacroix 2006; Chandrasekar et al. 2017; Dalgard et al. 2012; Bastien et al. 2015) The resulting inflammatory response occurs in parallel to the mechanical destruction of the blood-spinal cord barrier, and the development of tissue oedema and ischaemia combine to propagate damage to parts of the cord spared by the initial trauma.(Maikos and Shreiber 2007; Ahuja et al. 2017)

The microglial population at the lesion site have been observed to be significantly depleted immediately post-injury, due to death via both the apoptosis and mechanical injury in a rodent

795 model.(Bellver-Landete et al. 2019) Surviving microglia change in shape and migration patterns,  
796 and begin to produce ROS, oxidative metabolites and pro-inflammatory cytokines.(Pineau and  
797 Lacroix 2006; Bastien and Lacroix 2014) These cells can associate with damaged axons rapidly  
798 post-injury, but are thought to not actively phagocytose these cells until approximately 4 days  
799 post-trauma.(Bellver-Landete et al. 2019; Pineau and Lacroix 2006; Greenhalgh and David 2014)

800 The following hours and days post-injury are characterised by a substantive complement sys-  
801 tem activation and sequential leukocyte migration from the periphery into the injured neural  
802 parenchyma.(Brennan et al. 2015; S. L. Peterson and Anderson 2014; Qiao et al. 2006) Curiously,  
803 though the breakdown of the BSCB would presumably allow unrestricted access of circulating  
804 leukocytes into the injured cord segment, recruitment of these cells remains a highly controlled  
805 process.(Beck et al. 2010; Brennan et al. 2019) A mouse study reported lymphocytes, which  
806 account for approximately 80% of circulating leukocytes, only enter the cord in substantial  
807 numbers at least several weeks to months post-injury.(Beck et al. 2010) Early infiltrate is instead  
808 largely comprised of myeloid cells, predominantly neutrophils, which are a minority of circulating  
809 cells but are the swiftest peripheral responders to SCI, with studies detecting them at the lesion  
810 site within 4 hours of injury.(Wright et al. 2010) Neutrophil numbers have been reported to peak  
811 at 1 day post-trauma, but also to remain at the site for a minimum of 42 days post-injury.(Okada  
812 2016; Kigerl, McGaughy, and Popovich 2006)

813 This neutrophil recruitment is often viewed as principally detrimental to recovery following SCI, but  
814 also wound healing more generally. A recent study found circulating neutrophil numbers in ad-  
815 mission bloods from human SCI patients were negatively correlated with patient outcomes at dis-  
816 charge.(Brennan et al. 2019) The same study utilising a contusive SCI mouse model, showed the ex-  
817 tent of neutrophil presence at the lesion site inversely correlated with neurological outcomes, and  
818 depletion of said cells with an antibody against Ly6G improved recovery of motor function.(Brennan  
819 et al. 2019) However, other studies have suggested neutrophil activity which potentially benefits  
820 SCI recovery. A transgenic mouse contusion model study showed over-expression of secretory  
821 leukocyte protease inhibitor, which can arise from neutrophils and activated macrophages, im-  
822 proved locomotive functional outcomes, and reduced markers of secondary injury.(Ghasemlou  
823 et al. 2010) Another study, using a peripheral nerve injury mouse model, reported neutrophil  
824 infiltration and associated cytokine/chemokine production was vital for clearance of myelin de-  
825 bris.(Lindborg, Mack, and Zigmond 2017) Additionally, another study using a mouse contusion  
826 model found increased lesion sizes and impaired neurological outcomes following neutrophil de-  
827 pletion, though the Gr-1 antibody used also depletes inflammatory monocytes, muddying the pic-  
828 ture somewhat.(Stirling et al. 2009) Regardless, it is clear that the complexity of the role neutrophils  
829 play in the SCI response extends beyond any simple binary beneficial/harmful distinction.

830 Moving forward in the SCI pathology, newly proliferated and recruited microglia begin ac-  
831 tively phagocytosing necrotic cell debris, and begin accumulating around the lesion epicen-  
832 tre.(Greenhalgh and David 2014; Bellver-Landete et al. 2019; Pineau and Lacroix 2006) The  
833 presence of microglia appears to be vital, particularly during the first week post-SCI, as depletion  
834 via the colony stimulating factor-1 inhibitor PLX5622 has been linked to substantially worsened  
835 functional outcomes.(Bellver-Landete et al. 2019; Brennan et al. 2018) Relatedly, another  
836 mouse SCI model study found early enhancement of microglial activation can reduce secondary  
837 pathology.(Stirling et al. 2014)

838 Circulating inflammatory monocytes are also recruited during the first days post-trauma. Adoptive  
839 transfer experiments have shown recruitment to pick up at approximately 3 days post-injury,  
840 and peak at 7 days.(Blomster et al. 2013) Whilst monocyte turnover at the lesion appears to be  
841 high, infiltrating monocyte-derived macrophages remain at the site of weeks to months post-  
842 trauma.(Blomster et al. 2013; Shechter et al. 2009) Interestingly, the timing of monocyte recruit-  
843 ment appears to be delayed relative to non-neurological tissue injury. For instance, monocytes

are reported to be rapidly recruited to the heart following a myocardial infarction, as early as 1 day post-injury, and their numbers return to baseline by roughly 16 days post-injury.(Nahrendorf et al. 2007)

Owing to the diversity of monocyte subsets and macrophage phenotypes, a complete understanding of their role with respect to SCI pathology is still lacking, and requires under active research.(David and Kroner 2011) Some polarisation states associated with recruited macrophages are thought to be implicated in propagating secondary injury via fibrotic scar formation and demyelination of axons.(Kigerl et al. 2009; Popovich et al. 1999; Y. Zhu et al. 2015) Similarly, several studies have reported a reduction in infiltration of monocytes/macrophages is associated with better SCI outcomes.(Kigerl et al. 2009; Y. Zhu et al. 2015; Horn et al. 2008) Conversely, others have found depletion of circulating monocytes/macrophages significantly increased lesion size and results in worse function outcome, with restoration of blood monocyte numbers attenuating this phenotype.(Shechter et al. 2009) More recent *in vitro* studies suggested blood-derived macrophages can suppress microglial phagocytosis without reducing microglial proliferation and extension of processes.(Greenhalgh and David 2014; Greenhalgh et al. 2018) This literature represents an ongoing controversy over the role of monocytes/macrophages in relation to recovery post-SCI. Importantly, many of these studies are based on somewhat crude depletion of cell types, with little discrimination paid toward any potential subpopulations and/or cell polarisation status. Given the sheer complexity of the pathology at play, more nuanced approaches will likely be needed in future studies to paint a more complete picture.

B cell recruitment is yet another wave of immune cell infiltration, thought to occur several days post-injury. These cells can form follicle-like structures in combination with T cells, microglia and macrophages from roughly 28 days post-trauma, and remain present in the lesion well into the chronic phase of SCI.(Ankeny, Guan, and Popovich 2009) Whilst the extent of B cell presence has been reported to vary between animals, they have been correlated with self-reactive antibodies that recognise epitopes within protein homogenates of the spinal cord.(G. Sun et al. 2017) Adoptive transfer experiments in a mouse model isolated antibodies from SCI mice, and found injected them into the neural parenchyma of naïve animals induced significant damage, whereas mice lacking B cells have improved recovery post-SCI.(Ankeny, Guan, and Popovich 2009)

More evidence is needed to establish whether these self-reactive antibodies precede an autoimmune event, or signify a autoimmune disease. Alternatively, they may serve as a mechanism for opsonisation and debris clearance from the lesion site.(Nagele et al. 2013) Naturally occurring autoantibodies with well-established role in tissue regeneration and repair have been found to be elevated following SCI.(Palmer et al. 2016; Arevalo-Martin et al. 2018) Much like the aforementioned monocyte/macrophage controversy, it should be pointed out that any positive effects of these autoantibodies does not preclude any simultaneous negative impacts which could be modulated. For instance, another study reported naturally occurring IgM antibodies contribute to secondary injury during the more acute phase post-SCI.(Narang et al. 2017)

Neuro-inflammation is less understood at the chronic phase of SCI, as most studies focus on the first hours and days post-injury. By this stage, the glial scar has established a well-defined border between the lesion core and the healthy tissue flanking it.(Sofroniew and Vinters 2010) Infiltrating immune cells are largely restricted to within the lesion itself, as opposed to the surrounding spared tissue. B and T cells, macrophages and neutrophils have all been detected here many months post-trauma.(Beck et al. 2010; Ankeny, Guan, and Popovich 2009; Prüss et al. 2011) The chronic phase is also marked by substantial metabolic dysfunction, characterised by reduced lipid metabolites and increased oxidative stress, in addition to elevated pro-inflammatory mediators.(Dulin et al. 2013)

There are fewer studies that attempt to elucidate the underlying mechanisms driving this non-resolving inflammatory response in the chronic phase of SCI. One study suggested communica-



tion with infiltrating monocytes suppresses chronic microglial activation and inflammation after SCI.(Greenhalgh et al. 2018) Interruption of this communication was linked to worsened function outcomes, implying the initial microglial response to trauma may be beneficial, their protracted activation can eventually become detrimental.(Bellver-Landete et al. 2019; Greenhalgh et al. 2018) Furthermore, a rodent model study of chronic SCI, found use of the anti-inflammatory drug licoferone, applied daily for 1 month at 8 months post-injury, observed some improvement to metabolic functions, but no benefit to locomotor function.(Dulin et al. 2013) To summarise, understanding of persistent inflammation during the chronic phase of SCI is lacking, and particularly complicated by the plateaus in locomotive recovery that typically occurs well before the chronic SCI phase is reached. Thus, there is a need for further studies to uncover the role of the various immune cell populations with respect to ongoing neurological dysfunction and pathology during the chronic phase of SCI.

**5.2.1.1.1 Intravenous immunoglobulin** Intravenous immunoglobulin (IVIG) is increasingly used as an immunomodulatory strategy for managing acute neurological conditions, including neurotrauma. Originally developed as an antibody replacement therapy for immunodeficiency disorders, IVIG is a product comprised primarily of immunoglobulin G (IgG) taken from the blood plasma of healthy donors.(Bayry, Negi, and Kaveri 2011; Schwab and Nimmerjahn 2013) IVIG therapy was found to increase platelet number in idiopathic thrombocytopenic purpura (ITP) patients, which lead to an interest in using it as an immunomodulatory therapy.(Imbach et al. 1981) Its potent effects and limited side effects have lead high-dose IVIG therapy to be commonly used in a plethora of inflammatory and autoimmune disorders, including ITP, arthritis, Kawasaki's syndrome and Guillian-Barré syndrome.(Lünemann, Nimmerjahn, and Dalakas 2015; Stangel et al. 1998)

Some recent research using a contusive SCI mouse model has reported promising results of high-dose IVIG as a therapeutic for SCI.(Brennan et al. 2016) The study found that a clinical dose of IVIG (0.5-2g/kg body weight) lead to a 30-40% reduction in lesion size, and reductions in demyelination, central canal dilation, and axonal degeneration, though doses below 0.5g/kg were ineffective.(Brennan et al. 2016) The same study also found albumin treatment did not produce the same effects as IVIG, suggesting simple protein loading is not the causative mechanism. Likewise, rodent studies utilising purified human IgG in a high-level (C7-T1) clip aneurysm model, and another lower-level (T9) contusion SCI study, reported similar improvements.(Nguyen et al. 2012; Chio et al. 2019; Gok et al. 2009) Additionally, a Phase I/IIa clinical trial aiming to explore the safety and efficacy of IVIG therapy in human SCI patients is approved and underway (ACTRN12616001385437). However, whilst there are several pre-clinical studies reporting IVIG treatment can benefit outcomes in CNS injury from a range of neurological conditions, the exact mechanism/s behind any potential neuroprotective effects of IVIG for SCI are currently unclear.(Tzekou and Fehlings 2014)

In TBI mouse models, animals treated with IVIG were shown to have improved neurobehavioural outcomes, and a reduction in neuronal degeneration both acutely and chronically, relative to vehicle-treated controls in rotarod and Morris water maze experiments.(Jeong et al. 2014) Further mouse studies using cerebral artery occlusion, a model of stroke, reported high-dose IVIG significantly reduced infarct volumes, neurological impairment and mortality rates.(Arumugam et al. 2007; Widiapradja et al. 2012) Under condition of BBB/BSCB compromise, IVIG has been found to enter the neural parenchyma within hours of injury.(Brennan et al. 2016; Arumugam et al. 2007) SCI studies have found IVIG to localise to oligodendrocytes, astrocytes, neurons, macrophages, microglia, pericytes and blood vessels.(Brennan et al. 2016; Chio et al. 2019) Additionally, reductions in immune cells, as indicated by F4/80<sup>+</sup> microglia/macrophages and polymorphonuclear cells in brain and spinal injury models respectively, have also been reported.(Jeong et al. 2014; Nguyen et al. 2012; Chio et al. 2019) Relatedly, the aforementioned SCI IVIG mouse study found

940 reduced CD68<sup>+</sup> macrophages at and surrounding the lesion 35 days post-injury.(Brennan et al.  
941 2016) Importantly, these studies do not differentiate between resident microglial and infiltrating  
942 monocytes/macrophages. Thus, further research is needed to understand the influence of IVIG  
943 on both recruitment and activation states of these cell subsets.

944 **5.2.1.1.2 Speculative mechanisms of action for IVIG in SCI** As IVIG is made from pooled anti-  
945 bodies taken from thousands of donors, it includes a vast repertoire of antibodies specific against  
946 millions of unique antigens, allowing for a diverse variety of effects in differing disease contexts.  
947 Whilst there is extensive research of IVIG and autoimmune disorders, such as Guillain-Barré syn-  
948 drome, the immune pathology found in the acute phase of CNS injury is not typically considered  
949 to be driven by autoimmune processes.(Lünemann, Nimmerjahn, and Dalakas 2015; Stangel et  
950 al. 1998) There may be some overlap in therapeutic mechanism, but it seems more likely any  
951 benefits are coffered through modulation of the innate rather than adaptive immune responses.  
952 The potential mechanisms of IVIG can be split between those mediated via the IgG constant (Fc)  
953 fragment, which binds the Fc receptors, and the F(ab)<sub>2</sub> fragment, which governs antigen recogni-  
954 tion.(Schwab and Nimmerjahn 2013) In the context of neurological diseases, mechanisms related  
955 to F(ab)<sub>2</sub> are thought to potentially bind and therefore neutralise cell surface receptors, comple-  
956 ment, cytokines and autoantibodies. By contrast, Fc-dependent mechanisms are speculated to in-  
957 clude regulation of Fc receptor expression, saturation of the neonatal Fc receptor, block activation  
958 of Fc receptors, and modulate T cells.(Schwab and Nimmerjahn 2013; Lünemann, Nimmerjahn,  
959 and Dalakas 2015; Dalakas 2014) Furthermore, models of neurological injury suggest both F(ab)<sub>2</sub>  
960 and Fc-dependent signalling cascades could be involved in the modulation of several chemokines  
961 and cytokines.(Dalakas 2014)

962 Modulation via the variable F(ab)<sub>2</sub> region

963 Self-reactive antibodies have been found circulating in both chronic rodent SCI models and hu-  
964 man patients 1 year post-injury.(Ankeny, Guan, and Popovich 2009; Hayes et al. 2002) Whilst some  
965 studies have suggested potential relevance of naturally occurring autoantibodies (germline en-  
966 coded and produced by B1 cells) in acute SCI, it remains unclear whether IVIG treatment may have  
967 any impact on them.(Palmer et al. 2016; Narang et al. 2017) The impact or lack thereof of IVIG on  
968 chronic phase SCI autoimmunity also remains to be seen.

969 A separate potential F(ab)<sub>2</sub>-dependent mechanism involves the neutralisation of the cell death  
970 mediator Fas (AKA CD95). Studies of Lyell's syndrome, a disorder whereby active Fas ligand binds  
971 Fas present on keratinocytes, inducing apoptosis, reported IVIG therapy completely inhibited Fas  
972 ligand-induced cell death both *in vitro* and in human patients.(Viard et al. 1998; Altnauer et al.  
973 2003) Importantly, IVIG blocked Fas, as opposed to Fas ligand, in these studies, as this result was  
974 only observed with cells pre-treated with IVIG. Incubation of IVIG with soluble Fas ligand did not  
975 attenuate cell death, implying IVIG contains antibodies specific to Fas.(Viard et al. 1998; Altnauer  
976 et al. 2003) This modulatory effect of the Fas-Fas ligand pathway may have relevance in SCI, as a  
977 study using knock-out mice lacking Fas showed a reduction in both apoptosis at the lesion site and  
978 glial scarring, and improved motor function post-SCI.(Sobrido-Cameán and Barreiro-Iglesias 2018;  
979 W. R. Yu and Fehlings 2011) Neurons and glial cells from post-mortem human patients were found  
980 to be more Fas- and Fas ligand-positive, but this was limited to the acute phase of SCI, and not  
981 observed chronically, suggesting this pathway is more significant immediately post-injury.(W. R. Yu  
982 and Fehlings 2011) Therefore, acute IVIG treatment could act by attenuating secondary cell death  
983 by blocking Fas, thus disrupting this pathway.

984 Conversely, agonistic anti-Fas antibodies have also been reported withing IVIG prepara-  
985 tions.(Altnauer et al. 2003) Whilst it remains unknown how these agents may act in SCI,  
986 one could postulate a benefit if they induce apoptosis in circulating leukocytes, which could



otherwise do harm.(Schneider et al. 2017) Supporting this, papers have found reductions in polymorphonuclear cell populations within the lesion at 1 day post-injury in rodent models.(Nguyen et al. 2012; Chio et al. 2019; Gok et al. 2009) However, IVIG-induced apoptosis has only been observed in human leukocytes, not in rodents, casting doubt on this idea.(Altnauer et al. 2003; Schneider et al. 2017) Alternatively, the reduced recruitment could be a result of IVIG regulating the expression of adhesion molecules or molecules involved in leukocytes trafficking. A feline ischaemia-reperfusion injury model study found IVIG to down-regulate expression of integrins on leukocyte cell surfaces, inhibiting adhesion and subsequent extravasation of the cells into the damaged site.(Gill et al. 2005) Again however, these findings are contradicted by an experimental stroke study where IVIG was found to increase leukocyte and platelet trafficking to the injury, leading to formation of aggregates within cerebral vasculature.(Lapointe et al. 2004)

Finally, F(ab)<sub>2</sub> may act by complement scavenging. Both *in vitro* and *in vivo* studies have found the non-antigen-binding regions of F(ab)<sub>2</sub> can bind and neutralise the complement activation products C3a and C5a, thus preventing complement-mediated tissue damage.(Milan Basta et al. 2003; M. Basta et al. 1989) Multiple studies utilising various models of CNS injury have reported IVIG attenuating complement.(Brennan et al. 2016; Arumugam et al. 2007) Specifically in SCI, IVIG was found to reduce levels of the complement activation products C3b and C5a within the damaged cord.(Brennan et al. 2016) Similarly, an experimental stroke study reported IVIG reducing C3b levels in the infarct area.(Arumugam et al. 2007) Interestingly, whilst this study found IgG able to bind mouse C3b, supporting the hypothetical neutralisation of complement activation products, they also found IVIG able to attenuate oxygen deprivation-induced production of C3 itself in primary neuron cultures. This seems to suggest IVIG is able to scavenge both secreted complement activation products, and their local production.(Arumugam et al. 2007)

#### 1010 Modulation via the constant Fc region

With respect to the Fc region, this portion normally binds to Fc $\gamma$  receptors (Fc $\gamma$ Rs), which are present on most leukocytes and resident CNS cells. Many Fc $\gamma$ Rs act as activating receptors, such as inducing phagocytosis in response to opsonised targets, or as an inhibitory receptor that dampens effector cell responses.(Schwab and Nimmerjahn 2013) A given cell's response to an immunoglobulin isotype is determined by the combination of which Fc $\gamma$ Rs are expressed by said cell. Myeloid cells all express some combination of these activating Fc $\gamma$ Rs, as do some innate lymphoid cells which do not express more classical antigen receptors, such as natural killer cells, whereas T and B cells do not.(Perussia et al. 1989) The inhibitory Fc $\gamma$ RIIb receptor is also expressed on myeloid cells, in addition to B cells, but not natural killer cells or resting T cells.(Bruhns and Jönsson 2015) Whilst there is debate over the expression and function of Fc $\gamma$ Rs in neurons, *in vitro* work with neuronal cultures has detected mRNA for all Fc $\gamma$ Rs.(Thom et al. 2017) Astrocytes, microglia and oligodendrocyte precursors have also been found to express Fc $\gamma$ R, and up-regulate them under some disease states.(Thom et al. 2017)

Studies utilising just the Fc fragment have been found to be equally effective as normal IVIG in several non-neurological autoimmune diseases, including nephrotoxic nephritis, ITP and K/BxN arthritis models, suggesting Fc $\gamma$ Rs play a key role in the mechanism of IVIG.(Samuelsson, Towers, and Ravetch 2001; I. K. Campbell et al. 2014; Kaneko et al. 2006) With respect to CNS injury, some evidence suggesting a role of Fc $\gamma$ Rs comes from a mouse study with animals lacking the common  $\gamma$ -chain, and thus no functional Fc $\gamma$ Rs, which were found to be protected from experimental stroke and SCI.(Ankeny, Guan, and Popovich 2009; Komine-Kobayashi et al. 2004)

Within the context of antibody-mediated autoimmune disorders, high-dose IVIG may saturate Fc receptor and reduce the half-life of pathogenic endogenous IgG.(Schwab and Nimmerjahn 2013)

**5.2.1.1.3 Immunoglobulins** Several immunoglobulin components were identified here, including 3  $\lambda$  variable precursors (3-19, 3-10 and 2-18), 3 heavy variable precursors (3-15, 1-69 and 1-24) and 2 heavy constant gamma regions (2 and 4). For the  $\lambda$  variable precursors, acute AIS C improvers the precursors 3-19 and 3-10 were detected, whereas 3-10 and 2-18 were detected in acute C non-improvers. That acute C non-improvers expressed the 2-18 precursor whilst the improvers did not, suggests potential as a biomarker of poorer functional outcomes. It is difficult to comment on the biological mechanisms that may be at play here from this data, but one could infer that it is indicative of either a more robust, or a more maladaptive, immune response to the trauma. Given that the injuries are of the same severity by AIS grade, the latter seems more likely, though again, further research is needed to highlight the precise nature of this difference. Interestingly, whilst the acute C improvers do not express precursor 2-18, both the subacute C improvers and non-improvers, and subacute As do, whereas acute or subacute Ds do not, seemingly implying this precursor is also indicative of more severe injury in the latter phases of SCI.

In addition of acute C improvers, subacute As and acute Ds also express the 3-19 precursor, with subacute As possessing the greatest abundance. Again, this would seem to suggest this marker is indicative of positive outcomes or less severe injury in the acute phase, but may be more detrimental in the latter phases. The final  $\lambda$  precursor, 3-10, is present in acute As, subacute As and both subacute C groups as well as the aforementioned acute C improvers. The curious absence of 3-10 in both AIS D groups and C non-improvers groups suggests the marker is implicated in a more beneficial response, but perhaps this is limited to more severe injuries.

With respect to the immunoglobulin heavy variable precursors, 3-15 was present in all groups except acute As and acute C non-improvers, though there was insufficient power to confidently compare the fold change of groups expressing 3-15. Another heavy variable precursor, 1-69, was expressed in subacute As, both acute and subacute C improvers, and both acute and subacute Ds. The final heavy variable precursor, 1-24, was found in all groups except acute C improvers and non-improvers.

For the two immunoglobulin heavy constant  $\gamma$ s, 4 was significant in acute C improvers and non-improvers, relative to subacute As, whereas  $\gamma$  2 was only significant in acute C improvers relative to subacute Ds. Both acute C improvers and non-improvers had a lower abundance of  $\gamma$  4 relative to subacute As (-2.2 and -2.7 respectively), whilst  $\gamma$  2 had a -1.8 fold change between acute C improvers and subacute Ds.

## 5.2.2 Conclusion

Much like the iTRAQ experiments (5.1.9), the majority of proteins identified are functionally associated with the complement cascade. Unlike the iTRAQ however, many of the proteins were only detected in one group of the pairwise comparisons, suggesting greater suitability as biomarkers. PRX-2, a protein associated with oxidative stress, is of particular interest, both as a biomarker for improvement in acute AIS C patients, but also mechanistically in relation to functional recovery. Furthermore, several immunoglobulins were identified as differentially abundant, though further *in vitro/vivo* work is needed to elucidate the pathophysiological relevance of each precursor. The  $\lambda$  2-18 and 3-10 precursors are of particular relevance to acute and subacute AIS C improvement respectively, and both are of interest longitudinally in AIS As, with 2-18 potentially being linked to severity of injury.

The small number of statistically significant proteins speaks to the variability of human samples, and is likely exacerbated by the inconstant timing of sample collection relative to injury. Post-hoc power analysis of the data reveals that to identify a 2.5 fold change with an FDR of 0.5 and a power of 0.9, 14 biological replicates would be needed, in contrast to the 7-11 replicates used across groups here. Thus, a repeat of this experiment with a larger sample size will likely reveal many

more proteins of potential interest. Furthermore, a metabolomic analysis with a similar sample size would greatly compliment this work, particularly with regards to investigating further links to the liver.

## References

- Ahuja, Christopher S, Jefferson R Wilson, Satoshi Nori, Mark R N Kotter, Claudia Druschel, Armin Curt, and Michael G Fehlings. 2017. "Traumatic Spinal Cord Injury." *Nat Rev Dis Primers* 3: 17018. <https://doi.org/10.1038/nrdp.2017.18>.
- al., Szklarczyk D. et. 2019. "STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets." *Nucleic Acids Research (Database Issue)* 48.
- Alathea, Letaw. 2015. *Captioner: Numbers Figures and Creates Simple Captions*. <https://CRAN.R-project.org/package=captioner>.
- Altnauer, Frank, Stephan von Gunten, Peter Späth, and Hans-Uwe Simon. 2003. "Concurrent Presence of Agonistic and Antagonistic Anti-Cd95 Autoantibodies in Intravenous Ig Preparations." *Journal of Allergy and Clinical Immunology* 112 (6): 1185–90. <https://doi.org/10.1016/j.jaci.2003.09.045>.
- Anatol, Kontush, Chantepie Sandrine, and Chapman M. John. 2003. "Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress." *Arteriosclerosis, Thrombosis, and Vascular Biology* 23 (10): 1881–88. <https://doi.org/10.1161/01.ATV.0000091338.93223.E8>.
- Anderson, Mark A., Joshua E. Burda, Yilong Ren, Yan Ao, Timothy M. O'Shea, Riki Kawaguchi, Giovanni Coppola, Baljit S. Khakh, Timothy J. Deming, and Michael V. Sofroniew. 2016. "Astrocyte Scar Formation Aids Central Nervous System Axon Regeneration." *Nature* 532 (7598): 195–200. <https://doi.org/10.1038/nature17623>.
- Ankeny, Daniel P., Zhen Guan, and Phillip G. Popovich. 2009. "B Cells Produce Pathogenic Antibodies and Impair Recovery After Spinal Cord Injury in Mice." *The Journal of Clinical Investigation* 119 (10): 2990–99. <https://doi.org/10.1172/JCI39780>.
- Anthony, Daniel C., and Yvonne Couch. 2014. "The Systemic Response to CNS Injury." *Experimental Neurology*, Special Issue: Neuroimmunology of spinal cord injury, 258 (August): 105–11. <https://doi.org/10.1016/j.expneurol.2014.03.013>.
- Arevalo-Martin, Angel, Lukas Grassner, Daniel Garcia-Ovejero, Beatriz Paniagua-Torija, Gemma Barroso-Garcia, Alba G. Arandilla, Orpheus Mach, et al. 2018. "Elevated Autoantibodies in Subacute Human Spinal Cord Injury Are Naturally Occurring Antibodies." *Frontiers in Immunology* 9: 2365. <https://doi.org/10.3389/fimmu.2018.02365>.
- Arpaia, Nicholas, Clarissa Campbell, Xiyang Fan, Stanislav Dikiy, Joris van der Veeken, Paul deRoos, Hui Liu, et al. 2013. "Metabolites Produced by Commensal Bacteria Promote Peripheral Regulatory T-cell Generation." *Nature* 504 (7480): 451–55. <https://doi.org/10.1038/nature12726>.
- Arumugam, Thiruma V., Sung-Chun Tang, Justin D. Lathia, Aiwu Cheng, Mohamed R. Mughal, Srinivasulu Chigurupati, Tim Magnus, et al. 2007. "Intravenous Immunoglobulin (IVIg) Protects the Brain Against Experimental Stroke by Preventing Complement-Mediated Neuronal Cell Death." *Proceedings of the National Academy of Sciences of the United States of America* 104 (35): 14104–9. <https://doi.org/10.1073/pnas.0700506104>.
- Balmer, James E., and Rune Blomhoff. 2002. "Gene Expression Regulation by Retinoic Acid." *Journal of Lipid Research* 43 (11): 1773–1808. <https://doi.org/10.1194/jlr.R100015-JLR200>.
- Balmer, Maria L., Emma Slack, Andrea de Gottardi, Melissa A. E. Lawson, Siegfried Hapfelmeier, Luca Miele, Antonio Grieco, et al. 2014. "The Liver May Act as a Firewall Mediating Mutualism Between the Host and Its Gut Commensal Microbiota." *Science Translational Medicine* 6 (237): 237ra66–66. <https://doi.org/10.1126/scitranslmed.3008618>.
- Balzan, Silvio, Claudio De Almeida Quadros, Roberto De Cleva, Bruno Zilberstein, and Ivan Cecconello. 2007. "Bacterial Translocation: Overview of Mechanisms and Clinical Impact." *Journal*

- 1129 of *Gastroenterology and Hepatology* 22 (4): 464–71. [https://doi.org/10.1111/j.1440-1746.2007.](https://doi.org/10.1111/j.1440-1746.2007.04933.x)  
1130 04933.x.
- 1131 Banka, C. L., T. Yuan, M. C. de Beer, M. Kindy, L. K. Curtiss, and F. C. de Beer. 1995. "Serum Amyloid  
1132 A (SAA): Influence on HDL-mediated Cellular Cholesterol Efflux." *Journal of Lipid Research* 36 (5):  
1133 1058–65.
- 1134 Bao, Feng, Vanessa Omana, Arthur Brown, and Lynne C. Weaver. 2012. "The Systemic Inflam-  
1135 matory Response After Spinal Cord Injury in the Rat Is Decreased by  $\alpha 4\beta 1$  Integrin Blockade." *Journal of Neurotrauma* 29 (8): 1626–37. <https://doi.org/10.1089/neu.2011.2190>.
- 1136 Basta, Milan, Fredric Van Goor, Stefano Luccioli, Eric M. Billings, Alexander O. Vortmeyer, Lajos  
1137 Baranyi, Janos Szebeni, et al. 2003. "F(ab)<sup>I</sup>2-Mediated Neutralization of C3a and C5a Ana-  
1138 phylatoxins: A Novel Effector Function of Immunoglobulins." *Nature Medicine* 9 (4): 431–38.  
1139 <https://doi.org/10.1038/nm836>.
- 1140 Basta, M, P Kirshbom, M M Frank, and L F Fries. 1989. "Mechanism of Therapeutic Effect of High-  
1141 Dose Intravenous Immunoglobulin. Attenuation of Acute, Complement-Dependent Immune  
1142 Damage in a Guinea Pig Model." *Journal of Clinical Investigation* 84 (6): 1974–81. <https://doi.org/10.1172/JCI114387>.
- 1143 Bastien, Dominic, Victor Bellver Landete, Martine Lessard, Nicolas Vallières, Mathieu Champagne,  
1144 Akira Takashima, Marie-Ève Tremblay, Yannick Doyon, and Steve Lacroix. 2015. "IL-1 $\alpha$  Gene  
1145 Deletion Protects Oligodendrocytes After Spinal Cord Injury Through Upregulation of the Sur-  
1146 vival Factor Tox3." *The Journal of Neuroscience* 35 (30): 10715–30. <https://doi.org/10.1523/JNEUROSCI.0498-15.2015>.
- 1147 Bastien, Dominic, and Steve Lacroix. 2014. "Cytokine Pathways Regulating Glial and Leukocyte  
1148 Function After Spinal Cord and Peripheral Nerve Injury." *Experimental Neurology*, Special Issue:  
1149 Neuroimmunology of spinal cord injury, 258 (August): 62–77. <https://doi.org/10.1016/j.expneurol.2014.04.006>.
- 1150 Bauman, William A., and Ann M. Spungen. 2001. "Carbohydrate And Lipid Metabolism In Chronic  
1151 Spinal Cord Injury." *The Journal of Spinal Cord Medicine* 24 (4): 266–77. <https://doi.org/10.1080/10790268.2001.11753584>.
- 1152 Bayry, Jagadeesh, Vir Singh Negi, and Srini V. Kaveri. 2011. "Intravenous Immunoglobulin Therapy  
1153 in Rheumatic Diseases." *Nature Reviews Rheumatology* 7 (6): 349–59. <https://doi.org/10.1038/nr-rheum.2011.61>.
- 1154 Bazzocchi, Gabriele, Silvia Turroni, Maria Chiara Bulzamini, Federica D'Amico, Angelica Bava, Mirco  
1155 Castiglioni, Valentina Cagnetta, et al. 2021. "Changes in Gut Microbiota in the Acute Phase  
1156 After Spinal Cord Injury Correlate with Severity of the Lesion." *Scientific Reports* 11 (1): 12743.  
1157 <https://doi.org/10.1038/s41598-021-92027-z>.
- 1158 Beck, Kevin D., Hal X. Nguyen, Manuel D. Galvan, Desirée L. Salazar, Trent M. Woodruff, and Aileen  
1159 J. Anderson. 2010. "Quantitative Analysis of Cellular Inflammation After Traumatic Spinal Cord  
1160 Injury: Evidence for a Multiphasic Inflammatory Response in the Acute to Chronic Environment." *Brain* 133 (2): 433–47. <https://doi.org/10.1093/brain/awp322>.
- 1161 Bellver-Landete, Victor, Floriane Bretheau, Benoit Mailhot, Nicolas Vallières, Martine Lessard,  
1162 Marie-Eve Janelle, Nathalie Vernoux, et al. 2019. "Microglia Are an Essential Component of the  
1163 Neuroprotective Scar That Forms After Spinal Cord Injury." *Nature Communications* 10 (1): 518.  
1164 <https://doi.org/10.1038/s41467-019-08446-0>.
- 1165 Benditt, E. P., and N. Eriksen. 1977. "Amyloid Protein SAA Is Associated with High Density Lipopro-  
1166 tein from Human Serum." *Proceedings of the National Academy of Sciences* 74 (9): 4025–28.  
1167 <https://doi.org/10.1073/pnas.74.9.4025>.
- 1168 Bernardo Harrington, Gabriel Mateus, Paul Cool, Charlotte Hulme, Aheed Osman, Joy Chowdhury,  
1169 Naveen Kumar, Srinivasa Budithi, and Karina Wright. 2020. "Routinely Measured Haematologi-  
1170 cal Markers Can Help to Predict AIS Scores Following Spinal Cord Injury." *Journal of Neurotrauma*,  
1171 July. <https://doi.org/10.1089/neu.2020.7144>.
- 1172 Berry, Daniel C., Sheila M. O'Byrne, Amanda C. Vreeland, William S. Blaner, and Noa Noy. 2012.

1180 "Cross Talk Between Signaling and Vitamin A Transport by the Retinol-Binding Protein Receptor  
1181 Stra6." *Molecular and Cellular Biology* 32 (15): 3164–75. <https://doi.org/10.1128/MCB.00505-12>.

1182 Berthold, Michael R., Nicolas Cebron, Fabian Dill, Thomas R. Gabriel, Tobias Kötter, Thorsten Meinl,  
1183 Peter Ohl, Kilian Thiel, and Bernd Wiswedel. 2009. "KNIME - the Konstanz Information Miner:  
1184 Version 2.0 and Beyond." *ACM SIGKDD Explorations Newsletter* 11 (1): 26–31. [https://doi.org/10](https://doi.org/10.1145/1656274.1656280)  
1185 .1145/1656274.1656280.

1186 Bertolotti, Marco, Amedeo Lonardo, Chiara Mussi, Enrica Baldelli, Elisa Pellegrini, Stefano Ballestri,  
1187 Dante Romagnoli, and Paola Loria. 2014. "Nonalcoholic Fatty Liver Disease and Aging: Epi-  
1188 demiology to Management." *World Journal of Gastroenterology : WJG* 20 (39): 14185–204. <https://doi.org/10.3748/wjg.v20.i39.14185>.

1189 Bhargava, Prerna, and Chih-Hao Lee. 2012. "Role and Function of Macrophages in the Metabolic  
1190 Syndrome." *Biochemical Journal* 442 (2): 253–62. <https://doi.org/10.1042/BJ20111708>.

1191 Biglari, B., T. Swing, C. Child, A. Büchler, F. Westhauser, T. Bruckner, T. Ferbert, H. Jürgen Gerner,  
1192 and A. Moghaddam. 2015. "A Pilot Study on Temporal Changes in IL-1b and TNF-a Serum Levels  
1193 After Spinal Cord Injury: The Serum Level of TNF-a in Acute SCI Patients as a Possible Marker  
1194 for Neurological Remission." *Spinal Cord* 53 (7): 510–14. <https://doi.org/10.1038/sc.2015.28>.

1195 Bikman, Benjamin T. 2012. "A Role for Sphingolipids in the Pathophysiology of Obesity-Induced  
1196 Inflammation." *Cellular and Molecular Life Sciences* 69 (13): 2135–46. [https://doi.org/10.1007/s0](https://doi.org/10.1007/s00018-012-0917-5)  
1197 0018-012-0917-5.

1198 Blomhoff, Rune, and Heidi Kiil Blomhoff. 2006. "Overview of Retinoid Metabolism and Function." *Journal of Neurobiology* 66 (7): 606–30. <https://doi.org/10.1002/neu.20242>.

1199 Blomster, Linda V., Faith H. Brennan, Hong W. Lao, David W. Harle, Alan R. Harvey, and Marc  
1200 J. Ruitenberg. 2013. "Mobilisation of the Splenic Monocyte Reservoir and Peripheral Cx3cr1  
1201 Deficiency Adversely Affects Recovery from Spinal Cord Injury." *Experimental Neurology* 247  
1202 (September): 226–40. <https://doi.org/10.1016/j.expneurol.2013.05.002>.

1203 Bond, Jennifer E., George J. Cianciolo, and Salvatore V. Pizzo. 2007. "Incorporation of Low Molecular  
1204 Weight Molecules into Alpha2-Macroglobulin by Nucleophilic Exchange." *Biochemical and Bio-*  
1205 *physical Research Communications* 357 (2): 433–38. <https://doi.org/10.1016/j.bbrc.2007.03.151>.

1206 Brennan, Faith H., Richard Gordon, Hong W. Lao, Patrick J. Biggins, Stephen M. Taylor, Robin J.  
1207 M. Franklin, Trent M. Woodruff, and Marc J. Ruitenberg. 2015. "The Complement Receptor  
1208 C5aR Controls Acute Inflammation and Astroglia Following Spinal Cord Injury." *Journal of*  
1209 *Neuroscience* 35 (16): 6517–31. <https://doi.org/10.1523/JNEUROSCI.5218-14.2015>.

1210 Brennan, Faith H., Jodie C. E. Hall, Zhen Guan, and Phillip G. Popovich. 2018. "Microglia Limit Le-  
1211 sion Expansion and Promote Functional Recovery After Spinal Cord Injury in Mice," September,  
1212 410258. <https://doi.org/10.1101/410258>.

1213 Brennan, Faith H., Trisha Jogia, Ellen R. Gillespie, Linda V. Blomster, Xaria X. Li, Bianca Nowlan,  
1214 Gail M. Williams, et al. 2019. "Complement Receptor C3aR1 Controls Neutrophil Mobilization  
1215 Following Spinal Cord Injury Through Physiological Antagonism of Cxcr2." *JCI Insight* 4 (9). <https://doi.org/10.1172/jci.insight.98254>.

1216 Brennan, Faith H., Nyoman D. Kurniawan, Jana Vukovic, Perry F. Bartlett, Fabian Käsermann,  
1217 Thiruma V. Arumugam, Milan Basta, and Marc J. Ruitenberg. 2016. "IVIg Attenuates Comple-  
1218 ment and Improves Spinal Cord Injury Outcomes in Mice." *Annals of Clinical and Translational*  
1219 *Neurology* 3 (7): 495–511. <https://doi.org/10.1002/acn3.318>.

1220 Brown, Sharon J., Gabriel M. B. Harrington, Charlotte H. Hulme, Rachel Morris, Anna Bennett, Wai-  
1221 Hung Tsang, Aheed Osman, Joy Chowdhury, Naveen Kumar, and Karina T. Wright. 2019. "A  
1222 Preliminary Cohort Study Assessing Routine Blood Analyte Levels and Neurological Outcome  
1223 After Spinal Cord Injury." *Journal of Neurotrauma*, July. <https://doi.org/10.1089/neu.2019.6495>.

1224 Bruhns, Pierre, and Friederike Jönsson. 2015. "Mouse and Human FcR Effector Functions." *Im-*  
1225 *munological Reviews* 268 (1): 25–51. <https://doi.org/10.1111/imr.12350>.

1226 Buresova, Veronika, Ondrej Hajdusek, Zdenek Franta, Daniel Sojka, and Petr Kopacek. 2009.  
1227 "IrrAM—An A2-Macroglobulin from the Hard Tick Ixodes Ricinus: Characterization and Function  
1228  
1229  
1230



in Phagocytosis of a Potential Pathogen *Chryseobacterium Indologenes*." *Developmental & Comparative Immunology* 33 (4): 489–98. <https://doi.org/10.1016/j.dci.2008.09.011>.

Bursill Christina A., Castro Maria L., Beattie Douglas T., Nakhla Shirley, van der Vorst Emiel, Heather Alison K., Barter Philip J., and Rye Kerry-Anne. 2010. "High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo." *Arteriosclerosis, Thrombosis, and Vascular Biology* 30 (9): 1773–78. <https://doi.org/10.1161/ATVBAHA.110.211342>.

C, Niederau, Backmerhoff F, and Schumacher B. 1997. "Inflammatory Mediators and Acute Phase Proteins in Patients with Crohn's Disease and Ulcerative Colitis." *Hepato-Gastroenterology* 44 (13): 90–107.

Cai, Lei, Maria C. de Beer, Frederick C. de Beer, and Deneys R. van der Westhuyzen. 2005. "Serum Amyloid A Is a Ligand for Scavenger Receptor Class B Type I and Inhibits High Density Lipoprotein Binding and Selective Lipid Uptake\*." *Journal of Biological Chemistry* 280 (4): 2954–61. <https://doi.org/10.1074/jbc.M411555200>.

Campbell, Ian K, Sylvia Miescher, Donald R Branch, Patrick J Mott, Alan H Lazarus, Dongji Han, Eugene Maraskovsky, et al. 2014. "Therapeutic Effect of IVIG on Inflammatory Arthritis in Mice Is Dependent on the Fc Portion and Independent of Sialylation or Basophils." *Journal of Immunology (Baltimore, Md.* 192 (11): 5031–38. <https://doi.org/10.4049/jimmunol.1301611>.

Campbell, Sandra J., Daniel C. Anthony, Fiona Oakley, Harald Carlsen, Ahmed M. Elsharkawy, Rune Blomhoff, and Derek A. Mann. 2008. "Hepatic Nuclear Factor  $\kappa$ B Regulates Neutrophil Recruitment to the Injured Brain." *Journal of Neuropathology & Experimental Neurology* 67 (3): 223–30. <https://doi.org/10.1097/NEN.0b013e3181654957>.

Campbell, Sandra J., V. Hugh Perry, Fernando J. Pitossi, Angus G. Butchart, Mariela Chertoff, Sara Waters, Robert Dempster, and Daniel C. Anthony. 2005. "Central Nervous System Injury Triggers Hepatic CC and CXC Chemokine Expression That Is Associated with Leukocyte Mobilization and Recruitment to Both the Central Nervous System and the Liver." *The American Journal of Pathology* 166 (5): 1487–97. [https://doi.org/10.1016/S0002-9440\(10\)62365-6](https://doi.org/10.1016/S0002-9440(10)62365-6).

Campbell, Sandra J., Imran Zahid, Patrick Losey, Shing Law, Yanyan Jiang, Mehmet Bilgen, Nico van Rooijen, Damineh Morsali, Andrew E. M. Davis, and Daniel C. Anthony. 2008. "Liver Kupffer Cells Control the Magnitude of the Inflammatory Response in the Injured Brain and Spinal Cord." *Neuropharmacology* 55 (5): 780–87. <https://doi.org/10.1016/j.neuropharm.2008.06.074>.

Chambers, Matthew C., Brendan Maclean, Robert Burke, Dario Amodei, Daniel L. Ruderman, Steffen Neumann, Laurent Gatto, et al. 2012. "A Cross-Platform Toolkit for Mass Spectrometry and Proteomics." *Nature Biotechnology* 30 (10): 918–20. <https://doi.org/10.1038/nbt.2377>.

Chandrasekar, Akila, Florian olde Heuvel, Annette Palmer, Birgit Linkus, Albert C. Ludolph, Tobias M. Boeckers, Borna Relja, Markus Huber-Lang, and Francesco Roselli. 2017. "Acute Ethanol Administration Results in a Protective Cytokine and Neuroinflammatory Profile in Traumatic Brain Injury." *International Immunopharmacology* 51 (October): 66–75. <https://doi.org/10.1016/j.intimp.2017.08.002>.

Chang, Zhi-Qiang, Su-Yeon Lee, Hye-Jin Kim, Jung Ran Kim, Su-Jung Kim, In-Kyung Hong, Byung-Chul Oh, Cheol-Soo Choi, Ira J. Goldberg, and Tae-Sik Park. 2011. "Endotoxin Activates de Novo Sphingolipid Biosynthesis via Nuclear Factor Kappa B-mediated Upregulation of Sptlc2." *Prostaglandins & Other Lipid Mediators* 94 (1): 44–52. <https://doi.org/10.1016/j.prostaglandins.2010.12.003>.

Chen, P. S., C. -C. Wang, C. D. Bortner, G. -S. Peng, X. Wu, H. Pang, R. -B. Lu, P. -W. Gean, D. -M. Chuang, and J. -S. Hong. 2007. "Valproic Acid and Other Histone Deacetylase Inhibitors Induce Microglial Apoptosis and Attenuate Lipopolysaccharide-Induced Dopaminergic Neurotoxicity." *Neuroscience* 149 (1): 203–12. <https://doi.org/10.1016/j.neuroscience.2007.06.053>.

Chen, Yuying, Yin He, and Michael J. DeVivo. 2016. "Changing Demographics and Injury Profile of New Traumatic Spinal Cord Injuries in the United States, 1972–2014." *Archives of Physical Medicine and Rehabilitation* 97 (10): 1610–19. <https://doi.org/10.1016/j.apmr.2016.03.017>.

Chio, Jonathon Chon Teng, Jian Wang, Anna Badner, James Hong, Vithushan Surendran, and

- Michael G. Fehlings. 2019. "The Effects of Human Immunoglobulin G on Enhancing Tissue Protection and Neurobehavioral Recovery After Traumatic Cervical Spinal Cord Injury Are Mediated Through the Neurovascular Unit." *Journal of Neuroinflammation* 16 (1): 141. <https://doi.org/10.1186/s12974-019-1518-0>.
- Choi, Meena. 2014. "MSstats: An R Package for Statistical Analysis of Quantitative Mass Spectrometry-Based Proteomic Experiments." *Bioinformatics* 30.
- Choi, Meena, Ching-Yun Chang, Timothy Clough, Daniel Broudy, Trevor Killeen, Brendan MacLean, and Olga Vitek. 2014. "MSstats: An R Package for Statistical Analysis of Quantitative Mass Spectrometry-Based Proteomic Experiments." *Bioinformatics* 30 (17): 2524–26. <https://doi.org/10.1093/bioinformatics/btu305>.
- Chow, Diana S. L., Yang Teng, Elizabeth G. Toups, Bizhan Aarabi, James S. Harrop, Christopher I. Shaffrey, Michele M. Johnson, et al. 2012. "Pharmacology of Riluzole in Acute Spinal Cord Injury." *Journal of Neurosurgery: Spine* 17 (Suppl1): 129–40. <https://doi.org/10.3171/2012.5.AOSPIN12112>.
- Christison, J K, K A Rye, and R Stocker. 1995. "Exchange of Oxidized Cholesteryl Linoleate Between LDL and HDL Mediated by Cholesteryl Ester Transfer Protein." *Journal of Lipid Research* 36 (9): 2017–26. [https://doi.org/10.1016/S0022-2275\(20\)41119-8](https://doi.org/10.1016/S0022-2275(20)41119-8).
- Cockerill Gillian W., Rye Kerry-Anne, Gamble Jennifer R., Vadas Mathew A., and Barter Philip J. 1995. "High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules." *Arteriosclerosis, Thrombosis, and Vascular Biology* 15 (11): 1987–94. <https://doi.org/10.1161/01.ATV.15.11.1987>.
- Colbert, Melissa C., William W. Rubin, Elwood Linney, and Anthony-Samuel LaMantia. 1995. "Retinoid signaling and the generation of regional and cellular diversity in the embryonic mouse spinal cord." *Developmental Dynamics* 204 (1): 1–12. <https://doi.org/10.1002/aja.1002040102>.
- Crispe, Ian N. 2016. "Hepatocytes as Immunological Agents." *The Journal of Immunology* 196 (1): 17–21. <https://doi.org/10.4049/jimmunol.1501668>.
- Crozier-Shaw, Geoff, Hazel Denton, and Seamus Morris. 2020. "Management Strategies in Acute Traumatic Spinal Cord Injury: A Narrative Review." *Neuroimmunology and Neuroinflammation* 7 (September). <https://doi.org/10.20517/2347-8659.2019.005>.
- Czubowicz, Kinga, Henryk Jęsko, Przemysław Wencel, Walter J. Lukiw, and Robert P. Strosznajder. 2019. "The Role of Ceramide and Sphingosine-1-Phosphate in Alzheimer's Disease and Other Neurodegenerative Disorders." *Molecular Neurobiology* 56 (8): 5436–55. <https://doi.org/10.1007/s12035-018-1448-3>.
- Dalakas, Marinos C. 2014. "Mechanistic Effects of IVIg in Neuroinflammatory Diseases: Conclusions Based on Clinicopathologic Correlations." *Journal of Clinical Immunology* 34 (1): 120–26. <https://doi.org/10.1007/s10875-014-0024-5>.
- Dalgard, Clifton, Jeffrey Cole, William Kean, Jessica Lucky, Gauthaman Sukumar, David McMullen, Harvey Pollard, and William Watson. 2012. "The Cytokine Temporal Profile in Rat Cortex After Controlled Cortical Impact." *Frontiers in Molecular Neuroscience* 5: 6. <https://doi.org/10.3389/fnmol.2012.00006>.
- David, Samuel, and Antje Kroner. 2011. "Repertoire of Microglial and Macrophage Responses After Spinal Cord Injury." *Nature Reviews Neuroscience* 12 (7): 388–99. <https://doi.org/10.1038/nrn3053>.
- Davies, Andrew L., Keith C. Hayes, and Gregory A. Dekaban. 2007. "Clinical Correlates of Elevated Serum Concentrations of Cytokines and Autoantibodies in Patients With Spinal Cord Injury." *Archives of Physical Medicine and Rehabilitation* 88 (11): 1384–93. <https://doi.org/10.1016/j.apmr.2007.08.004>.
- de Beer, Maria C., Ailing Ji, Anisa Jahangiri, Ashley M. Vaughan, Frederick C. de Beer, Deney R. van der Westhuyzen, and Nancy R. Webb. 2011. "ATP Binding Cassette G1-dependent Cholesterol Efflux During Inflammation1." *Journal of Lipid Research* 52 (2): 345–53. <https://doi.org/10.1194/jlr.M012328>.

- de Beer, Maria C., Nancy R. Webb, Joanne M. Wroblewski, Victoria P. Noffsinger, Debra L. Rateri, Ailing Ji, Deneys R. van der Westhuyzen, and Frederick C. de Beer. 2010. "Impact of Serum Amyloid A on High Density Lipoprotein Composition and Levels." *Journal of Lipid Research* 51 (11): 3117–25. <https://doi.org/10.1194/jlr.M005413>.
- DeLeve, Laurie D. 2007. "Hepatic Microvasculature in Liver Injury." *Seminars in Liver Disease* 27 (04): 390–400. <https://doi.org/10.1055/s-2007-991515>.
- Derebe, Mehabaw G, Clare M Zlatkov, Sureka Gattu, Kelly A Ruhn, Shipra Vaishnava, Gretchen E Diehl, John B MacMillan, Noelle S Williams, and Lora V Hooper. 2014. "Serum Amyloid A Is a Retinol Binding Protein That Transports Retinol During Bacterial Infection." Edited by Fiona M Powrie. *eLife* 3 (July): e03206. <https://doi.org/10.7554/elife.03206>.
- "Devil in the Details." 2011. *Nature* 470 (7334): 305–6. <https://doi.org/10.1038/470305b>.
- Diraison, Frederique, and Michel Beylot. 1998. "Role of Human Liver Lipogenesis and Reesterification in Triglycerides Secretion and in FFA Reesterification." *American Journal of Physiology-Endocrinology and Metabolism* 274 (2): E321–27. <https://doi.org/10.1152/ajpendo.1998.274.2.E321>.
- Dong, Zhe, Tingting Wu, Weidong Qin, Chuankai An, Zhihao Wang, Mingxiang Zhang, Yun Zhang, Cheng Zhang, and Fengshuang An. 2011. "Serum Amyloid A Directly Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice." *Molecular Medicine* 17 (11): 1357–64. <https://doi.org/10.2119/molmed.2011.00186>.
- Dowle, Matt, and Arun Srinivasan. 2021. *Data.table: Extension of 'Data.frame'*. <https://CRAN.R-project.org/package=data.table>.
- Dulin, Jennifer N., Edward D. Karoly, Ying Wang, Henry W. Strobel, and Raymond J. Grill. 2013. "Licofelone Modulates Neuroinflammation and Attenuates Mechanical Hypersensitivity in the Chronic Phase of Spinal Cord Injury." *Journal of Neuroscience* 33 (2): 652–64. <https://doi.org/10.1523/JNEUROSCI.6128-11.2013>.
- Elliot, T. R., M. Kurylo, Y. Chen, and B. Hicken. 2002. "Alcohol Abuse History and Adjustment Following Spinal Cord Injury." *Rehabilitation Psychology* 47 (3): 278–90. <https://doi.org/10.1037/0090-5550.47.3.278>.
- Elliott, David A., Woojin S. Kim, David A. Jans, and Brett Garner. 2007. "Apoptosis Induces Neuronal Apolipoprotein-E Synthesis and Localization in Apoptotic Bodies." *Neuroscience Letters* 416 (2): 206–10. <https://doi.org/10.1016/j.neulet.2007.02.014>.
- Eng, Jimmy K., Tahmina A. Jahan, and Michael R. Hoopmann. 2013. "Comet: An Open-Source MS/MS Sequence Database Search Tool." *PROTEOMICS* 13 (1): 22–24. <https://doi.org/10.1002/pmic.201200439>.
- Farkas, Gary J., and David R. Gater. 2018. "Neurogenic Obesity and Systemic Inflammation Following Spinal Cord Injury: A Review." *The Journal of Spinal Cord Medicine* 41 (4): 378–87. <https://doi.org/10.1080/10790268.2017.1357104>.
- Fleming, Jennifer C., Christopher S. Bailey, Hans Hundt, Kevin R. Gurr, Stewart I. Bailey, Gediminas Cepinskas, Abdel-rahman Lawendy, and Amit Badhwar. 2012. "Remote Inflammatory Response in Liver Is Dependent on the Segmental Level of Spinal Cord Injury." *Journal of Trauma and Acute Care Surgery* 72 (5): 1194–1201. <https://doi.org/10.1097/ta.0b013e31824d68bd>.
- Francois, Romain. 2020. *Bibtex: Bibtex Parser*. <https://CRAN.R-project.org/package=bibtex>.
- Friedman, G., P. Froom, L. Sazbon, I. Grinblatt, M. Shochina, J. Tsenter, S. Babaey, A. Ben Yehuda, and Z. Groswasser. 1999. "Apolipoprotein E-ε4 Genotype Predicts a Poor Outcome in Survivors of Traumatic Brain Injury." *Neurology* 52 (2): 244–44. <https://doi.org/10.1212/WNL.52.2.244>.
- Frost, Frederick, Mary Jo Roach, Irving Kushner, and Peter Schreiber. 2005. "Inflammatory C-reactive Protein and Cytokine Levels in Asymptomatic People with Chronic Spinal Cord Injury." *Archives of Physical Medicine and Rehabilitation* 86 (2): 312–17. <https://doi.org/10.1016/j.apmr.2004.02.009>.
- Fujita, Tomoko, and Shuh Narumiya. 2016. "Roles of Hepatic Stellate Cells in Liver Inflammation: A New Perspective." *Inflammation and Regeneration* 36 (1). <https://doi.org/10.1186/s41232-016->



- 0005-6.
- Fujiyoshi, Masachika, Masanori Tachikawa, Sumio Ohtsuki, Shingo Ito, Yasuo Uchida, Shin-ichi Akanuma, Junichi Kamiie, et al. 2011. "Amyloid- $\beta$  Peptide(1-40) Elimination from Cerebrospinal Fluid Involves Low-Density Lipoprotein Receptor-Related Protein 1 at the Blood-Cerebrospinal Fluid Barrier." *Journal of Neurochemistry* 118 (3): 407–15. <https://doi.org/10.1111/j.1471-4159.2011.07311.x>.
- Fuller, Heidi R., Robert Slade, Nataša Jovanov-Milošević, Mirjana Babić, Goran Sedmak, Goran Šimić, Matthew A. Fuszard, Sally L. Shirran, Catherine H. Botting, and Monte A. Gates. 2015. "Stathmin Is Enriched in the Developing Corticospinal Tract." *Molecular and Cellular Neuroscience* 69 (November): 12–21. <https://doi.org/10.1016/j.mcn.2015.09.003>.
- Furlan, Julio C, Sivakumar Gulasingham, and B Catharine Craven. 2017. "The Health Economics of the Spinal Cord Injury or Disease Among Veterans of War : A Systematic Review." *The Journal of Spinal Cord Medicine* 40 (6): 649–64. <https://doi.org/10.1080/10790268.2017.1368267>.
- Gabay, Cem, and Irving Kushner. 1999. "Acute-Phase Proteins and Other Systemic Responses to Inflammation." Edited by Franklin H. Epstein. *New England Journal of Medicine* 340 (6): 448–54. <https://doi.org/10.1056/NEJM199902113400607>.
- Gan, Yu, Xunming Ji, Xiaoming Hu, Yumin Luo, Lili Zhang, Peiying Li, Xiangrong Liu, et al. 2012. "Transgenic Overexpression of Peroxiredoxin-2 Attenuates Ischemic Neuronal Injury Via Suppression of a Redox-Sensitive Pro-Death Signaling Pathway." *Antioxidants & Redox Signaling* 17 (5): 719–32. <https://doi.org/10.1089/ars.2011.4298>.
- Gao, Chun-Hui. 2021. *ggVennDiagram: A 'Ggplot2' Implement of Venn Diagram*. <https://CRAN.R-project.org/package=ggVennDiagram>.
- Garcia-Bonilla, Lidia, and Costantino Iadecola. 2012. "Peroxiredoxin Sets the Brain on Fire After Stroke." *Nature Medicine* 18 (6): 858–59. <https://doi.org/10.1038/nm.2797>.
- García-López, P., A. Martínez-Cruz, G. Guízar-Sahagún, and G. Castañeda-Hernández. 2007. "Acute Spinal Cord Injury Changes the Disposition of Some, but Not All Drugs Given Intravenously." *Spinal Cord* 45 (9): 603–8. <https://doi.org/10.1038/sj.sc.3102001>.
- Ghasemlou, Nader, Delphine Bouhy, Jingxuan Yang, Rubèn López-Vales, Michael Haber, Thusanth Thuraisingam, Guoan He, Danuta Radzioch, Aihao Ding, and Samuel David. 2010. "Beneficial Effects of Secretory Leukocyte Protease Inhibitor After Spinal Cord Injury." *Brain* 133 (1): 126–38. <https://doi.org/10.1093/brain/awp304>.
- Gill, Varinder, Christopher Doig, Derrice Knight, Emma Love, and Paul Kubes. 2005. "Targeting Adhesion Molecules as a Potential Mechanism of Action for Intravenous Immunoglobulin." *Circulation* 112 (13): 2031–39. <https://doi.org/10.1161/CIRCULATIONAHA.105.546150>.
- Goecks, Jeremy, Anton Nekrutenko, James Taylor, and The Galaxy Team. 2010. "Galaxy: A Comprehensive Approach for Supporting Accessible, Reproducible, and Transparent Computational Research in the Life Sciences." *Genome Biology* 11 (8): R86. <https://doi.org/10.1186/gb-2010-11-8-r86>.
- Gok, Beril, Daniel M. Sciubba, Ozerk Okutan, Etem Beskonakli, Selcuk Palaoglu, Husamettin Erdamar, and Mustafa F. Sargon. 2009. "Immunomodulation of Acute Experimental Spinal Cord Injury with Human Immunoglobulin G." *Journal of Clinical Neuroscience* 16 (4): 549–53. <https://doi.org/10.1016/j.jocn.2008.04.024>.
- Goodus, Matthew T., Andrew D. Sauerbeck, Phillip G. Popovich, Richard S. Bruno, and Dana M. McTigue. 2018. "Dietary Green Tea Extract Prior to Spinal Cord Injury Prevents Hepatic Iron Overload but Does Not Improve Chronic Hepatic and Spinal Cord Pathology in Rats." *Journal of Neurotrauma* 35 (24): 2872–82. <https://doi.org/10.1089/neu.2018.5771>.
- Gordon, A. H., and A. Koj, eds. 1985. *The Acute-phase Response to Injury and Infection: The Roles of Interleukin I and Other Mediators*. Research Monographs in Cell and Tissue Physiology, v. 10. Amsterdam ; New York : New York, NY, USA: Elsevier ; Sole distributors for the USA and Canada, Elsevier Science Pub. Co.
- Greenhalgh, Andrew D., and Samuel David. 2014. "Differences in the Phagocytic Response of Mi-

1435       croglia and Peripheral Macrophages After Spinal Cord Injury and Its Effects on Cell Death." *The*  
1436       *Journal of Neuroscience* 34 (18): 6316–22. <https://doi.org/10.1523/JNEUROSCI.4912-13.2014>.

1437       Greenhalgh, Andrew D., Juan G. Zarruk, Luke M. Healy, Sam J. Baskar Jesudasan, Priya Jhelum,  
1438       Christopher K. Salmon, Albert Formanek, et al. 2018. "Peripherally Derived Macrophages  
1439       Modulate Microglial Function to Reduce Inflammation After CNS Injury." *PLOS Biology* 16 (10):  
1440       e2005264. <https://doi.org/10.1371/journal.pbio.2005264>.

1441       Gris, Denis, Ellis F. Hamilton, and Lynne C. Weaver. 2008. "The Systemic Inflammatory Response  
1442       After Spinal Cord Injury Damages Lungs and Kidneys." *Experimental Neurology* 211 (1): 259–70.  
1443       <https://doi.org/10.1016/J.EXPNEUROL.2008.01.033>.

1444       Grolemund, Garrett, and Hadley Wickham. 2011. "Dates and Times Made Easy with lubridate." *Journal of Statistical Software* 40 (3): 1–25. <https://www.jstatsoft.org/v40/i03/>.

1445       Gruys, E., M. J. M. Toussaint, T. A. Niewold, and S. J. Koopmans. 2005. "Acute Phase Reaction  
1446       and Acute Phase Proteins." *Journal of Zhejiang University. Science. B* 6 (11): 1045–56. <https://doi.org/10.1631/jzus.2005.B1045>.

1447       Gungor, Bilgi, Emre Adiguzel, Ihsan Gursel, Bilge Yilmaz, and Mayda Gursel. 2016. "Intestinal Mi-  
1448       crobiota in Patients with Spinal Cord Injury." *PLOS ONE* 11 (1): e0145878. <https://doi.org/10.1371/journal.pone.0145878>.

1449       Gunnarsson, Martin, and Poul Erik H. Jensen. 1998. "Binding of Soluble Myelin Basic Protein to  
1450       Various Conformational Forms of A2-Macroglobulin." *Archives of Biochemistry and Biophysics*  
1451       359 (2): 192–98. <https://doi.org/10.1006/abbi.1998.0902>.

1452       Hall, Jodie C. E., John V. Priestley, V. Hugh Perry, and Adina T. Michael-Titus. 2012. "Docosahex-  
1453       aenoic Acid, but Not Eicosapentaenoic Acid, Reduces the Early Inflammatory Response Fol-  
1454       lowing Compression Spinal Cord Injury in the Rat." *Journal of Neurochemistry* 121 (5): 738–50.  
1455       <https://doi.org/10.1111/j.1471-4159.2012.07726.x>.

1456       Hall, Philip K., Lynn P. Nelles, James Travis, and Ronald C. Roberts. 1981. "Proteolytic Cleavage Sites  
1457       on A2-Macroglobulin Resulting in Proteinase Binding Are Different for Trypsin and Staphylococ-  
1458       cus Aureus V-8 Proteinase." *Biochemical and Biophysical Research Communications* 100 (1): 8–16.  
1459       [https://doi.org/10.1016/S0006-291X\(81\)80055-1](https://doi.org/10.1016/S0006-291X(81)80055-1).

1460       Harrell Jr, Frank E. 2021. *Hmisc: Harrell Miscellaneous*. <https://CRAN.R-project.org/package=Hmisc>.

1461       Haskell, Gloria Thompson, Thomas Michael Maynard, Ron Andrew Shatzmiller, and Anthony-  
1462       Samuel Lamantia. 2002. "Retinoic Acid Signaling at Sites of Plasticity in the Mature  
1463       Central Nervous System." *Journal of Comparative Neurology* 452 (3): 228–41. <https://doi.org/10.1002/cne.10369>.

1464       Hasturk, Askin, Basar Atalay, Tarkan Calisaneller, Ozgur Ozdemir, Hakan Oruckaptan, and Nur Al-  
1465       tinors. 2009. "Analysis of Serum Levels After Rat Spinal Cord Ischemia/Reperfusion Injury and  
1466       Correlation with Tissue Damage." *Turkish Neurosurgery* 19: 353–59.

1467       Hayes, K.c., T.c.l. Hull, G.a. Delaney, P.j. Potter, K.a.j. Sequeira, K. Campbell, and P.g. Popovich.  
1468       2002. "Elevated Serum Titers of Proinflammatory Cytokines and CNS Autoantibodies in Patients  
1469       with Chronic Spinal Cord Injury." *Journal of Neurotrauma* 19 (6): 753–61. <https://doi.org/10.1089/08977150260139129>.

1470       Henry, Lionel, and Hadley Wickham. 2020. *Purrr: Functional Programming Tools*. <https://CRAN.R-project.org/package=purrr>.

1471       ———. 2022. *Rlang: Functions for Base Types and Core r and 'Tidyverse' Features*. <https://CRAN.R-project.org/package=rlang>.

1472       Ho, Wei-Te, Kuo-Cheng Yeh, and Shin-Liang Pan. 2021. "Increased Risk of Acute Pancreatitis in  
1473       Persons with Spinal Cord Injury: A Population-Based, Propensity Score-Matched Longitudinal  
1474       Follow-up Study." *Spinal Cord*, June, 1–7. <https://doi.org/10.1038/s41393-021-00643-3>.

1475       Horn, Kevin P., Sarah A. Busch, Alicia L. Hawthorne, Nico van Rooijen, and Jerry Silver. 2008. "An-  
1476       other Barrier to Regeneration in the CNS: Activated Macrophages Induce Extensive Retraction  
1477       of Dystrophic Axons Through Direct Physical Interactions." *The Journal of Neuroscience* 28 (38):  
1478       9330–41. <https://doi.org/10.1523/JNEUROSCI.2488-08.2008>.

Hulme, C. H., S. J. Brown, H. R. Fuller, J. Riddell, A. Osman, J. Chowdhury, N. Kumar, W. E. Johnson, and K. T. Wright. 2017. "The Developing Landscape of Diagnostic and Prognostic Biomarkers for Spinal Cord Injury in Cerebrospinal Fluid and Blood." *Spinal Cord* 55 (2): 114–25. <https://doi.org/10.1038/sc.2016.174>.

Hulstaert, Niels, Jim Shofstahl, Timo Sachsenberg, Mathias Walzer, Harald Barsnes, Lennart Martens, and Yasset Perez-Riverol. 2020. "ThermoRawFileParser: Modular, Scalable, and Cross-Platform RAW File Conversion." *Journal of Proteome Research* 19 (1): 537–42. <https://doi.org/10.1021/acs.jproteome.9b00328>.

Hundt, H., J. C. Fleming, J. T. Phillips, A. Lawendy, K. R. Gurr, S. I. Bailey, D. Sanders, et al. 2011. "Assessment of Hepatic Inflammation After Spinal Cord Injury Using Intravital Microscopy." *Injury* 42 (7): 691–96. <https://doi.org/10.1016/j.injury.2010.12.013>.

Hurst, Robert E., Przemyslaw Waliszewski, Mirosława Waliszewska, Rebecca B. Bonner, Doris M. Benbrook, Arindam Dar, and George P. Hemstreet. 1999. "Complexity, Retinoid-Responsive Gene Networks, and Bladder Carcinogenesis." In *Advances in Bladder Research*, edited by Laurence S. Baskin and Simon W. Hayward, 462:449–67. Advances in Experimental Medicine and Biology. Boston, MA: Springer US. [https://doi.org/10.1007/978-1-4615-4737-2\\_35](https://doi.org/10.1007/978-1-4615-4737-2_35).

Iannone, Richard. 2022. *DiagrammeR: Graph/Network Visualization*. <https://CRAN.R-project.org/package=DiagrammeR>.

Imbach, P., V. d'APUZZO, A. Hirt, E. Rossi, M. Vest, S. Barandun, C. Baumgartner, A. Morell, M. Schöni, and H. P. Wagner. 1981. "HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOOD." *The Lancet* 317 (8232): 1228–31. [https://doi.org/10.1016/S0140-6736\(81\)92400-4](https://doi.org/10.1016/S0140-6736(81)92400-4).

Iwata, Akira, Kevin D. Browne, Xiao-Han Chen, Takamichi Yuguchi, and Douglas H. Smith. 2005. "Traumatic Brain Injury Induces Biphasic Upregulation of ApoE and ApoJ Protein in Rats." *Journal of Neuroscience Research* 82 (1): 103–14. <https://doi.org/10.1002/jnr.20607>.

Jassal, Bijay, Lisa Matthews, Guilherme Viteri, Chuqiao Gong, Pascual Lorente, Antonio Fabregat, Konstantinos Sidiropoulos, et al. 2020. "The Reactome Pathway Knowledgebase." *Nucleic Acids Research* 48 (D1): D498–503. <https://doi.org/10.1093/nar/gkz1031>.

Jenne, Craig N., and Paul Kubes. 2013. "Immune Surveillance by the Liver." *Nature Immunology* 14 (10): 996–1006. <https://doi.org/10.1038/ni.2691>.

Jeong, Seongtae, Beilei Lei, Haichen Wang, Hana N. Dawson, and Michael L. James. 2014. "Intravenous Immunoglobulin G Improves Neurobehavioral and Histological Outcomes After Traumatic Brain Injury in Mice." *Journal of Neuroimmunology* 276 (1): 112–18. <https://doi.org/10.1016/j.jneuroim.2014.08.626>.

Jha, Amitabh, Daniel P Lammertse, Joseph R Coll, Susan Charlifue, Christopher T Coughlin, Gale G Whiteneck, and Gordon Worley. 2008. "Apolipoprotein E E4 Allele and Outcomes of Traumatic Spinal Cord Injury." *The Journal of Spinal Cord Medicine* 31 (2): 171–76.

Kaneko, Yoshikatsu, Falk Nimmerjahn, Michael P. Madaio, and Jeffrey V. Ravetch. 2006. "Pathology and Protection in Nephrotoxic Nephritis Is Determined by Selective Engagement of Specific Fc Receptors." *Journal of Experimental Medicine* 203 (3): 789–97. <https://doi.org/10.1084/jem.20051900>.

Karlsson, A.-K. 1999. "Insulin Resistance and Sympathetic Function in High Spinal Cord Injury." *Spinal Cord* 37 (7): 494–500. <https://doi.org/10.1038/sj.sc.3100844>.

Kazankov, Konstantin, Simon Mark Dahl Jørgensen, Karen Louise Thomsen, Holger Jon Møller, Hendrik Vilstrup, Jacob George, Detlef Schuppan, and Henning Grønbaek. 2019. "The Role of Macrophages in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis." *Nature Reviews Gastroenterology & Hepatology* 16 (3): 145–59. <https://doi.org/10.1038/s41575-018-0082-x>.

Khan, S. 2004. "Oxidized Caprine Alpha-2-Macroglobulin: Damaged but Not Completely Dysfunctional." *Biochimica Et Biophysica Acta (BBA) - General Subjects*, July. <https://doi.org/10.1016/j.bbagen.2004.06.008>.

Kigerl, Kristina A., John C. Gensel, Daniel P. Ankeny, Jessica K. Alexander, Dustin J. Donnelly, and

1537 Phillip G. Popovich. 2009. "Identification of Two Distinct Macrophage Subsets with Divergent  
1538 Effects Causing Either Neurotoxicity or Regeneration in the Injured Mouse Spinal Cord." *Journal*  
1539 *of Neuroscience* 29 (43): 13435–44. <https://doi.org/10.1523/JNEUROSCI.3257-09.2009>.

1540 Kigerl, Kristina A., Jodie C. E. Hall, Lingling Wang, Xiaokui Mo, Zhongtang Yu, and Phillip G. Popovich.  
1541 2016. "Gut Dysbiosis Impairs Recovery After Spinal Cord Injury." *Journal of Experimental Medicine*  
1542 213 (12): 2603–20. <https://doi.org/10.1084/jem.20151345>.

1543 Kigerl, Kristina A., Violeta M. McGaughy, and Phillip G. Popovich. 2006. "Comparative Analysis  
1544 of Lesion Development and Intraspinal Inflammation in Four Strains of Mice Following Spinal  
1545 Contusion Injury." *Journal of Comparative Neurology* 494 (4): 578–94. <https://doi.org/10.1002/cn>  
1546 e.20827.

1547 Kigerl, Kristina A., Klauss Mostacada, and Phillip G. Popovich. 2018. "Gut Microbiota Are Disease-  
1548 Modifying Factors After Traumatic Spinal Cord Injury." *Neurotherapeutics* 15 (1): 60–67. <https://doi.org/10.1007/s13311-017-0583-2>.

1549

1550 Kim, Hyeon Ju, Michael Rowe, Ming Ren, Jau-Shyong Hong, Po-See Chen, and De-Maw Chuang.  
1551 2007. "Histone Deacetylase Inhibitors Exhibit Anti-Inflammatory and Neuroprotective Effects in  
1552 a Rat Permanent Ischemic Model of Stroke: Multiple Mechanisms of Action." *Journal of Pharma-*  
1553 *cology and Experimental Therapeutics* 321 (3): 892–901. <https://doi.org/10.1124/jpet.107.120188>.

1554 Kim, Myung-Hee, Maria C. de Beer, Joanne M. Wroblewski, Nancy R. Webb, and Frederick C. de  
1555 Beer. 2013. "SAA Does Not Induce Cytokine Production in Physiological Conditions." *Cytokine*  
1556 61 (2): 506–12. <https://doi.org/10.1016/j.cyto.2012.10.019>.

1557 Kim, So Yong, Tae Jin Kim, and Ki-Young Lee. 2008. "A Novel Function of Peroxiredoxin 1 (Prx-1) in  
1558 Apoptosis Signal-Regulating Kinase 1 (Ask1)-Mediated Signaling Pathway." *FEBS Letters* 582 (13):  
1559 1913–18. <https://doi.org/10.1016/j.febslet.2008.05.015>.

1560 Kisilevsky, R. 1991. "Serum Amyloid A (SAA), a Protein Without a Function: Some Suggestions with  
1561 Reference to Cholesterol Metabolism." *Medical Hypotheses* 35 (4): 337–41. <https://doi.org/10.1>  
1562 016/0306-9877(91)90280-C.

1563 Kisilevsky, Robert, and Paul N. Manley. 2012. "Acute-Phase Serum Amyloid A: Perspectives on Its  
1564 Physiological and Pathological Roles." *Amyloid* 19 (1): 5–14. <https://doi.org/10.3109/13506129>  
1565 .2011.654294.

1566 Kisilevsky, R., and L. Subrahmanyam. 1992. "Serum Amyloid A Changes High Density Lipoprotein's  
1567 Cellular Affinity. A Clue to Serum Amyloid A's Principal Function." *Laboratory Investigation; a*  
1568 *Journal of Technical Methods and Pathology* 66 (6): 778–85.

1569 Komine-Kobayashi, Miki, Nei Chou, Hideki Mochizuki, Atsuhito Nakao, Yoshikuni Mizuno, and  
1570 Takao Urabe. 2004. "Dual Role of Fc $\gamma$  Receptor in Transient Focal Cerebral Ischemia in Mice." *Stroke* 35 (4): 958–63. <https://doi.org/10.1161/01.STR.0000120321.30916.8E>.

1571

1572 Kwon, Brian K., Ona Bloom, Ina-Beate Wanner, Armin Curt, Jan M. Schwab, James Fawcett, and  
1573 Kevin K. Wang. 2019. "Neurochemical Biomarkers in Spinal Cord Injury." *Spinal Cord* 57 (10):  
1574 819–31. <https://doi.org/10.1038/s41393-019-0319-8>.

1575 Kwon, Brian K, Anthea M T Stammers, Lise M Belanger, Arlene Bernardo, Donna Chan, Carole M  
1576 Bishop, Gerard P Slobogean, et al. 2010. "Cerebrospinal Fluid Inflammatory Cytokines and  
1577 Biomarkers of Injury Severity in Acute Human Spinal Cord Injury." *Journal of Neurotrauma* 27  
1578 (4): 669–82. <https://doi.org/10.1089/neu.2009.1080>.

1579 Lane, Michelle A., and Sarah J. Bailey. 2005. "Role of Retinoid Signalling in the Adult Brain." *Progress*  
1580 *in Neurobiology* 75 (4): 275–93. <https://doi.org/10.1016/j.pneurobio.2005.03.002>.

1581 Lapointe, Benoît M., Leonie M. Herx, Varinder Gill, Luanne M. Metz, and Paul Kubes. 2004. "IVig  
1582 Therapy in Brain Inflammation: Etiology-Dependent Differential Effects on Leucocyte Recruit-  
1583 ment." *Brain* 127 (12): 2649–56. <https://doi.org/10.1093/brain/awh297>.

1584 Larios, Jorge A., and Maria-Paz Marzolo. 2012. "Novel Aspects of the Apolipoprotein-E Receptor  
1585 Family: Regulation and Functional Role of Their Proteolytic Processing." *Frontiers in Biology* 7  
1586 (2): 113–43. <https://doi.org/10.1007/s11515-011-1186-7>.

1587 Lavoie, J. -M., and M. -S. Gauthier. 2006. "Regulation of Fat Metabolism in the Liver: Link to Non-

- Alcoholic Hepatic Steatosis and Impact of Physical Exercise." *Cellular and Molecular Life Sciences CMLS* 63 (12): 1393–1409. <https://doi.org/10.1007/s00018-006-6600-y>.
- Lee, Matthew, Jonathan Myers, Amy Hayes, Sherna Madan, Victor F. Froelicher, Inder Perakash, and B. Jenny Kiratli. 2004. "C-Reactive Protein, Metabolic Syndrome, and Insulin Resistance in Individuals With Spinal Cord Injury." *The Journal of Spinal Cord Medicine* 28 (1): 20–25. <https://doi.org/10.1080/10790268.2005.11753794>.
- Lin, Zhenxin, Andy Lo, Diane M. Simeone, Mack T. Ruffin, and David M. Lubman. 2012. "An N-glycosylation Analysis of Human Alpha-2-Macroglobulin Using an Integrated Approach." *Journal of Proteomics & Bioinformatics* 5 (May): 127–34. <https://doi.org/10.4172/jpb.1000224>.
- Lindborg, Jane A., Matthias Mack, and Richard E. Zigmond. 2017. "Neutrophils Are Critical for Myelin Removal in a Peripheral Nerve Injury Model of Wallerian Degeneration." *Journal of Neuroscience* 37 (43): 10258–77. <https://doi.org/10.1523/JNEUROSCI.2085-17.2017>.
- Liu, Chia-Chen, Takahisa Kanekiyo, Huaxi Xu, and Guojun Bu. 2013. "Apolipoprotein E and Alzheimer Disease: Risk, Mechanisms, and Therapy." *Nature Reviews. Neurology* 9 (2): 106–18. <https://doi.org/10.1038/nrneurol.2012.263>.
- Liu, JianWei, Hong An, DianMing Jiang, Wei Huang, HaiBo Zou, ChunYang Meng, and HongYu Li. 2004. "Study of Bacterial Translocation From Gut After Paraplegia Caused by Spinal Cord Injury in Rats." *Spine* 29 (2): 164–69. <https://doi.org/10.1097/01.BRS.0000107234.74249.CD>.
- Low, Felicia M., Mark B. Hampton, and Christine C. Winterbourn. 2008. "Peroxiredoxin 2 and Peroxide Metabolism in the Erythrocyte." *Antioxidants & Redox Signaling* 10 (9): 1621–30. <https://doi.org/10.1089/ars.2008.2081>.
- Lu, Jinghua, Yadong Yu, Iowis Zhu, Yifan Cheng, and Peter D. Sun. 2014. "Structural Mechanism of Serum Amyloid A-mediated Inflammatory Amyloidosis." *Proceedings of the National Academy of Sciences* 111 (14): 5189–94. <https://doi.org/10.1073/pnas.1322357111>.
- Lu, Yue, Xiang-Sheng Zhang, Zi-Huan Zhang, Xiao-Ming Zhou, Yong-Yue Gao, Guang-Jie Liu, Han Wang, Ling-Yun Wu, Wei Li, and Chun-Hua Hang. 2018. "Peroxiredoxin 2 Activates Microglia by Interacting with Toll-like Receptor 4 After Subarachnoid Hemorrhage." *Journal of Neuroinflammation* 15 (1): 87. <https://doi.org/10.1186/s12974-018-1118-4>.
- Lu, Yue, Xiang-Sheng Zhang, Xiao-Ming Zhou, Yong-Yue Gao, Chun-Lei Chen, Jing-Peng Liu, Zhen-Nan Ye, et al. 2019. "Peroxiredoxin 1/2 Protects Brain Against H<sub>2</sub>O<sub>2</sub>-induced Apoptosis After Subarachnoid Hemorrhage." *The FASEB Journal* 33 (2): 3051–62. <https://doi.org/10.1096/fj.201801150R>.
- Lubieniecka, Joanna M., Femke Streijger, Jae H. T. Lee, Nikolay Stoyanov, Jie Liu, Randy Mottus, Tom Pfeifer, et al. 2011. "Biomarkers for Severity of Spinal Cord Injury in the Cerebrospinal Fluid of Rats." *PLOS ONE* 6 (4): e19247. <https://doi.org/10.1371/journal.pone.0019247>.
- Lünemann, Jan D., Falk Nimmerjahn, and Marinos C. Dalakas. 2015. "Intravenous Immunoglobulin in Neurology—mode of Action and Clinical Efficacy." *Nature Reviews Neurology* 11 (2): 80–89. <https://doi.org/10.1038/nrneurol.2014.253>.
- Mackness, Michael I., Paul N. Durrington, and Bharti Mackness. 2004. "The Role of Paraoxonase 1 Activity in Cardiovascular Disease." *American Journal of Cardiovascular Drugs* 4 (4): 211–17. <https://doi.org/10.2165/00129784-200404040-00002>.
- Maden, M., D. E. Ong, and F. Chytil. 1990. "Retinoid-Binding Protein Distribution in the Developing Mammalian Nervous System." *Development* 109 (1): 75–80.
- Mahley, Robert W., and Stanley C. Rall. 2000. "Apolipoprotein E: Far More Than a Lipid Transport Protein." *Annual Review of Genomics and Human Genetics* 1 (1): 507–37. <https://doi.org/10.1146/annurev.genom.1.1.507>.
- Mahley, Robert W., Karl H. Weisgraber, and Yadong Huang. 2006. "Apolipoprotein E4: A Causative Factor and Therapeutic Target in Neuropathology, Including Alzheimer's Disease." *Proceedings of the National Academy of Sciences* 103 (15): 5644–51. <https://doi.org/10.1073/pnas.0600549103>.
- Maikos, Jason T., and David I. Shreiber. 2007. "Immediate Damage to The Blood-Spinal Cord Barrier



- Due to Mechanical Trauma." *Journal of Neurotrauma* 24 (3): 492–507. <https://doi.org/10.1089/neu.2006.0149>.
- Malaspina, Andrea, Narendra Kaushik, and Jackie De Bellerocche. 2001. "Differential Expression of 14 Genes in Amyotrophic Lateral Sclerosis Spinal Cord Detected Using Gridded cDNA Arrays." *Journal of Neurochemistry* 77 (1): 132–45. <https://doi.org/10.1046/j.1471-4159.2001.00231.x>.
- Maruyama, Y., M. Mizuguchi, T. Yaginuma, M. Kusaka, H. Yoshida, K. Yokoyama, Y. Kasahara, and T. Hosoya. 2008. "Serum Leptin, Abdominal Obesity and the Metabolic Syndrome in Individuals with Chronic Spinal Cord Injury." *Spinal Cord* 46 (7): 494–99. <https://doi.org/10.1038/sj.sc.3102171>.
- Marzi, Carola, Cornelia Huth, Christian Herder, Jens Baumert, Barbara Thorand, Wolfgang Rathmann, Christa Meisinger, et al. 2013. "Acute-Phase Serum Amyloid A Protein and Its Implication in the Development of Type 2 Diabetes in the KORA S4/F4 Study." *Diabetes Care* 36 (5): 1321–26. <https://doi.org/10.2337/dc12-1514>.
- Matsuzawa, Atsushi, Kaoru Saegusa, Takuya Noguchi, Chiharu Sadamitsu, Hideki Nishitoh, Shigenori Nagai, Shigeo Koyasu, Kunihiro Matsumoto, Kohsuke Takeda, and Hide-nori Ichijo. 2005. "ROS-dependent Activation of the TRAF6-ASK1-p38 Pathway Is Selectively Required for TLR4-mediated Innate Immunity." *Nature Immunology* 6 (6): 587–92. <https://doi.org/10.1038/ni1200>.
- McDaid, David, A.-La Park, Angela Gall, Mariel Purcell, and Mark Bacon. 2019. "Understanding and Modelling the Economic Impact of Spinal Cord Injuries in the United Kingdom." *Spinal Cord* 57 (9): 778–88. <https://doi.org/10.1038/s41393-019-0285-1>.
- Meek, R. L., S. Urieli-Shoval, and E. P. Benditt. 1994. "Expression of Apolipoprotein Serum Amyloid A mRNA in Human Atherosclerotic Lesions and Cultured Vascular Cells: Implications for Serum Amyloid A Function." *Proceedings of the National Academy of Sciences* 91 (8): 3186–90. <https://doi.org/10.1073/pnas.91.8.3186>.
- Milosevic, Ivana, Ankica Vujovic, Aleksandra Barac, Marina Djelic, Milos Korac, Aleksandra Radovanovic Spurnic, Ivana Gmizic, et al. 2019. "Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature." *International Journal of Molecular Sciences* 20 (2): 395. <https://doi.org/10.3390/ijms20020395>.
- Mimura, Yoshihiro, Shotaro Sakisaka, Masaru Harada, Michio Sata, and Kyuichi Tanikawa. 1995. "Role of Hepatocytes in Direct Clearance of Lipopolysaccharide in Rats." *Gastroenterology* 109 (6): 1969–76. [https://doi.org/10.1016/0016-5085\(95\)90765-3](https://doi.org/10.1016/0016-5085(95)90765-3).
- Mishra, Aarti, and Roberta D. Brinton. 2018. "Inflammation: Bridging Age, Menopause and Apoe4 Genotype to Alzheimer's Disease." *Frontiers in Aging Neuroscience* 10. <https://doi.org/10.3389/fnagi.2018.00312>.
- Miyata, M., and J. D. Smith. 1996. "Apolipoprotein E Allele-Specific Antioxidant Activity and Effects on Cytotoxicity by Oxidative Insults and Beta-Amyloid Peptides." *Nature Genetics* 14 (1): 55–61. <https://doi.org/10.1038/ng0996-55>.
- Morgan, Martin. 2021. *BiocManager: Access the Bioconductor Project Package Repository*. <https://CRAN.R-project.org/package=BiocManager>.
- Myers, Jonathan, Matthew Lee, and Jenny Kiratli. 2007. "Cardiovascular Disease in Spinal Cord Injury: An Overview of Prevalence, Risk, Evaluation, and Management." *American Journal of Physical Medicine & Rehabilitation* 86 (2): 142–52. <https://doi.org/10.1097/PHM.0b013e31802f0247>.
- Myers, Scott A., Leila Gobejishvili, Sujata Saraswat Ohri, C. Garrett Wilson, Kariena R. Andres, Amberly S. Riegler, Hridgandh Donde, Swati Joshi-Barve, Shirish Barve, and Scott R. Whittemore. 2019. "Following Spinal Cord Injury, Pde4b Drives an Acute, Local Inflammatory Response and a Chronic, Systemic Response Exacerbated by Gut Dysbiosis and Endotoxemia." *Neurobiology of Disease* 124 (April): 353–63. <https://doi.org/10.1016/j.nbd.2018.12.008>.
- Nagele, Eric P., Min Han, Nimish K. Acharya, Cassandra DeMarshall, Mary C. Kosciuk, and Robert G. Nagele. 2013. "Natural IgG Autoantibodies Are Abundant and Ubiquitous in Human Sera,

and Their Number Is Influenced By Age, Gender, and Disease." *PLOS ONE* 8 (4): e60726. <https://doi.org/10.1371/journal.pone.0060726>.

Nahrendorf, Matthias, Filip K. Swirski, Elena Aikawa, Lars Stangenberg, Thomas Wurdinger, Jose-Luiz Figueiredo, Peter Libby, Ralph Weissleder, and Mikael J. Pittet. 2007. "The Healing Myocardium Sequentially Mobilizes Two Monocyte Subsets with Divergent and Complementary Functions." *The Journal of Experimental Medicine* 204 (12): 3037–47. <https://doi.org/10.1084/jem.20070885>.

Narang, Aarti, Fei Qiao, Carl Atkinson, Hong Zhu, Xiaofeng Yang, Liudmila Kulik, V. Michael Holers, and Stephen Tomlinson. 2017. "Natural IgM Antibodies That Bind Neoepitopes Exposed as a Result of Spinal Cord Injury, Drive Secondary Injury by Activating Complement." *Journal of Neuroinflammation* 14 (1): 120. <https://doi.org/10.1186/s12974-017-0894-6>.

Neuwirth, Erich. 2014. *RColorBrewer: ColorBrewer Palettes*. <https://CRAN.R-project.org/package=RColorBrewer>.

Nguyen, Dung Hoang, Newton Cho, Kajana Satkunendrarajah, James W Austin, Jian Wang, and Michael G Fehlings. 2012. "Immunoglobulin G (IgG) Attenuates Neuroinflammation and Improves Neurobehavioral Recovery After Cervical Spinal Cord Injury." *Journal of Neuroinflammation* 9 (September): 224. <https://doi.org/10.1186/1742-2094-9-224>.

O'Connor, Gregory, Elisabeth Jeffrey, Derik Madorma, Alexander Marcillo, Maria T. Abreu, Sapna K. Deo, W. Dalton Dietrich, and Sylvia Daunert. 2018. "Investigation of Microbiota Alterations and Intestinal Inflammation Post-Spinal Cord Injury in Rat Model." *Journal of Neurotrauma* 35 (18): 2159–66. <https://doi.org/10.1089/neu.2017.5349>.

Okada, Seiji. 2016. "The Pathophysiological Role of Acute Inflammation After Spinal Cord Injury." *Inflammation and Regeneration* 36 (October): 20. <https://doi.org/10.1186/s41232-016-0026-1>.

Pagadala, Mangesh, Takhar Kasumov, Arthur J. McCullough, Nizar N. Zein, and John P. Kirwan. 2012. "Role of Ceramides in Nonalcoholic Fatty Liver Disease." *Trends in Endocrinology & Metabolism* 23 (8): 365–71. <https://doi.org/10.1016/j.tem.2012.04.005>.

Palmers, Ilse, Elke Ydens, Eric Put, Bart Depreitere, Helma Bongers-Janssen, Peter Pickkers, Sven Hendrix, and Veerle Somers. 2016. "Antibody Profiling Identifies Novel Antigenic Targets in Spinal Cord Injury Patients." *Journal of Neuroinflammation* 13 (1): 243. <https://doi.org/10.1186/s12974-016-0713-5>.

Park, Jin-Sun, Moon-Sook Woo, So-Young Kim, Won-Ki Kim, and Hee-Sun Kim. 2005. "Repression of Interferon- $\gamma$ -Induced Inducible Nitric Oxide Synthase (iNOS) Gene Expression in Microglia by Sodium Butyrate Is Mediated Through Specific Inhibition of ERK Signaling Pathways." *Journal of Neuroimmunology* 168 (1): 56–64. <https://doi.org/10.1016/j.jneuroim.2005.07.003>.

Pedersen, Thomas Lin, and Michaël Benesty. 2021. *Lime: Local Interpretable Model-Agnostic Explanations*. <https://CRAN.R-project.org/package=lime>.

Pepys, M. B., and Marilyn L. Baltz. 1983. "Acute Phase Proteins with Special Reference to C-Reactive Protein and Related Proteins (Pentaxins) and Serum Amyloid A Protein." In *Advances in Immunology*, edited by Frank J. Dixon and Henry G. Kunkel, 34:141–212. Academic Press. [https://doi.org/10.1016/S0065-2776\(08\)60379-X](https://doi.org/10.1016/S0065-2776(08)60379-X).

Perussia, B, M M Tutt, W Q Qiu, W A Kuziel, P W Tucker, G Trinchieri, M Bennett, J V Ravetch, and V Kumar. 1989. "Murine Natural Killer Cells Express Functional Fc Gamma Receptor II Encoded by the Fc Gamma R Alpha Gene." *Journal of Experimental Medicine* 170 (1): 73–86. <https://doi.org/10.1084/jem.170.1.73>.

Peterson, P. A. 1971. "Studies on the Interaction Between Prealbumin, Retinol-Binding Protein, and Vitamin A." *The Journal of Biological Chemistry* 246 (1): 44–49.

Peterson, Sheri L., and Aileen J. Anderson. 2014. "Complement and Spinal Cord Injury: Traditional and Non-Traditional Aspects of Complement Cascade Function in the Injured Spinal Cord Microenvironment." *Experimental Neurology*, Special Issue: Neuroimmunology of spinal cord injury, 258 (August): 35–47. <https://doi.org/10.1016/j.expneurol.2014.04.028>.

Pierani, Alessandra, Susan Brenner-Morton, Chin Chiang, and Thomas M Jessell. 1999. "A Sonic

Hedgehog-Independent, Retinoid-Activated Pathway of Neurogenesis in the Ventral Spinal Cord." *Cell* 97 (7): 903–15. [https://doi.org/10.1016/S0092-8674\(00\)80802-8](https://doi.org/10.1016/S0092-8674(00)80802-8).

Pineau, Isabelle, and Steve Lacroix. 2006. "Proinflammatory Cytokine Synthesis in the Injured Mouse Spinal Cord : Multiphasic Expression Pattern and Identification of the Cell Types Involved." *Journal of Comparative Neurology* 285 (2): 267–85. <https://doi.org/10.1002/cne.21149>.

Poirier, Jules. 1994. "Apolipoprotein E in Animal Models of CNS Injury and in Alzheimer's Disease." *Trends in Neurosciences* 17 (12): 525–30. [https://doi.org/10.1016/0166-2236\(94\)90156-2](https://doi.org/10.1016/0166-2236(94)90156-2).

Popovich, Phillip G., Zhen Guan, Ping Wei, Inge Huitinga, Nico van Rooijen, and Bradford T. Stokes. 1999. "Depletion of Hematogenous Macrophages Promotes Partial Hindlimb Recovery and Neuroanatomical Repair After Experimental Spinal Cord Injury." *Experimental Neurology* 158 (2): 351–65. <https://doi.org/10.1006/exnr.1999.7118>.

Prüss, Harald, Marcel A Kopp, Benedikt Brommer, Nicole Gatzemeier, Ines Laginha, Ulrich Dirnagl, and Jan M Schwab. 2011. "Non-Resolving Aspects of Acute Inflammation After Spinal Cord Injury (SCI): Indices and Resolution Plateau." *Brain Pathology (Zurich, Switzerland)* 21 (6): 652–60. <https://doi.org/10.1111/j.1750-3639.2011.00488.x>.

Qiao, Fei, Carl Atkinson, Hongbin Song, Ravinder Pannu, Inderjit Singh, and Stephen Tomlinson. 2006. "Complement Plays an Important Role in Spinal Cord Injury and Represents a Therapeutic Target for Improving Recovery Following Trauma." *The American Journal of Pathology* 169 (3): 1039–47. <https://doi.org/10.2353/ajpath.2006.060248>.

R Core Team. 2022. *R: A Language and Environment for Statistical Computing*. Vienna, Austria: R Foundation for Statistical Computing. <https://www.R-project.org/>.

Rehman, Ahmed A., Haseeb Ahsan, and Fahim H. Khan. 2013. "Alpha-2-Macroglobulin: A Physiological Guardian." *Journal of Cellular Physiology* 228 (8): 1665–75. <https://doi.org/10.1002/jcp.24266>.

Revelle, William. 2022. *Psych: Procedures for Psychological, Psychometric, and Personality Research*. Evanston, Illinois: Northwestern University. <https://CRAN.R-project.org/package=psych>.

Rhee, Sue Goo, and Hyun Ae Woo. 2011. "Multiple Functions of Peroxiredoxins: Peroxidases, Sensors and Regulators of the Intracellular Messenger H<sub>2</sub>O<sub>2</sub>, and Protein Chaperones." *Antioxidants & Redox Signaling* 15 (3): 781–94. <https://doi.org/10.1089/ars.2010.3393>.

Röst, Hannes L., Timo Sachsenberg, Stephan Aiche, Chris Bielow, Hendrik Weisser, Fabian Aicheler, Sandro Andreotti, et al. 2016. "OpenMS: A Flexible Open-Source Software Platform for Mass Spectrometry Data Analysis." *Nature Methods* 13 (9): 741–48. <https://doi.org/10.1038/nmeth.3959>.

Salzano, Sonia, Paola Checconi, Eva-Maria Hanschmann, Christopher Horst Lillig, Lucas D. Bowler, Philippe Chan, David Vaudry, et al. 2014. "Linkage of Inflammation and Oxidative Stress via Release of Glutathionylated Peroxiredoxin-2, Which Acts as a Danger Signal." *Proceedings of the National Academy of Sciences* 111 (33): 12157–62. <https://doi.org/10.1073/pnas.1401712111>.

Samuelsson, Astrid, Terri L. Towers, and Jeffrey V. Ravetch. 2001. "Anti-Inflammatory Activity of IVIG Mediated Through the Inhibitory Fc Receptor." *Science* 291 (5503): 484–86. <https://doi.org/10.1126/science.291.5503.484>.

Santo, Carmela De, Ramon Arscott, Sarah Booth, Ioannis Karydis, Margaret Jones, Ruth Asher, Mariolina Salio, Mark Middleton, and Vincenzo Cerundolo. 2010. "Invariant NKT Cells Modulate the Suppressive Activity of IL-10-secreting Neutrophils Differentiated with Serum Amyloid A." *Nature Immunology* 11 (11): 1039–46. <https://doi.org/10.1038/ni.1942>.

Sauerbeck, Andrew D., J. Lukas Laws, Veera V. R. Bandaru, Phillip G. Popovich, Norman J. Haughey, and Dana M. McTigue. 2014. "Spinal Cord Injury Causes Chronic Liver Pathology in Rats." *Journal of Neurotrauma* 32 (3): 159–69. <https://doi.org/10.1089/neu.2014.3497>.

Schilling, Joel D., Heather M. Machkovech, Li He, Rohini Sidhu, Hideji Fujiwara, Cassandra Weber, Daniel S. Ory, and Jean E. Schaffer. 2013. "Palmitate and Lipopolysaccharide Trigger Synergistic Ceramide Production in Primary Macrophages \*." *Journal of Biological Chemistry* 288 (5): 2923–32. <https://doi.org/10.1074/jbc.M112.419978>.



- 1792 Schneider, Christoph, Simone Wicki, Stefanie Graeter, Tankica M. Timcheva, Christian W. Keller,  
1793 Isaak Quast, Danila Leontyev, et al. 2017. "IVIG Regulates the Survival of Human but Not Mouse  
1794 Neutrophils." *Scientific Reports* 7 (1): 1296. <https://doi.org/10.1038/s41598-017-01404-0>.
- 1795 Schwab, Inessa, and Falk Nimmerjahn. 2013. "Intravenous Immunoglobulin Therapy: How Does  
1796 IgG Modulate the Immune System?" *Nature Reviews Immunology* 13 (3): 176–89. <https://doi.org/10.1038/nri3401>.
- 1797 Segal, J. L., E. Gonzales, S. Yousefi, L. Jamshidipour, and S. R. Brunnemann. 1997. "Circulating Levels  
1798 of IL-2r, ICAM-1, and IL-6 in Spinal Cord Injuries." *Archives of Physical Medicine and Rehabilitation*  
1799 78 (1): 44–47. [https://doi.org/10.1016/s0003-9993\(97\)90008-3](https://doi.org/10.1016/s0003-9993(97)90008-3).
- 1800 Seitz, Alexander, Maja Kragol, Elsa Aglow, Louise Showe, and Ellen Heber-Katz. 2003. "Apolipoprotein E Expression After Spinal Cord Injury in the Mouse." *Journal of Neuroscience Research* 71 (3):  
1801 417–26. <https://doi.org/10.1002/jnr.10482>.
- 1802 Shah, Chandrabala, Ranjeeta Hari-Dass, and John G. Raynes. 2006. "Serum Amyloid A Is an Innate  
1803 Immune Opsonin for Gram-negative Bacteria." *Blood* 108 (5): 1751–57. <https://doi.org/10.1182/blood-2005-11-011932>.
- 1804 Shavelle, Robert M., Michael J. DeVivo, Jordan C. Brooks, David J. Strauss, and David R. Paculdo.  
1805 2015. "Improvements in Long-Term Survival After Spinal Cord Injury?" *Archives of Physical  
1806 Medicine and Rehabilitation* 96 (4): 645–51. <https://doi.org/10.1016/j.apmr.2014.11.003>.
- 1807 Shechter, Ravid, Anat London, Chen Varol, Catarina Raposo, Melania Cusimano, Gili Yovel, Asya  
1808 Rolls, et al. 2009. "Infiltrating Blood-Derived Macrophages Are Vital Cells Playing an Anti-  
1809 inflammatory Role in Recovery from Spinal Cord Injury in Mice." *PLOS Medicine* 6 (7): e1000113.  
1810 <https://doi.org/10.1371/journal.pmed.1000113>.
- 1811 Shichita, Takashi, Eiichi Hasegawa, Akihiro Kimura, Rimpei Morita, Ryota Sakaguchi, Ichiro Takada,  
1812 Takashi Sekiya, et al. 2012. "Peroxiredoxin Family Proteins Are Key Initiators of Post-Ischemic  
1813 Inflammation in the Brain." *Nature Medicine* 18 (6): 911–17. <https://doi.org/10.1038/nm.2749>.
- 1814 Silva, Barbara Ferreira da, Chen Meng, Dominic Helm, Fiona Pacht, Jürgen Schiller, Emad Ibrahim,  
1815 Charles M. Lynne, Nancy L. Brackett, Ricardo Pimenta Bertolla, and Bernhard Kuster. 2016. "To-  
1816 wards Understanding Male Infertility After Spinal Cord Injury Using Quantitative Proteomics."  
1817 *Molecular & Cellular Proteomics* 15 (4): 1424–34. <https://doi.org/10.1074/mcp.M115.052175>.
- 1818 Smith, C, D I Graham, L S Murray, J Stewart, and J A R Nicoll. 2006. "Association of APOE E4 and  
1819 Cerebrovascular Pathology in Traumatic Brain Injury." *Journal of Neurology, Neurosurgery, and  
1820 Psychiatry* 77 (3): 363–66. <https://doi.org/10.1136/jnnp.2005.074617>.
- 1821 Sobrido-Cameán, Daniel, and Antón Barreiro-Iglesias. 2018. "Role of Caspase-8 and Fas in Cell  
1822 Death After Spinal Cord Injury." *Frontiers in Molecular Neuroscience* 11: 101. <https://doi.org/10.3389/fnmol.2018.00101>.
- 1823 Sockanathan, Shanthini, and Thomas M Jessell. 1998. "Motor Neuron-Derived Retinoid Signaling  
1824 Specifies the Subtype Identity of Spinal Motor Neurons." *Cell* 94 (4): 503–14. [https://doi.org/10.1016/S0092-8674\(00\)81591-3](https://doi.org/10.1016/S0092-8674(00)81591-3).
- 1825 Sofroniew, Michael V., and Harry V. Vinters. 2010. "Astrocytes: Biology and Pathology." *Acta Neu-  
1826 ropathologica* 119 (1): 7–35. <https://doi.org/10.1007/s00401-009-0619-8>.
- 1827 Song, Guoqing, Cate Cechvala, Daniel K. Resnick, Robert J. Dempsey, and Vemuganti L. Raghaven-  
1828 dra Rao. 2001. "GeneChip Analysis After Acute Spinal Cord Injury in Rat." *Journal of Neurochem-  
1829 istry* 79 (4): 804–15. <https://doi.org/10.1046/j.1471-4159.2001.00626.x>.
- 1830 Sottrup-Jensen, L., T. M. Stepanik, T. Kristensen, D. M. Wierzbicki, C. M. Jones, P. B. Lønblad, S.  
1831 Magnusson, and T. E. Petersen. 1984. "Primary Structure of Human Alpha 2-Macroglobulin. V.  
1832 The Complete Structure." *The Journal of Biological Chemistry* 259 (13): 8318–27.
- 1833 Spiess, Martina R., Roland M. Müller, Rüdiger Rupp, Christian Schuld, and Hubertus J. A. van Hedel.  
1834 2009. "Conversion in ASIA Impairment Scale During the First Year After Traumatic Spinal Cord  
1835 Injury." *Journal of Neurotrauma* 26 (11): 2027–36. <https://doi.org/10.1089/neu.2008.0760>.
- 1836 Stangel, Martin, Hans-Peter Hartung, Peter Marx, and Ralf Gold. 1998. "Intravenous Immunoglob-  
1837 ulin Treatment of Neurological Autoimmune Diseases." *Journal of the Neurological Sciences* 153  
1838

(2): 203–14. [https://doi.org/10.1016/S0022-510X\(97\)00292-X](https://doi.org/10.1016/S0022-510X(97)00292-X).

Steel, Diana M., and Alexander S. Whitehead. 1994. "The Major Acute Phase Reactants: C-reactive Protein, Serum Amyloid P Component and Serum Amyloid A Protein." *Immunology Today* 15 (2): 81–88. [https://doi.org/10.1016/0167-5699\(94\)90138-4](https://doi.org/10.1016/0167-5699(94)90138-4).

Stenson, Katherine W., Anne Deutsch, Allen W. Heinemann, and David Chen. 2011. "Obesity and Inpatient Rehabilitation Outcomes for Patients With a Traumatic Spinal Cord Injury." *Archives of Physical Medicine and Rehabilitation* 92 (3): 384–90. <https://doi.org/10.1016/j.apmr.2010.07.235>.

Stirling, David P., Karen Cummins, Manoj Mishra, Wulin Teo, V. Wee Yong, and Peter Stys. 2014. "Toll-Like Receptor 2-Mediated Alternative Activation of Microglia Is Protective After Spinal Cord Injury." *Brain* 137 (3): 707–23. <https://doi.org/10.1093/brain/awt341>.

Stirling, David P., Shuhong Liu, Paul Kubes, and V. Wee Yong. 2009. "Depletion of Ly6G/Gr-1 Leukocytes After Spinal Cord Injury in Mice Alters Wound Healing and Worsens Neurological Outcome." *Journal of Neuroscience* 29 (3): 753–64. <https://doi.org/10.1523/JNEUROSCI.4918-08.2009>.

Stoscheck, Christa M. 1987. "Protein Assay Sensitive at Nanogram Levels." *Analytical Biochemistry* 160 (2): 301–5. [https://doi.org/10.1016/0003-2697\(87\)90051-0](https://doi.org/10.1016/0003-2697(87)90051-0).

Strauss, David J., Michael J. DeVivo, David R. Paculdo, and Robert M. Shavelle. 2006. "Trends in Life Expectancy After Spinal Cord Injury." *Archives of Physical Medicine and Rehabilitation* 87 (8): 1079–85. <https://doi.org/10.1016/j.apmr.2006.04.022>.

Sun, ChongYi, GuangRong Ji, QingPeng Liu, and Meng Yao. 2011. "Apolipoprotein E Epsilon 4 Allele and Outcomes of Traumatic Spinal Cord Injury in a Chinese Han Population." *Molecular Biology Reports* 38 (7): 4793–96. <https://doi.org/10.1007/s11033-010-0620-2>.

Sun, Guodong, Shuxian Yang, Guangchao Cao, Qianghua Wang, Jianlei Hao, Qiong Wen, Zhizhong Li, et al. 2017. "Gammadelta T Cells Provide the Early Source of IFN-gamma to Aggravate Lesions in Spinal Cord Injury." *Journal of Experimental Medicine* 215 (2): 521–35. <https://doi.org/10.1084/jem.20170686>.

Sun, Lei, and Richard D. Ye. 2016. "Serum Amyloid A1: Structure, Function and Gene Polymorphism." *Gene* 583 (1): 48–57. <https://doi.org/10.1016/j.gene.2016.02.044>.

Sun, Xin, Zachary B. Jones, Xiao-ming Chen, Libing Zhou, Kwok-Fai So, and Yi Ren. 2016. "Multiple Organ Dysfunction and Systemic Inflammation After Spinal Cord Injury: A Complex Relationship." *Journal of Neuroinflammation* 13 (1): 260. <https://doi.org/10.1186/s12974-016-0736-y>.

Szalai, Alexander J., Frederik W. van Ginkel, Yue Wang, Jerry R. McGhee, and John E. Volanakis. 2000. "Complement-Dependent Acute-Phase Expression of C-Reactive Protein and Serum Amyloid P-Component." *The Journal of Immunology* 165 (2): 1030–35. <https://doi.org/10.4049/jimmunol.165.2.1030>.

Szklarczyk, Damian, Annika L. Gable, David Lyon, Alexander Junge, Stefan Wyder, Jaime Huerta-Cepas, Milan Simonovic, et al. 2019. "STRING V11: Protein-Protein Association Networks with Increased Coverage, Supporting Functional Discovery in Genome-Wide Experimental Datasets." *Nucleic Acids Research* 47 (D1): D607–13. <https://doi.org/10.1093/nar/gky1131>.

Tape, C., R. Tan, M. Neshejm, and R. Kisilevsky. 1988. "Direct Evidence for Circulating apoSAA as the Precursor of Tissue AA Amyloid Deposits." *Scandinavian Journal of Immunology* 28 (3): 317–24. <https://doi.org/10.1111/j.1365-3083.1988.tb01455.x>.

Teasdale, Graham M., James AR Nicoll, Gordon Murray, and Matilda Fiddes. 1997. "Association of Apolipoprotein E Polymorphism with Outcome After Head Injury." *The Lancet* 350 (9084): 1069–71. [https://doi.org/10.1016/S0140-6736\(97\)04318-3](https://doi.org/10.1016/S0140-6736(97)04318-3).

The UniProt Consortium. 2021. "UniProt: The Universal Protein Knowledgebase in 2021." *Nucleic Acids Research* 49 (D1): D480–89. <https://doi.org/10.1093/nar/gkaa1100>.

Thom, Vivien, Thiruma V. Arumugam, Tim Magnus, and Mathias Gelderblom. 2017. "Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury." *Frontiers in Immunology* 8: 875. <https://doi.org/10.3389/fimmu.2017.00875>.

Tierney, Nicholas, Di Cook, Miles McBain, and Colin Fay. 2021. *Naniar: Data Structures, Summaries,*

- and Visualisations for Missing Data. <https://CRAN.R-project.org/package=nanianr>.
- Travis, J., and G. S. Salvesen. 1983. "Human Plasma Proteinase Inhibitors." *Annual Review of Biochemistry* 52 (1): 655–709. <https://doi.org/10.1146/annurev.bi.52.070183.003255>.
- Tzekou, Apostolia, and Michael G. Fehlings. 2014. "Treatment of Spinal Cord Injury with Intravenous Immunoglobulin G: Preliminary Evidence and Future Perspectives." *Journal of Clinical Immunology* 34 (1): 132–38. <https://doi.org/10.1007/s10875-014-0021-8>.
- Vallon, Rüdiger, Felix Freuler, Netsanet Desta-Tsedu, Anna Robeva, Janet Dawson, Peter Wenner, Petra Engelhardt, et al. 2001. "Serum Amyloid A (apoSAA) Expression Is Up-Regulated in Rheumatoid Arthritis and Induces Transcription of Matrix Metalloproteinases." *The Journal of Immunology* 166 (4): 2801–7. <https://doi.org/10.4049/jimmunol.166.4.2801>.
- van der Hilst, J. C. H., T. Yamada, H. J. M. Op den Camp, J. W. M. van der Meer, J. P. H. Drenth, and A. Simon. 2008. "Increased Susceptibility of Serum Amyloid A 1.1 to Degradation by MMP-1: Potential Explanation for Higher Risk of Type AA Amyloidosis." *Rheumatology* 47 (11): 1651–54. <https://doi.org/10.1093/rheumatology/ken371>.
- van der Westhuyzen, Deney R., Lei Cai, Maria C. de Beer, and Frederick C. de Beer. 2005. "Serum Amyloid A Promotes Cholesterol Efflux Mediated by Scavenger Receptor B-1\*." *Journal of Biological Chemistry* 280 (43): 35890–95. <https://doi.org/10.1074/jbc.M505685200>.
- van Oosten, Marijke, Edwin S. van Amersfoort, Theo J. C. van Berkel, and Johan Kuiper. 2001. "Scavenger Receptor-Like Receptors for the Binding of Lipopolysaccharide and Lipoteichoic Acid to Liver Endothelial and Kupffer Cells." *Journal of Endotoxin Research* 7 (5): 381–84. <https://doi.org/10.1177/09680519010070050601>.
- Viard, Isabelle, Philippe Wehrli, Roberto Bullani, Pascal Schneider, Nils Holler, Denis Salomon, Thomas Hunziker, Jean-Hilaire Saurat, Jürg Tschopp, and Lars E. French. 1998. "Inhibition of Toxic Epidermal Necrolysis by Blockade of Cd95 with Human Intravenous Immunoglobulin." *Science* 282 (5388): 490–93. <https://doi.org/10.1126/science.282.5388.490>.
- Vickers, Kasey C., Brian T. Palmisano, Bassem M. Shoucri, Robert D. Shamburek, and Alan T. Remaley. 2011. "MicroRNAs Are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins." *Nature Cell Biology* 13 (4): 423–33. <https://doi.org/10.1038/ncb2210>.
- Vidaurre, Oscar G., Jeffery D. Haines, Ilana Katz Sand, Kadidia P. Adula, Jimmy L. Huynh, Corey A. McGraw, Fan Zhang, et al. 2014. "Cerebrospinal Fluid Ceramides from Patients with Multiple Sclerosis Impair Neuronal Bioenergetics." *Brain* 137 (8): 2271–86. <https://doi.org/10.1093/brain/awu139>.
- Vodovotz, Yoram, Shubing Liu, Carol McCloskey, Richard Shapiro, Angela Green, and Timothy R. Billiar. 2001. "The Hepatocyte as a Microbial Product-Responsive Cell." *Journal of Endotoxin Research* 7 (5): 365–73. <https://doi.org/10.1177/09680519010070050401>.
- Vorst, Emiel P. C. van der, Laura Z. Vanags, Louise L. Dunn, Hamish C. Prosser, Kerry-Anne Rye, and Christina A. Bursill. 2013. "High-Density Lipoproteins Suppress Chemokine Expression and Proliferation in Human Vascular Smooth Muscle Cells." *The FASEB Journal* 27 (4): 1413–25. <https://doi.org/10.1096/fj.12-212753>.
- Wang, Kevin K., Zhihui Yang, Tian Zhu, Yuan Shi, Richard Rubenstein, J. Adrian Tyndall, and Geoff T. Manley. 2018. "An Update on Diagnostic and Prognostic Biomarkers for Traumatic Brain Injury." *Expert Review of Molecular Diagnostics* 18 (2): 165–80. <https://doi.org/10.1080/14737159.2018.1428089>.
- Weiskirchen, Ralf, and Frank Tacke. 2014. "Cellular and Molecular Functions of Hepatic Stellate Cells in Inflammatory Responses and Liver Immunology." *Hepatobiliary Surgery and Nutrition* 3 (6): 34463–363. <https://doi.org/10.3978/j.issn.2304-3881.2014.11.03>.
- White, F., J. A. R. Nicoll, A. D. Roses, and K. Horsburgh. 2001. "Impaired Neuronal Plasticity in Transgenic Mice Expressing Human Apolipoprotein E4 Compared to E3 in a Model of Entorhinal Cortex Lesion." *Neurobiology of Disease* 8 (4): 611–25. <https://doi.org/10.1006/nbdi.2001.0401>.
- Wickham, Hadley. 2019. *Stringr: Simple, Consistent Wrappers for Common String Operations*. <https://CRAN.R-project.org/package=stringr>.

- Wickham, Hadley, Mara Averick, Jennifer Bryan, Winston Chang, Lucy D'Agostino McGowan, Romain François, Garrett Grolemond, et al. 2019. "Welcome to the tidyverse." *Journal of Open Source Software* 4 (43): 1686. <https://doi.org/10.21105/joss.01686>.
- Wickham, Hadley, and Jennifer Bryan. 2019. *Readxl: Read Excel Files*. <https://CRAN.R-project.org/package=readxl>.
- Widiapradja, Alexander, Viktor Vegh, Ker Zhing Lok, Silvia Manzanero, John Thundyil, Mathias Gelderblom, Yi-Lin Cheng, et al. 2012. "Intravenous Immunoglobulin Protects Neurons Against Amyloid Beta-Peptide Toxicity and Ischemic Stroke by Attenuating Multiple Cell Death Pathways." *Journal of Neurochemistry* 122 (2): 321–32. <https://doi.org/10.1111/j.1471-4159.2012.07754.x>.
- Wilhelmsson, Ulrika, Eric A. Bushong, Diana L. Price, Benjamin L. Smarr, Van Phung, Masako Terada, Mark H. Ellisman, and Milos Pekny. 2006. "Redefining the Concept of Reactive Astrocytes as Cells That Remain Within Their Unique Domains Upon Reaction to Injury." *Proceedings of the National Academy of Sciences of the United States of America* 103 (46): 17513–18. <https://doi.org/10.1073/pnas.0602841103>.
- Wright, Helen L., Robert J. Moots, Roger C. Bucknall, and Steven W. Edwards. 2010. "Neutrophil Function in Inflammation and Inflammatory Diseases." *Rheumatology* 49 (9): 1618–31. <https://doi.org/10.1093/rheumatology/keq045>.
- Wyatt, Amy R., and Mark R. Wilson. 2013. "Acute Phase Proteins Are Major Clients for the Chaperone Action of A2-Macroglobulin in Human Plasma." *Cell Stress & Chaperones* 18 (2): 161–70. <https://doi.org/10.1007/s12192-012-0365-z>.
- Xie, Yihui. 2014. "Knitr: A Comprehensive Tool for Reproducible Research in R." In *Implementing Reproducible Computational Research*, edited by Victoria Stodden, Friedrich Leisch, and Roger D. Peng. Chapman; Hall/CRC. <http://www.crcpress.com/product/isbn/9781466561595>.
- Xu, He, David I. Finkelstein, and Paul A. Adlard. 2014. "Interactions of Metals and Apolipoprotein E in Alzheimer's Disease." *Frontiers in Aging Neuroscience* 6. <https://doi.org/10.3389/fnagi.2014.00121>.
- Yang, Chih-Ya, Jiun-Bo Chen, Ting-Fen Tsai, Yi-Chen Tsai, Ching-Yen Tsai, Pi-Hui Liang, Tsui-Ling Hsu, et al. 2013. "Clec4f Is an Inducible C-Type Lectin in F4/80-Positive Cells and Is Involved in Alpha-Galactosylceramide Presentation in Liver." *PLOS ONE* 8 (6): e65070. <https://doi.org/10.1371/journal.pone.0065070>.
- Yang, Xuan, Shurui Chen, Zhenya Shao, Yuanlong Li, He Wu, Xian Li, Liang Mao, et al. 2018. "Apolipoprotein E Deficiency Exacerbates Spinal Cord Injury in Mice: Inflammatory Response and Oxidative Stress Mediated by NF- $\kappa$ B Signaling Pathway." *Frontiers in Cellular Neuroscience* 12 (May): 142. <https://doi.org/10.3389/fncel.2018.00142>.
- Yao, Xin-Qiang, Zhong-Yuan Liu, Jia-Ying Chen, Zu-Cheng Huang, Jun-Hao Liu, Bai-Hui Sun, Qing-An Zhu, Ruo-Ting Ding, and Jian-Ting Chen. 2021. "Proteomics and Bioinformatics Reveal Insights into Neuroinflammation in the Acute to Subacute Phases in Rat Models of Spinal Cord Contusion Injury." *The FASEB Journal* 35 (7): e21735. <https://doi.org/10.1096/fj.202100081RR>.
- Yu, Guangchuang, and Qing-Yu He. 2016a. "ReactomePA: An R/Bioconductor Package for Reactome Pathway Analysis and Visualization." *Molecular BioSystems* 12 (12): 477–79. <https://doi.org/10.1039/C5MB00663E>.
- . 2016b. "ReactomePA: An R/Bioconductor Package for Reactome Pathway Analysis and Visualization." *Molecular BioSystems* 12 (2): 477–79. <https://doi.org/10.1039/c5mb00663e>.
- Yu, Wen Ru, and Michael G. Fehlings. 2011. "Fas/FasL-mediated Apoptosis and Inflammation Are Key Features of Acute Human Spinal Cord Injury: Implications for Translational, Clinical Application." *Acta Neuropathologica* 122 (6): 747–61. <https://doi.org/10.1007/s00401-011-0882-3>.
- Yvan-Charvet, Laurent, Tamara Pagler, Emmanuel L. Gautier, Serine Avagyan, Read L. Stry, Seon-gah Han, Carrie L. Welch, et al. 2010. "ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation." *Science* 328 (5986): 1689–93. <https://doi.org/10.1126/science.1189731>.

- 1996 Zerrad-Saadi Amal, Therond Patrice, Chantepie Sandrine, Couturier Martine, Rye Kerry-Anne,  
1997 Chapman M. John, and Kontush Anatol. 2009. "Hdl3-Mediated Inactivation of LDL-Associated  
1998 Phospholipid Hydroperoxides Is Determined by the Redox Status of Apolipoprotein A-I and  
1999 HDL Particle Surface Lipid Rigidity." *Arteriosclerosis, Thrombosis, and Vascular Biology* 29 (12):  
2000 2169–75. <https://doi.org/10.1161/ATVBAHA.109.194555>.
- 2001 Zhang, Chao, Wenhao Zhang, Jie Zhang, Yingli Jing, Mingliang Yang, Liangjie Du, Feng Gao, et al.  
2002 2018. "Gut Microbiota Dysbiosis in Male Patients with Chronic Traumatic Complete Spinal Cord  
2003 Injury." *Journal of Translational Medicine* 16 (1): 353. [https://doi.org/10.1186/s12967-018-1735-](https://doi.org/10.1186/s12967-018-1735-9)  
2004 9.
- 2005 Zhu, Hao. 2021. *kableExtra: Construct Complex Table with 'Kable' and Pipe Syntax*. [https://CRAN.R-](https://CRAN.R-project.org/package=kableExtra)  
2006 [project.org/package=kableExtra](https://CRAN.R-project.org/package=kableExtra).
- 2007 Zhu, Y., C. Soderblom, V. Krishnan, J. Ashbaugh, J. R. Bethea, and J. K. Lee. 2015. "Hematogenous  
2008 Macrophage Depletion Reduces the Fibrotic Scar and Increases Axonal Growth After Spinal Cord  
2009 Injury." *Neurobiology of Disease* 74 (February): 114–25. [https://doi.org/10.1016/j.nbd.2014.10.](https://doi.org/10.1016/j.nbd.2014.10.024)  
2010 024.